3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

ABSTRACT

The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to Korean Patent Application No. 10-2018-0161725, filed Dec. 14, 2018, and Korean Patent Application No. 10-2019-0137387, filed Oct. 31, 2019, the entire contents of each of which are incorporated by reference herein in their entirety.

FIELD

The present technology relates to 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof having inhibitory activity on vascular adhesion protein (VAP-1), a process for the preparation thereof, a pharmaceutical composition comprising the same, and uses thereof.

BACKGROUND

Vascular adhesion protein-1 (VAP-1) is a semicarbazide-sensitive amine oxidase (SSAO), which is abundantly present in human plasma. VAP-1 is an ectoenzyme comprising a short cytoplasmic tail, a single transmembrane domain, and an extracellular domain with large and high glycosylation containing the center of activity. In addition, VAP-1 exists not only as a membrane-bound form in the endothelium, but also as a soluble form in serums (soluble VAP-1, sVAP-1). This form was shown to be a product cleaved from the membrane-bound VAP-1, and appears to have similar properties as the tissue-bound form. It has been also reported that VAP-1 is normally stored in intracellular granules within endothelial cells, but when an inflammatory response is evoked in response to inflammatory stimuli, it is translocated onto the cell membrane, and its expression is upregulated, and therefore, it is expressed more strongly in inflamed tissues than in normal tissues.

Substrates for VAP-1 include endogenous methylamine and aminoacetone as well as some xenobiotic amines such as tyramine and benzylamine.

VAP-1 has two physiological functions: the first is amine oxidase activity stated earlier in this section, and the second is cell adhesion activity. Due to these two activities, VAP-1 has been shown to play a key role in the leakage of inflammatory cells as it acts as an adhesion protein for leukocytes in inflamed sites [Trends Immunol. (2001) 22: 211]. VAP-1-deficient transgenic mice are healthy, develop normally, and fertile, and phenotypically normal, but exhibit a marked decrease in the inflammatory responses evoked in response to various inflammatory stimuli [Immunity. (2005) 22: 105].

In addition, inhibitory activity of VAP-1 in multiple animal models of human diseases (e.g., carrageenan-induced paw inflammation, oxazolone-induced colitis, lipopolysaccharide-induced lung inflammation, collagen-induced arthritis, endotoxin-induced uveitis) by the use of antibodies or small molecules has been shown to prevent leukocyte from rolling, adhering, and leaking, and reduce levels of inflammatory cytokines and chemokines, thereby reducing the severity of the disease [Eur J Immunol. (2005) 35: 3119; J Pharmacol Exp Ther. (2005) 315: 553; Annu Rep Med Chem. (2007) 42: 229; FASEB J. (2008) 22: 1094]. Inflammation is the first reaction of the immune system to infection or stimulus, and in such a process, the movement of leukocytes into the tissue through circulation is an important step. The leukocytes are first bound to adhesion proteins and then adhered to the endothelium before they start to pass through blood vessel walls. VAP-1 is highly expressed in endothelial venules (HEV) such as high endothelial venules in lymphoid organs, as well as hepatic sinusoidal endothelial cells, (HSEC), smooth muscle cells, and adipocytes. The VAP-1 expression on the cell surface of endothelial cells is strictly regulated and is increased during inflammation. VAP-1 activates NF-κB when it is present in the substrate, and the NF-κB is activated within the HSEC while E-selectin and chemokine IL-8 that are other adhesion molecules are upregulated ex vivo. This suggests that VAP-1 may be a key factor for the regulation of the inflammatory response. Therefore, it seems likely that VAP-1 inhibitors may be effective anti-inflammatory drugs in a wide range of human diseases.

Nonalcoholic fatty liver disease (NAFLD), histologically, encompasses simple steatosis, nonalcoholic hepatosteatosis (NASH), and liver cirrhosis. Among these, unlike simple steatosis (non-alcoholic fatty liver, NAFL), NASH potentially progresses to liver cirrhosis and hepatoma (hepatocellular carcinoma). In NASH, insulin resistance is known to play an important role in the progression of disease, along with oxidative stress, inflammatory cascade, and fibrosis. In patients with NAFLD, sVAP-1 levels were found to be elevated, and in VAP-1 knockout (K/O) mice, carbon tetrachloride-induced liver fibrosis was reduced compared with that in wild type animals. In addition, improvement of liver fibrosis by VAP-1 inhibition following administration of VAP-1 antibody was identified by histological changes [J Clin Invest (2015) 125: 501]. Thus, VAP-1 was found to be associated with NASH in clinical studies and animal models of diseases. Inhibitory activity of VAP-1 in the carbon tetrachloride-induced animal model appears to be due to a reduction in infiltration of leukocytes such as T cells, B cells, NKT cells, and NK cells observed in liver fibrosis, and VAP-1 inhibitors have the potential for treating fibrotic diseases.

Thus, a substance that inhibits VAP-1 may be applied to prevention and treatment of various inflammatory diseases and fibrotic diseases.

SUMMARY

The present inventors found that triazolones having 3,3-difluoroallylamine groups or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1. Therefore, the 3,3-difluoroallylamines or their salts can be usefully used in the treatment and prophylaxis of various VAP-1 mediated diseases, for example, nonalcoholic hepatosteatosis (NASH).

Therefore, the present technology provides the 3,3-difluoroallylamines or their pharmaceutically acceptable salts, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof.

In accordance with one aspect of the present technology, there is provided a 3,3-difluoroallylamine or its pharmaceutically acceptable salt.

In accordance with another aspect of the present technology, there is provided a preparation process of the 3,3-difluoroallylamine or its pharmaceutically acceptable salt.

In accordance with another aspect of the present technology, there is provided a pharmaceutical composition comprising the 3,3-difluoroallylamine or its pharmaceutically acceptable salt as an active ingredient.

In accordance with another aspect of the present technology, there is provided a method of treatment comprising administering the 3,3-difluoroallylamine or its pharmaceutically acceptable salt.

In accordance with another aspect of the present technology, there is provided the use of the 3,3-difluoroallylamine or its pharmaceutically acceptable salt in the manufacture of a medicament for inhibition of vascular adhesion protein-1.

It was found by the present technology that triazolones having 3,3-difluoroallylamine groups or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1. Therefore, the compounds according to the present technology or pharmaceutically acceptable salts thereof can be usefully applied for the treatment and prophylaxis of VAP-1 mediated various diseases, for example, nonalcoholic hepatosteatosis (NASH).

Provided herein in one aspect is a compound of Formula X

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

n is 0, 1 or 2; and

A is an aryl group or a heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic; and wherein said aryl group or said heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R; and

R is a substituted or unsubstituted cyclic ring, optionally containing 1 to 5 heteroatom ring members chosen from O, N, or S, and said cyclic ring is aromatic or non-aromatic. In some embodiments, A is aryl optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments, A is phenyl substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments, A is a heterocyclic group having 1 to 5 heteroatom ring members chosen from O, N, or S; said heterocyclic group is aromatic or non-aromatic; and said heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments, A is a heteroaryl group having 1 to 5 heteroatom ring members chosen from O, N, or S; and said heteroaryl group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments, A is pyridine, pyrazine, or thiophene, wherein A is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments, R is a cyclic ring optionally containing 1-5 heteroatom ring members, and said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, pyrrolidinonyl, and pyrrolidinyl. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

Provided herein in another aspect is a compound, of Formula Y

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

n is 0, 1 or 2;

A is an aryl or heteroaryl group selected from the group consisting of phenyl, pyridine, pyrazine, thiophene, and benzothiophene;

wherein said aryl or heteroaryl group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R;

wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 3,4-dihydro-1,4-benzoxazine, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene;

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, pyrrolidinonyl, and pyrrolidinyl.

In some embodiments, n is 0 or 1, and A is phenyl, pyridine or thiophene, optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments, said aryl or heteroaryl group is substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, and —R. In some embodiments, said R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole and 3,4-dihydroquinolin-2-one, said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl. In some embodiments, said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl. In some embodiments, n is 0; A is phenyl; wherein said phenyl is substituted with one or two substituents selected from the group consisting of halogen and —R; wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, 3,4-dihydroquinolin-2-one and pyrazole; and wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl. In some embodiments, n is 0; A is pyridine; wherein said pyridine is substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, and —R; wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, 3,4-dihydroquinolin-2-one and pyrazole; and wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl. In some embodiments, n is 0; A is thiophene; wherein said thiophene is substituted with one or two cyclic rings selected from the group consisting of benzene, pyridine, pyridin-2-one, 3,4-dihydroquinolin-2-one and pyrazole; and wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl. In some embodiments, A is phenyl optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments, A is phenyl substituted with —R. In some embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one; wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinonyl. In some embodiments, A is pyridine substituted with —R. In some embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrimidine, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene. wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinonyl. In some embodiments, A is thiophene substituted with —R. In some embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 2,3-dihydro-1,4-benzoxazine, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, pyrido[2,3-b][1,4]oxazin-2-one, and 1,4-dihydroquinazolin-2-one; wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl. In some embodiments, A is benzothiophene substituted with —R. In some embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one, wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

Provided herein in another aspect is a compound of Formula 12

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is phenyl substituted with triazolyl, C₁₋₆ alkylsulfonyl, or piperazinyl. In some embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is substituted or unsubstituted pyrazole. In some embodiments, R² is pyrazole substituted with C₁₋₆ alkyl or difluoromethyl.

Provided herein in another aspect is a compound of Formula 13

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aralkoxy group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In some embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is substituted or unsubstituted pyrazole. In some embodiments, R² is pyrazole substituted with C₁₋₆ alkyl. In some embodiments, R² is substituted or unsubstituted pyridin-2-one. In some embodiments, R² is pyridin-2-one substituted with C₁₋₆ alkyl. In some embodiments, R² is substituted or unsubstituted aralkoxy group. In some embodiments, R² is substituted or unsubstituted benzyloxy.

Provided herein in another aspect is a compound of Formula 14

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments, the compound is of Formula 14a

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is of Formula 14b

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is of Formula 14c

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is phenyl substituted with one to three substituents selected from the group consisting of with halogen, C₁₋₆ alkoxy, mono- or di-C₁₋₆ alkylamino, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, morpholinylcarbonyl, piperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, and pyrrolidinonyl. In some embodiments, R² is benzodioxole, benzoxadiazole, benzothiazole, indazole, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, 3,4-dihydroquinolin-2-one, or benzoxazole, wherein R² is optionally substituted with C₁₋₆ alkyl or amino. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with C₁₋₆ alkoxy, trifluoromethyl, piperazinyl, morpholinyl, or mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is pyrimidine, 1H-pyrrolo[2,3-b]pyridine, pyrazole, or thiophene, wherein R² is optionally substituted with C₁₋₆ alkyl, difluoromethyl, C₁₋₆ alkoxy-C₁₋₆ alkylamino, or C₁₋₆ alkylcarbonyl. In some embodiments, R² is substituted or unsubstituted pyridin-2-one. In some embodiments, R² is pyridin-2-one substituted with C₁₋₆ alkyl.

Provided herein in another aspect is a compound of Formula 15

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S group.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is 2,3-dihydro-1,4-benzoxazine or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with morpholinyl or mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, or pyrazole, wherein said pyrazole is optionally substituted with C₁₋₆ alkyl.

Provided herein in another aspect is a compound of Formula 16

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In some embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is substituted or unsubstituted pyrazole. In some embodiments, R² is pyrazole substituted with C₁₋₆ alkyl.

Provided herein in another aspect is a compound of Formula 17

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is phenyl substituted with one to three substituents selected from the group consisting of C₁₋₆ alkoxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylsulfonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, mono- or di-C₁₋₆ alkylaminocarbonyl, morpholinylcarbonyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, piperazinyl, and acetylpiperazinyl. In some embodiments, R² is 3,4-dihydroisoquinolin-1-one, quinolin-2-one, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, benzothiazole, benzoxadiazole, indazole, benzodioxole, 1,3-dihydroindol-2-one, or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkylcarbonylamino, or halogen. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with one to three substituents selected from the group consisting of halogen, trifluoromethyl, C₁₋₆ alkoxy, piperazinyl and mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is substituted or unsubstituted pyrazole. In some embodiments, R² is pyrazole substituted with C₁₋₆ alkyl, difluoromethyl, benzyl, (cycloalkyl)alkyl, alkylsulfonyl, or cycloalkylsulfonyl. In some embodiments, R² is 5,6,7,8-tetrahydronaphthyridine, pyrimidine, imidazole, or triazolo[1,5-a]pyridine; wherein R² is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, and C₁₋₆ alkoxy-C₁₋₆ alkylamino. In some embodiments, R² is [1,2,4]triazolo[1,5-a]pyridine. In some embodiments, R² is tetrahydropyridine or pyridin-2-one, wherein said tetrahydropyridine and said pyridin-2-one are optionally substituted with C₁₋₆ alkyl or C₁₋₆ alkylcarbonyl.

Provided herein in another aspect is a compound of Formula 18

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is 2,3-dihydro-1,4-benzoxazine or 3,4-dihydroquinolin-2-one. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with morpholinyl or mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is substituted or unsubstituted pyrazole. In some embodiments, R² is pyrazole substituted with C₁₋₆ alkyl. In some embodiments, R² is 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, or pyrido[3,2-b][1,4]oxazin-3-one.

Provided herein in another aspect is a compound of Formula 19

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In some embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is substituted or unsubstituted pyrazole. In some embodiments, R² is pyrazole substituted with C₁₋₆ alkyl.

Provided herein in another aspect is a compound of Formula 20

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments, R¹ is hydrogen. In some embodiments, R¹ is halogen. In some embodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted aryl group. In some embodiments, R² is substituted or unsubstituted phenyl. In some embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In some embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, R² is substituted or unsubstituted pyridine. In some embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In some embodiments, R² is substituted or unsubstituted pyrazole. In some embodiments, R² is pyrazole substituted with C₁₋₆ alkyl. In some embodiments, R² is a substituted or unsubstituted pyridine-2-one. In some embodiments, R² is pyridine-2-one substituted with C₁₋₆ alkyl. In some embodiments, the compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, is selected from Table 1.

Provided herein in another aspect is a pharmaceutical composition comprising the compound disclosed herein, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient

Provided herein in another aspect is a method of inhibiting vascular adhesion protein (VAP-1), comprising administering to a mammal, a therapeutically effective amount of the compound disclosed herein, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

Provided herein in another aspect is a method of treating NASH in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound disclosed herein, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition disclosed herein.

Provided herein in another aspect is a use of the compound disclosed herein, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of NASH.

Provided herein in another aspect is a compound disclosed herein, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use in treating NASH.

Provided herein in another aspect is a composition disclosed herein for use in treating NASH.

Provided herein in another aspect is a compound disclosed herein, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use in inhibiting VAP-1.

Provided herein in another aspect is a composition disclosed herein for use in inhibiting VAP-1.

Provided herein in another aspect is a method of treating a disease mediated by VAP-1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound disclosed herein, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition disclosed herein. In some embodiments, the disease mediated by VAP-1 is selected from the group consisting of lipid and lipoprotein disorders, conditions and diseases which result from chronic fatty and fibrotic degeneration of organs due to accumulated lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways, Type I or Type II Diabetes and clinical complications of Type I and Type II Diabetes, chronic intrahepatic or some forms of extrahepatic cholestatic conditions, liver fibrosis, acute intraheptic cholestatic conditions, obstructive or chronic inflammatory disorders that arise out of improper bile composition, gastrointestinal conditions with a reduced uptake of dietary fat and fat-soluble dietary vitamins, inflammatory bowel diseases, obesity and metabolic syndrome (combined conditions of dyslipidemia, diabetes and abnormally high body-mass index), persistent infections by intracellular bacteria or parasitic protozoae, non-malignant hyperproliferative disorders, malignant hyperproliferative disorders, colon adenocarcinoma and hepatocellular carcinoma in particular, liver steatosis and associated syndromes, Hepatitis B infection, Hepatitis C infection and/or of cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis, liver failure or liver malfunction as an outcome of chronic liver diseases or of surgical liver resection, acute myocardial infarction, acute stroke, thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis, osteoarthritis, rheumatoid arthritis, psoriasis, and cerebral infarction, individually or any combination thereof.

Provided herein in another aspect is a method of preparing a compound of Formula 1aa, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

the method comprising

(a) reacting a compound of Formula 2 with a compound of Formula 3a or a compound of Formula 3b to obtain a compound of Formula 1a

wherein

Boc is an amine protecting group;

n is 0, 1, or 2;

A′ is aryl or heteroaryl group selected from the group consisting of phenyl, pyridine, pyrazine, thiophene, and benzothiophene; wherein said aryl or heteroaryl group is optionally substituted with C₁₋₃ alkyl or halogen;

Z is boronic acid (B(OH)₂) or boronic acid pinacol ester;

R′ is —R, —CH═CH—R, or —C≡C—R; and

R is a substituted or unsubstituted cyclic ring, optionally containing 1 to 5 heteroatom ring members chosen from O, N, or S, and said cyclic ring is aromatic or non-aromatic; and

(b) removing Boc from the compound of Formula 1a under reaction conditions to obtain the compound of Formula 1aa, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof.

In some embodiments, the cyclic ring is selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 3,4-dihydro-1,4-benzoxazine, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene; wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

DETAILED DESCRIPTION

It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely”, “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

As used herein, the term “comprising” or “comprises” is intended to mean that the compositions and methods include the recited elements, but not excluding others. A composition or method “consisting essentially” of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed technology. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this technology. When an embodiment is defined by one of these terms (e.g., “comprising”) it should be understood that this disclosure also includes alternative embodiments, such as “consisting essentially of” and “consisting of” for said embodiment.

“Substantially” or “essentially” means nearly totally or completely, for instance, 95%, 96%, 97%, 98%, 99%, or greater of some given quantity.

As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” will mean up to plus or minus 10% of the particular term.

Certain ranges are presented herein with numerical values being preceded by the term “about”. The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the present technology. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the present technology, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the present technology.

In general, “substituted” refers to an organic group (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms. Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom. The present disclosure is understood to include embodiments where, for instance a “substituted alkyl” optionally contains one or more alkene and/or alkyne. A substituted group will be substituted with one or more substituents, unless otherwise specified. In some embodiments, a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents. Examples of substituent groups include: alkyl groups; haloalkyl groups; halogens (i.e., F, Cl, Br, and I); hydroxyls; alkoxy, alkenoxy, alkynoxy, aryloxy, aralkyloxy, heterocyclyloxy, and heterocyclylalkoxy groups; aryl groups; heteroaryl groups; cycloalkyl groups; heterocyclyl groups; carbonyls (oxo); carboxyls; esters; carbamates; urethanes; ureas; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitro groups; nitriles (i.e., CN); and the like. The substituent may be a substituted or unsubstituted cyclic ring. As used herein, an “optionally substituted” group refers to substituted or unsubstituted group. Accordingly, “optionally substituted” and “substituted or unsubstituted” may be used interchangeably.

Substituted ring groups such as substituted cyclic, substituted cycloalkyl, substituted aryl, substituted heterocyclic and substituted heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cyclic, substituted cycloalkyl, substituted aryl, substituted heterocyclic and substituted heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.

As used herein, the term “cyclic ring” refers to an aromatic or non-aromatic ring, optionally containing one or more heteroatoms. Exemplary heteroatoms include, but are not limited to, N, O, S, or B. In some embodiments, the cyclic ring optionally contains 1 to 5 heteroatom ring members chosen from O, N, or S. In some embodiments, the cyclic ring optionally contains 1 to 4 heteroatom ring members chosen from O, N, or S. In some embodiments, the cyclic ring optionally contains 1 to 3 heteroatom ring members chosen from O, N, or S. Cyclic rings include aryl, cycloalkyl, and heterocyclic groups. In some embodiments, the cyclic ring is selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 3,4-dihydro-1,4-benzoxazine, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene. As used herein, triazolo[1,5-a]pyridine includes [1,2,4]triazolo[1,5-a]pyridine and [1,2,3]triazolo[1,5-a]pyridine.

As used herein, an “aryl group” refers to a cyclic aromatic hydrocarbon that does not contain heteroatoms. Aryl groups include monocyclic, bicyclic and polycyclic ring systems. Thus, aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenylenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups. Although the phrase “aryl groups” includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., benzodioxole, indanyl, tetrahydronaphthyl, and the like), it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl groups. Representative substituted aryl groups may be mono-substituted or substituted more than once. For example, monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above.

As used herein, the term “cycloalkyl group” refers to a cyclic alkyl group such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group has 3 to 8 carbon ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7. Cycloalkyl groups further include mono-, bicyclic and polycyclic ring systems, such as, for example bridged cycloalkyl groups as described below, and fused rings, such as, but not limited to, decalinyl, and the like. In some embodiments, polycyclic cycloalkyl groups have three rings. Substituted cycloalkyl groups may be substituted one or more times with non-hydrogen and non-carbon groups as defined above. However, substituted cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4-2,5- or 2,6-di-substituted cyclohexyl groups, which may be substituted with substituents such as those listed above. In some embodiments, a cycloalkyl group has one or more alkene bonds, but is not aromatic. As used herein, the term “(cycloalkyl)alkyl” refers to an alkyl group substituted with a cycloalkyl group.

As used herein, the term “heterocyclic” or “heterocyclyl” includes aromatic (also referred to as heteroaryl) and non-aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, S or B. In some embodiments, heterocyclic groups include 3 to 20 ring members, whereas other such groups have 3 to 6, 3 to 10, 3 to 12, or 3 to 15 ring members. The heterocyclic group may have 1 to 5 heteroatom ring members chosen from O, N, or S. Heterocyclic groups encompass unsaturated, partially saturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl groups. The phrase “heterocyclic group” includes fused ring species including those comprising fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, 2,3-dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl. The phrase also includes bridged polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl. However, the phrase does not include heterocyclic groups that have other groups, such as alkyl, oxo or halo groups, bonded to one of the ring members. Rather, these are referred to as “substituted heterocyclic groups”. Heterocyclic groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrothiopyranyl, oxathiane, dioxyl, dithianyl, pyranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridyl, dihydrodithiinyl, dihydrodithionyl, homopiperazinyl, quinuclidyl, indolyl, indolinyl, isoindolyl, azaindolyl (pyrrolopyridyl), indazolyl, indolizinyl, benzotriazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzthiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithiinyl, benzoxathiinyl, benzothiazinyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[1,3]dioxolyl, pyrazolopyridyl, imidazopyridyl (azabenzimidazolyl), triazolopyridyl, isoxazolopyridyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, quinolizinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, thianaphthalenyl, dihydrobenzothiazinyl, dihydrobenzofuranyl, dihydroindolyl, dihydrobenzodioxinyl, tetrahydroindolyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydrobenzotriazolyl, tetrahydropyrrolopyridyl, tetrahydropyrazolopyridyl, tetrahydroimidazopyridyl, tetrahydrotriazolopyridyl, and tetrahydroquinolinyl groups. Representative substituted heterocyclic groups may be mono-substituted or substituted more than once, such as, but not limited to, pyridyl or piperazinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed above.

As used herein, the term “heteroaryl group” refers to an aromatic ring compound containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, S or B. In some embodiments, one or more heteroatoms are chosen from N, O, or S. In some embodiments, 1 to 4 heteroatoms are chosen from N, O, or S. In some embodiments, 1 to 5 heteroatoms are chosen from N, O, or S. In some embodiments, heteroaryl groups include 5 to 14 ring members, whereas other such groups have 5 to 6, 5 to 9, 5 to 10, 6 to 9, 6 to 10, or 6 to 14 ring members. For example, a 5-membered heteroaryl group has 5 ring members; a 6-membered heteroaryl group has 6 ring members; and a 9-membered heteroaryl group has 9 ring members (such as, but not limited to, benzothiophene). Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl, azaindolyl (pyrrolopyridyl), indazolyl, benzimidazolyl, imidazopyridyl (azabenzimidazolyl), pyrazolopyridyl, triazolopyridyl, benzotriazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridyl, isoxazolopyridyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Although the phrase “heteroaryl groups” includes fused ring compounds such as indolyl and 2,3-dihydro indolyl, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as “substituted heteroaryl groups.” Representative substituted heteroaryl groups may be substituted one or more times with various substituents such as those listed above. An azolyl group is a 5-membered heteroaryl group containing a nitrogen atom and at least one other atom selected from nitrogen, sulfur, and oxygen as part of the ring. Azolyl groups include imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pentazole, oxazole, isoxazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, thiazole, isothiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, and 1,3,4-thiadiazole.

As used herein, the term “alkyl” refers to an aliphatic hydrocarbon radical, which encompasses both straight and branched hydrocarbon radicals. In some embodiments, alkyl has from 1 to about 20 carbon atoms, from 1 to 12 carbons, from 1 to 8 carbons, 1 to 6 carbons, or 1 to 4 carbon atoms. For example, C₁₋₆ alkyl refers to an aliphatic hydrocarbon having 1 to 6 carbons, which includes methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and the like.

As used herein, the term “hydroxy” is defined as —OH.

As used herein, the term “alkoxy,” unless particularly defined herein, refers to a radical formed by substituting the hydrogen atom of a hydroxyl group with an alkyl. For example, C₁₋₆ alkoxy includes methoxy, ethoxy, propoxy, n-butoxy, n-pentyloxy, isopropoxy, sec-butoxy, tert-butoxy, neopentyloxy, isopentyloxy, and the like. An aralkoxy group is an alkoxy group substituted with an aryl group. One non-limiting example of an aralkoxy group is a substituted or unsubstituted benzyloxy group.

In addition, the term “halogen” refers to fluorine, bromine, chlorine, and iodine.

In addition, the term “amino” is defined as —NH₂, and the term “alkylamino” refers to a mono- or di-alkyl substituted amino. For example, C₁₋₆ alkylamino includes mono- or di-C₁₋₆ alkyl substituted amino.

In addition, the term “alkylthio” is defined as —SR (wherein R is alkyl), and the term “cyano” is defined as —CN.

Those of skill in the art will appreciate that compounds of the present technology may exhibit the phenomena of tautomerism, conformational isomerism, geometric isomerism and/or optical isomerism. As the formula drawings within the specification and claims can represent only one of the possible tautomeric, conformational isomeric, optical isomeric or geometric isomeric forms, it should be understood that the present technology encompasses any tautomeric, conformational isomeric, optical isomeric and/or geometric isomeric forms of the compounds having one or more of the utilities described herein, as well as mixtures of these various different forms. As used herein, “isomer” refers to a tautomer, conformation isomer, optical isomer, geometric isomer, or any combination thereof, of a compound. Structural isomers are not included in the meaning of “isomer” as used herein.

As readily understood by one skilled in the art, a wide variety of functional groups and other structures may exhibit tautomerism, and all tautomers of compounds as described herein are within the scope of the present technology.

Stereoisomers of compounds, also known as “optical isomers,” include all chiral, diastereomeric, and racemic forms of a structure, unless the specific stereochemistry is expressly indicated. Thus, compounds used in the present technology include enriched or resolved optical isomers at any or all stereogenic atoms as are apparent from the depictions. Both racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these are all within the scope of the present technology.

By “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. When the term “pharmaceutically acceptable” is used to refer to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.

Generally, reference to a certain moiety capable of being protected (such as hydroxy, amine, carbonyl, etc.) includes the protected groups in some embodiments of the disclosure. For example, in some embodiments, an —OH moiety as included herein also includes —OP, where P is a protecting group. Protecting groups, as referred to herein may be selected by one of ordinary skill in the art, and include the groups and strategies set forth in the art, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Greene's protective groups in organic synthesis, John Wiley & Sons (2006); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

“Subject” refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. “Subject” and “patient” may be used interchangeably, unless otherwise indicated. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

The terms “therapeutically effective amount” and “effective amount” are used interchangibly and refer to an amount of a compound that is sufficient to effect treatment as defined below, when administered to a patient (e.g., a human) in need of such treatment in one or more doses. The therapeutically effective amount will vary depending upon the patient, the disease being treated, the weight and/or age of the patient, the severity of the disease, or the manner of administration as determined by a qualified prescriber or care giver.

The term “treatment” or “treating” means administering a compound disclosed herein for the purpose of: (i) delaying the onset of a disease, that is, causing the clinical symptoms of the disease not to develop or delaying the development thereof, (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or (iii) relieving the disease, that is, causing the regression of clinical symptoms or the severity thereof.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this present technology belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present technology, representative illustrative methods and materials are described herein.

The present technology provides a compound having inhibitory activity on VAP-1 or its salt, that is, a compound of Formula X:

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

n is 0, 1 or 2; and

A is an aryl group or a heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic; and wherein said aryl group or said heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R; and

R is a substituted or unsubstituted cyclic ring, optionally containing 1 to 5 heteroatom ring members chosen from O, N, or S, and said cyclic ring is aromatic or non-aromatic.

In another aspect, provided herein is a compound of Formula Y:

or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

wherein

n is 0, 1 or 2,

A is an aryl or heteroaryl group selected from the group consisting of phenyl, pyridine, pyrazine, thiophene, and benzothiophene,

wherein said aryl or heteroaryl group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R,

wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 3,4-dihydro-1,4-benzoxazine, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene,

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, pyrrolidinonyl, and pyrrolidinyl.

In some embodiments of a compound of Formula X or Y, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In another aspect, provided herein is a compound of Formula 1:

or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

wherein

n is 0, 1 or 2,

A is an aryl or heteroaryl group selected from the group consisting of phenyl, pyridine, pyrazine, and thiophene, wherein said aryl or heteroaryl group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R,

wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 3,4-dihydro-1,4-benzoxazine, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, and pyrido[3,2-b][1,4]oxazin-3-one,

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, and pyrazolyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is aryl optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is phenyl substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is a heterocyclic group having 1 to 5 heteroatom ring members chosen from O, N, or S; said heterocyclic group is aromatic or non-aromatic; and said heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is a heteroaryl group having 1 to 5 heteroatom ring members chosen from O, N, or S; and said heteroaryl group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is pyridine, pyrazine, or thiophene, wherein A is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C═C—R.

In the compound of Formulas X, Y, or 1, or the stereoisomer thereof, or its pharmaceutically acceptable salt thereof according to the present technology, n may preferably be 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

Further, in the compound of Formulas X, Y, or 1, or the stereoisomer thereof, or its pharmaceutically acceptable salt thereof according to the present technology, A may preferably be phenyl, pyridine, or thiophene, each of which is optionally substituted as described above.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is phenyl, optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In further embodiments, A is phenyl substituted with —R. In some embodiments, A is phenyl substituted with —CH═CH—R or —C≡C—R. In some embodiments, A is phenyl substituted with —CH═CH—R. In some embodiments, A is phenyl substituted with —C═C—R. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one, wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is pyridine, optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In further embodiments, A is pyridine substituted with —R. In some embodiments, A is pyridine substituted with —CH═CH—R or —C≡C—R. In some embodiments, A is pyridine substituted with —CH═CH—R. In some embodiments, A is pyridine substituted with —C≡C—R. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrimidine, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrimidine, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene, wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is thiophene, optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In further embodiments, A is thiophene substituted with —R. In some embodiments, A is thiophene substituted with —CH═CH—R or —C≡C—R. In some embodiments, A is thiophene substituted with —CH═CH—R. In some embodiments, A is thiophene substituted with —C≡C—R. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 2,3-dihydro-1,4-benzoxazine, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, pyrido[2,3-b][1,4]oxazin-2-one, and 1,4-dihydroquinazolin-2-one. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 2,3-dihydro-1,4-benzoxazine, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, pyrido[2,3-b][1,4]oxazin-2-one, and 1,4-dihydroquinazolin-2-one; wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, A is benzothiophene, optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R. In further embodiments, A is benzothiophene substituted with —R. In some embodiments, A is benzothiophene substituted with —CH═CH—R or —C≡C—R. In some embodiments, A is benzothiophene substituted with —CH═CH—R. In some embodiments, A is benzothiophene substituted with —C≡C—R. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one. In still further embodiments, —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one; wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

Further, in the compound of Formulas X, Y, or 1, or the stereoisomer thereof, or its pharmaceutically acceptable salt thereof according to the present technology, said aryl or heteroaryl group may preferably be substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, and —R. Preferably, said R may be a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, and 3,4-dihydroquinolin-2-one. More preferably, said cyclic ring may be substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl.

In one embodiment of the present technology, a compound, wherein n is 0; A is phenyl; said phenyl is substituted with one or two substituents selected from the group consisting of halogen and —R; said R is a cyclic ring selected from the group consisting of benzene, pyridine, 3,4-dihydroquinolin-2-one, and pyrazole; and said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl; or a pharmaceutically acceptable salt thereof is provided.

In another embodiment of the present technology, a compound wherein n is 0; wherein A is pyridine; wherein said pyridine is substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, and —R; wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, 3,4-dihydroquinolin-2-one, and pyrazole;

wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl, or a pharmaceutically acceptable salt thereof is provided.

In another embodiment of the present technology, a compound wherein n is 0; A is thiophene; wherein said thiophene is substituted with one or two cyclic rings selected from the group consisting of benzene, pyridine, pyridin-2-one, 3,4-dihydroquinolin-2-one, and pyrazole; and said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl; or a pharmaceutically acceptable salt thereof is provided.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted benzene. In some embodiments, R is benzene substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, pyrrolidinonyl, and pyrrolidinyl. In some embodiments, R is benzene substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted pyridine. In some embodiments, R is pyridine substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted tetrahydropyridine. In some embodiments, R is tetrahydropyridine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted pyridin-2-one. In some embodiments, R is pyridin-2-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted pyrimidine. In some embodiments, R is pyrimidine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted imidazole. In some embodiments, R is imidazole, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted pyrazole. In some embodiments, R is pyrazole, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted benzodioxole. In some embodiments, R is benzodioxole, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted benzoxadiazole. In some embodiments, R is benzoxadiazole, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted benzothiazole. In some embodiments, R is benzothiazole, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted indazole. In some embodiments, R is indazole, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 1,3-dihydroindol-2-one. In some embodiments, R is 1,3-dihydroindol-2-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted quinolin-2-one. In some embodiments, R is quinolin-2-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 3,4-dihydroisoquinolin-1-one. In some embodiments, R is 3,4-dihydroisoquinolin-1-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 3,4-dihydroquinolin-2-one. In some embodiments, R is 3,4-dihydroquinolin-2-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 3,4-dihydro-1,4-benzoxazine. In some embodiments, R is 3,4-dihydro-1,4-benzoxazine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 2,3-dihydro-1,4-benzoxazine. In some embodiments, R is 2,3-dihydro-1,4-benzoxazine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 1,4-benzoxazin-3-one. In some embodiments, R is 1,4-benzoxazin-3-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 1,4-dihydro-3,1-benzoxazin-2-one. In some embodiments, R is 1,4-dihydro-3,1-benzoxazin-2-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 5,6,7,8-tetrahydronaphthyridine. In some embodiments, R is 5,6,7,8-tetrahydronaphthyridine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted triazolo[1,5-a]pyridine. In some embodiments, R is triazolo[1,5-a]pyridine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 2,3-dihydro-pyrido[2,3-b][1,4]oxazine. In some embodiments, R is 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 3,4-dihydro-pyrido[3,2-b][1,4]oxazine. In some embodiments, R is 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted pyrido[2,3-b][1,4]oxazin-2-one. In some embodiments, R is pyrido[2,3-b][1,4]oxazin-2-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted pyrido[3,2-b][1,4]oxazin-3-one. In some embodiments, R is pyrido[3,2-b][1,4]oxazin-3-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 1,4-dihydroquinazolin-2-one. In some embodiments, R is 1,4-dihydroquinazolin-2-one, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted 1H-pyrrolo[2,3-b]pyridine. In some embodiments, R is 1H-pyrrolo[2,3-b]pyridine, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted benzoxazole. In some embodiments, R is benzoxazole, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In some embodiments of a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, R is substituted or unsubstituted thiophene. In some embodiments, R is thiophene, optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

In another aspect, provided herein is a compound of Formula 12

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments of a compound of Formula 12, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is phenyl substituted with triazolyl, C₁₋₆ alkylsulfonyl, or piperazinyl. In other embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 12, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is substituted or unsubstituted pyrazole. In further embodiments, R² is pyrazole substituted with C₁₋₆ alkyl or difluoromethyl.

In another aspect, provided herein is a compound of Formula 13

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aralkoxy group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments of a compound of Formula 13, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aralkoxy group. In further embodiments, R² is substituted or unsubstituted benzyloxy.

In some embodiments of a compound of Formula 13, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In other embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 13, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is substituted or unsubstituted pyrazole. In further embodiments, R² is pyrazole substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 13, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is substituted or unsubstituted pyridin-2-one. In further embodiments, R² is pyridin-2-one substituted with C₁₋₆ alkyl.

In another aspect, provided herein is a compound of Formula 14

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments of a compound of Formula 14, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, the compound is of Formula 14a

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

In some embodiments of a compound of Formula 14, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, the compound is of Formula 14b

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

In some embodiments of a compound of Formula 14, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, the compound is of Formula 14c

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

In some embodiments of a compound of Formula 14, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is phenyl substituted with one to three substituents selected from the group consisting of with halogen, C₁₋₆ alkoxy, mono- or di-C₁₋₆ alkylamino, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, morpholinylcarbonyl, piperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, and pyrrolidinonyl. In other embodiments, R² is benzodioxole, benzoxadiazole, benzothiazole, indazole, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, 3,4-dihydroquinolin-2-one, or benzoxazole, wherein R² is optionally substituted with C₁₋₆ alkyl or amino.

In some embodiments of a compound of Formula 14, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with C₁₋₆ alkoxy, trifluoromethyl, piperazinyl, morpholinyl, or mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is pyrimidine, 1H-pyrrolo[2,3-b]pyridine, pyrazole, or thiophene, wherein R² is optionally substituted with C₁₋₆ alkyl, difluoromethyl, C₁₋₆ alkoxy-C₁₋₆ alkylamino, or C₁₋₆ alkylcarbonyl.

In some embodiments of a compound of Formula 14, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is substituted or unsubstituted pyridin-2-one. In further embodiments, R² is pyridin-2-one substituted with C₁₋₆ alkyl.

In another aspect, provided herein is a compound of Formula 15

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S group.

In some embodiments of a compound of Formula 15, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is 2,3-dihydro-1,4-benzoxazine or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 15, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with morpholinyl or mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, or pyrazole, wherein said pyrazole is optionally substituted with C₁₋₆ alkyl.

In another aspect, provided herein is a compound of Formula 16

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments of a compound of Formula 16, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In other embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 16, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is substituted or unsubstituted pyrazole. In further embodiments, R² is pyrazole substituted with C₁₋₆ alkyl.

In another aspect, provided herein is a compound of Formula 17

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments of a compound of Formula 17, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is phenyl substituted with one to three substituents selected from the group consisting of C₁₋₆ alkoxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylsulfonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, mono- or di-C₁₋₆ alkylaminocarbonyl, morpholinylcarbonyl, pyrazolyl, triazolyl, piperazinyl, and acetylpiperazinyl. In some embodiments, R² is phenyl substituted with one to three substituents selected from the group consisting of C₁₋₆ alkoxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylsulfonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, mono- or di-C₁₋₆ alkylaminocarbonyl, morpholinylcarbonyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, piperazinyl, and acetylpiperazinyl. In other embodiments, R² is 3,4-dihydroisoquinolin-1-one, quinolin-2-one, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, benzothiazole, benzoxadiazole, indazole, benzodioxole, 1,3-dihydroindol-2-one, or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkylcarbonylamino, or halogen.

In some embodiments of a compound of Formula 17, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with one to three substituents selected from the group consisting of halogen, trifluoromethyl, C₁₋₆ alkoxy, piperazinyl and mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is substituted or unsubstituted pyrazole. In further embodiments, R² is pyrazole substituted with C₁₋₆ alkyl, difluoromethyl, benzyl, (cycloalkyl)alkyl, alkylsulfonyl, or cycloalkylsulfonyl. In other embodiments, R² is 5,6,7,8-tetrahydronaphthyridine, pyrimidine, imidazole, or triazolo[1,5-a]pyridine; wherein R² is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, and C₁₋₆ alkoxy-C₁₋₆ alkylamino.

In some embodiments of a compound of Formula 17, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is tetrahydropyridine or pyridin-2-one, wherein said tetrahydropyridine and said pyridin-2-one are optionally substituted with C₁₋₆ alkyl or C₁₋₆ alkylcarbonyl.

In another aspect, provided herein is a compound of Formula 18

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments of a compound of Formula 18, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In other embodiments, R² is 2,3-dihydro-1,4-benzoxazine or 3,4-dihydroquinolin-2-one.

In some embodiments of a compound of Formula 18, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with morpholinyl or mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is substituted or unsubstituted pyrazole. In further embodiments, R² is pyrazole substituted with C₁₋₆ alkyl. In other embodiments, R² is 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, or pyrido[3,2-b][1,4]oxazin-3-one.

In another aspect, provided herein is a compound of Formula 19

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

In some embodiments of a compound of Formula 19, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In other embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 19, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is substituted or unsubstituted pyrazole. In further embodiments, R² is pyrazole substituted with C₁₋₆ alkyl.

In another aspect, provided herein is a compound of Formula 20

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

In some embodiments of a compound of Formula 20, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted aryl group. In further embodiments, R² is substituted or unsubstituted phenyl. In still further embodiments, R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl. In other embodiments, R² is benzodioxole or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 20, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S. In further embodiments, R² is substituted or unsubstituted pyridine. In still further embodiments, R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino. In other embodiments, R² is substituted or unsubstituted pyrazole. In further embodiments, R² is pyrazole substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formula 20, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R² is a substituted or unsubstituted pyridine-2-one. In further embodiments, R² is pyridine-2-one substituted with C₁₋₆ alkyl.

In some embodiments of a compound of Formulas 12, 13, 14, 15, 16, 17, 18, 19, or 20, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R¹ is hydrogen.

In some embodiments of a compound of Formulas 12, 13, 14, 15, 16, 17, 18, 19, or 20, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R¹ is halogen.

In some embodiments of a compound of Formulas 12, 13, 14, 15, 16, 17, 18, 19, or 20, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, R¹ is C₁₋₆ alkyl.

The compounds provided in the description are inhibitors of VAP-1. VAP-1 inhibition may be measured, for example, by determining the half maximal inhibitory concentration (IC₅₀). One method for determining an IC₅₀ for VAP-1 is provided herein.

In one embodiment, the compounds are inhibitors of VAP-1. Selectivity may be determined, for example, by comparing inhibition of VAP-1 to inhibition of other aminooxidaxes such as MAO-A (monoamine oxidase-A), MAO-B (monoamine oxidase-B), and DAO (diamine oxidase). In one embodiment, said “significantly high inhibitory activity” means that IC₅₀ for VAP-1 obtained from the in vitro enzyme assay test is at least 3000 times lower than IC₅₀ of MAO-A, at least 100 times lower than IC₅₀ of MAO-B, and at least 100 times lower than IC₅₀ of DAO. In an alternative embodiment, “significantly high inhibitory activity” means the IC₅₀ for VAP-1 obtained from the in vitro enzyme analysis (in vitro enzyme assay) test is at least 3000 times lower than IC₅₀ of MAO-A, at least 100 times lower than IC₅₀ of MAO-B, or at least 100 times lower than IC₅₀ of DAO.

In another aspect, a compound of Formulas X, Y, or 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is selected from the following compounds or a pharmaceutically acceptable salt thereof:

-   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-fluorophenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(3-bromophenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(3,4-difluorophenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-3-fluoro-phenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-fluoro-phenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-methyl-phenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-3-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(2-bromo-4-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromo-3-methyl-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-4-methyl-3-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-5-methyl-3-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromo-3-fluoro-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-3-methyl-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromopyrazin-2-yl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(dimethylamino)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1,3-benzodioxol-5-yl)phenyl]-1,2,4-triazol-3-one; -   6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-ethylpyrazol-4-yl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-3-fluoro-phenyl]-1,2,4-triazol-3-one;     2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-3-fluoro-phenyl]-1,2,4-triazol-3-one;     6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-fluoro-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one;     2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-3-fluoro-phenyl]-1,2,4-triazol-3-one;     2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-2-fluoro-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-2-fluoro-phenyl]-1,2,4-triazol-3-one; -   6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-fluoro-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-2-fluoro-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-methylsulfonylphenyl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-piperazin-1-ylphenyl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(trifluoromethyl)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-3-pyridyl]-1,2,4-triazol-3-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1-ethylpyrazol-4-yl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   6-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-4-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(4-methylsulfonylphenyl)-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(4-piperazin-1-ylphenyl)-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[6-(dimethylamino)-3-pyridyl]-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(1,3-benzodioxol-5-yl)-4-pyridyl]-1,2,4-triazol-3-one; -   6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(1-ethylpyrazol-4-yl)-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(dimethylamino)-3-pyridyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-methyl-6-(4-methylsulfonylphenyl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-methyl-6-[6-(trifluoromethyl)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-5-methyl-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-5-methyl-3-pyridyl]-1,2,4-triazol-3-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)-3-fluoro-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-fluoro-3-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-fluoro-3-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)-3-fluoro-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(4-methylsulfonylphenyl)-pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(4-piperazin-1-ylphenyl)pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(trifluoromethyl)-3-pyridyl]pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(dimethylamino)-3-pyridyl]pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)pyrazin-2-yl]-1,2,4-triazol-3-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]pyrazin-2-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(4-benzyloxyphenyl)methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(5-bromo-2-thienyl)methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(4-bromo-2-thienyl)methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(5-bromo-3-methyl-2-thienyl)methyl]-1,2,4-triazol-3-one; -   4-[[5-(4-acetylphenyl)-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methylsulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3-methyl     sulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   3-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N,N-dimethyl-benzenesulfonamide; -   4-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N-methyl-benzamide; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3,4,5-trimethoxyphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   4-[[5-[4-(4-acetylpiperazin-1-yl)phenyl]-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-morpholine-4-carbonyl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1H-pyrazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(6-methoxy-3-pyridyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(6-piperazin-1-yl-3-pyridyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-5-fluoro-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-aminopyrimidin-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-ethoxypyrimidin-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2-methoxyethylamino)pyrimidin-5-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-chloro-3-methyl-imidazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-methyl-pyridin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-ethyl-pyridin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-isopropyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1H-indazol-6-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2,1,3-benzoxadiazol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-7-fluoro-indolin-2-one; -   N-[6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,3-benzothiazol-2-yl]acetamide; -   7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3,4-dihydro-2H-isoquinolin-1-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-methyl-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-fluoro-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-fluoro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(5-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-4H-1,4-benzoxazin-3-one; -   7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-4-methyl-1,4-benzoxazin-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-methyl     sulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(dimethylamino)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1,3-benzodioxol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-ethylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-(4-methylsulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one; -   7-[(E)-2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]vinyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-[6-(dimethylamino)-3-pyridyl]ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(6-morpholino-3-pyridyl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   7-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one; -   7-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(2-thienyl)ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(4-methyl     sulfonylphenyl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(4-piperazin-1-ylphenyl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-[6-(dimethylamino)-3-pyridyl]-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(1,3-benzodioxol-5-yl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(1-ethylpyrazol-4-yl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   3-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N,N-dimethyl-benzamide; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3-methyl-1,4-dihydroquinazolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[1-(difluoromethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-isopropylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-3-methyl-1,4-dihydroquinazolin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-isopropyl-pyridin-2-one; -   4-[[4-[4-(4-acetylpiperazin-1-yl)phenyl]-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-8-fluoro-1H-quinolin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-methyl-pyridin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-3,4-dihydro-1H-quinolin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[1-(difluoromethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-isopropylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(4-piperazin-1-ylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-[6-(trifluoromethyl)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-[6-(dimethylamino)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(1,3-benzodioxol-5-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-6-yl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-6-yl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(1-ethylpyrazol-4-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-piperazin-1-ylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   5-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(6-piperazin-1-yl-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[4-(morpholine-4-carbonyl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(6-morpholino-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(3-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[3-(dimethylamino)-4-fluoro-phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   5-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-ethyl-pyridin-2-one; -   7-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(6-piperazin-1-yl-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-4H-1,4-benzoxazin-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2-methoxyethylamino)pyrimidin-5-yl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3,4,5-trimethoxyphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(6-methoxy-3-pyridyl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   4-[5-(2-amino-1,3-benzothiazol-5-yl)-3-methyl-2-pyridyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(2,1,3-benzoxadiazol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzoxazol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[4-(2-oxopyrrolidin-1-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   4-[5-(5-acetyl-2-thienyl)-3-methyl-2-pyridyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[3-(1H-pyrazol-3-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1H-indazol-6-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[4-(morpholine-4-carbonyl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-morpholinophenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   4-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-N,N-dimethyl-benzenesulfonamide; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-[6-(dimethylamino)-3-pyridyl]ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[2-(6-morpholino-3-pyridyl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one; -   7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one; -   6-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-3-methyl-1,4-dihydroquinazolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[1-(difluoromethyl)pyrazol-4-yl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-isopropylpyrazol-4-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(dimethylamino)-3-pyridyl]-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1,3-benzodioxol-5-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one; -   6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl-phenyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-ethylpyrazol-4-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[1-(difluoromethyl)pyrazol-4-yl]-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-isopropylpyrazol-4-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-[3-(1H-1,2,4-triazol-3-yl)phenyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-piperazin-1-ylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   6-[4-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   5-[4-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   6-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-methyl-3,4-dihydroquinolin-2-one; -   5-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(4-piperazin-1-ylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-methyl-3,4-dihydroquinolin-2-one; -   5-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[4-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[4-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[3-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[4-(1-ethylpyrazol-4-yl)phenyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[3-(1-ethylpyrazol-4-yl)phenyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1H-pyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methylsulfonylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-cyclopropylsulfonylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[1-(cyclopropylmethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-benzylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-fluoro-5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4-fluoro-2-thienyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-3-fluoro-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4-fluoro-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-3-fluoro-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-(2-(aminomethyl)-3,3-difluoroallyl)-4-((5-(6-(dimethylamino)pyridin-3-yl)-3-fluorothiophen-2-yl)methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;     and -   6-(5-((1-(2-(aminomethyl)-3,3-difluoroallyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)methyl)-4-fluorothiophen-2-yl)-8-methyl-3,4-dihydroquinolin-2(1H)-one.

As for the compound of Formula 1, or its stereoisomer, or its pharmaceutically acceptable salt, the more preferred compound may be a compound selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof:

-   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-fluorophenyl)-1,2,4-triazol-3-one;     and -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-fluoro-phenyl)-1,2,4-triazol-3-one.

The compound of Formula 1 of the present technology can be in the form of a pharmaceutically acceptable salt. The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds of the present technology which are water or oil-soluble or dispersible; which are suitable for treatment of diseases without undue toxicity, irritation, and allergic-response; which are commensurate with a reasonable benefit/risk ratio; and which are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by, for example, reacting the appropriate compound in the form of the free base with a suitable acid. Such salts include conventional acid addition salts, e.g., a salt derived from inorganic acid such as hydrochloric acid, bromic acid, sulfuric acid, sulfamic acid, phosphoric acid, or nitric acid and a salt derived from organic acid such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, citric acid, maleic acid, malonic acid, methanesulfonic acid, tartaric acid, malic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, 2-acetoxybenzoic acid, fumaric acid, p-toluenesulfonic acid, oxalic acid or trifluoroacetic acid. Further, said salts include conventional metal salt types, e.g., a salt derived from a metal such as lithium, sodium, potassium, magnesium, or calcium. Said acid addition salt or metal salt can be prepared according to conventional methods.

The compound of Formulas X, Y, or 1, or the stereoisomer thereof, or a salt thereof according to the present technology may be prepared by various methods. For example, the compound of Formula 1, or a stereoisomer thereof, or a salt thereof according to the present technology can be prepared by a preparation process comprising the step of reacting a compound of Formula 2 with a compound of Formula 3a or a compound of Formula 3b to obtain a compound of Formula 1a; and the step of deprotecting said compound of Formula 1a.

In said Formulae 1, 1a, 2,3a and 3b, Boc is an amine protecting group (e.g., tert-butoxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), benzyloxycarbonyl (CBZ), triphenylmethyl (trityl), etc.), A′ is an aryl or heteroaryl group selected from the group consisting of phenyl, pyridine, pyrazine, and thiophene; Z is a boronic acid (B(OH)₂) or boronic acid pinacol ester, R′ is one or two groups chosen from C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, or —C≡C—R, and A and R are the same as defined above.

The reaction of the compound of Formula 2 above with a commercially available compound of Formula 3a may be carried out via Suzuki reaction. Said reaction can be carried out by using a palladium catalyst. The palladium catalyst includes palladium diacetate (Pd(OAc)₂), tris(dibenzylideneacetone)dipalladium (Pd₂(dba)₃), tetrakis(triphenylphosphine)palladium (Pd(PPh₃)₄) or palladiumdi[1,1′-bis(diphenylphosphino)ferrocene]dichloride (PdCl₂(dppf)₂), etc. In the reaction carried out under a palladium catalyst, a ligand and a base can be added in addition to the palladium catalyst. Said ligand includes (S)-2,2-bis(diphenylphospino)-1,1-binaphthyl(BINAP), 1,1′-bis(diphenylphospino)ferrocene (dppf), (tri-O-tolyl)phosphine (P(O-Tol)₃), or the like and said base includes an inorganic base such as cesium carbonate (Cs₂CO₃), sodium carbonate (Na₂CO₃), potassium carbonate (K₂CO₃), potassium fluoride (KF), cesium fluoride (CsF), sodium hydroxide (NaOH), potassium phosphonate (K₃PO₄), sodium tert-butoxide (tert-BuONa), potassium tert-butoxide (tert-BuOK), or the like. The reaction may be carried out in a non-polar organic solvent such as benzene or toluene, or a polar solvent such as dioxane, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, N,N-dimethylformamide, or the like, at a temperature ranging from 50° C. to 150° C., preferably from 80° C. to 110° C. Other reaction conditions, including e.g., reaction time, may be determined from the reaction conditions for conventional Suzuki reaction (Barbara Czako and Laszlo Kurti, STRATEGIC APPLICATIONS of NAMED REACTIONS in ORGANIC SYNTHESIS, 2005). Further, the reaction of the compound of Formula 2 with a commercially available compound of Formula 3b (i.e., an ethyne derivative) can be carried out via Sonogashira coupling reaction using a palladium reagent such as bis(triphenylphosphine)palladium(II) dichloride, tetrakis(triphenylphosphine)palladium(0), etc., and a copper iodide. The coupling reaction may be carried out at room temperature or a heated temperature, e.g., a temperature ranging from 20° C. to 60° C. In addition, in order to improve reaction rate and reaction yield, said coupling reaction can be carried out in the presence of a base such as a diisopropylamine, a triethylamine, etc., and a ligand such as triphenylphosphine or the like.

Deprotection of the compound of Formula 1a can be carried out according to conventional methods (e.g., Theodora W. Greene and Peter G. M. Wuts, Protective groups in organic synthesis, 3rd Ed., 1999). For example, said amine protecting group in an organic solvent such as dichloromethane, dioxane, ethyl acetate, etc., can be removed by using an acid such as trifluoroacetate or hydrochloric acid gas at room temperature.

The compound of Formula 2 can be prepared according to the following Reaction Scheme 1.

In Reaction Scheme 1, A′, n, and Boc are the same as defined in the above.

A compound of Formula 4 is commercially available. The compound of Formula 4 can be converted to a compound of Formula 5 via nucleophilic acylsubstitution reaction. Said nucleophilic acylsubstitution reaction can be carried out at 0° C. to room temperature by using pyridine, triethylamine, or the like in a solvent such as ethyl acetate, tetrahydrofuran, etc. (Chunquan Sheng; Xiaoying Che; Wenya Wang; Shengzheng Wang; Yongbing Cao; Zhenyuan Miao; Jianzhong Yao; Wannian Zhang, European Journal of Medicinal Chemistry, 46, 5276-5282, 2011).

The compound of Formula 5 can be converted to a compound of Formula 6 via hydrazinolysis reaction. The hydrazinolysis reaction can be carried out according to known methods (e.g., WO 2005/014583, etc.).

The compound of Formula 6 can be converted to a compound of Formula 10 via cyclization reaction. The cyclization reaction can be carried out at room temperature to 80° C. by using a formamidineacetate and an acetic acid in N,N-dimethylformamide or 1-propanol (Chunquan Sheng; Xiaoying Che; Wenya Wang; Shengzheng Wang; Yongbing Cao; Zhenyuan Miao; Jianzhong Yao; Wannian Zhang, European Journal of Medicinal Chemistry, 46, 5276-5282, 2011).

In another method, the compound of Formula 4 can be converted to a compound of Formula 10 via cyclization reaction with a compound of Formula 7. Said cyclization reaction can be performed in a solvent such as methanol, N,N-dimethylformamide, or the like, by using sodium methoxide or potassium hydroxide at a temperature between 50° C. to 150° C. The compound of Formula 7 above can be prepared by formylation reaction of a commercially available ethyl carbazate. Said formylation reaction may preferably be orthoester reaction, which can be carried out, for example, by using triethyl orthoformate or trimethyl orthoformate. Said formylation reaction can be performed in a solvent such as methanol, N,N-dimethylformamide, or the like at a temperature between 80° C.−150° C.

In another method, the compound of Formula 8 also can be converted to a compound of Formula 10 via C—N alkylation reaction with a compound of Formula 9. The compound of Formula 8 and Formula 9 are both commercially available. Said alkylation reaction can be performed in organic solvent such as N,N-dimethylformamide or the like, by using sodium hydride or potassium carbonate at a temperature between 20° C. to 60° C.

The reaction of the compound of Formula 10 above with a compound of Formula 11 can be carried out via Mitsunobu reaction. For example, said reaction can be carried out in the presence of triphenylphosphine or trin-butylphosphine using diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD). The reaction solvent may be a polar organic solvent such as dichloromethane, dioxane, tetrahydrofuran, dimethylformamide, etc. The reaction may be carried out at 0° C. to room temperature, and can be carried out at a higher temperature on occasion. Other reaction conditions including reaction time may be determined from the reaction conditions for conventional Mitsunobu reaction (Barbara Czako and Laszlo Kurti, STRATEGIC APPLICATIONS of NAMED REACTIONS in ORGANIC SYNTHESIS, 2005).

The compound of Formula 11 can be prepared according to the following Reaction Scheme 2.

In Reaction Scheme 2, TBDMS is tert-butyldimethylsilyl, which is a hydroxyl protecting group and Boc is the same as defined in the above.

A compound of Formula 11a is commercially available and can be prepared according to known methods (e.g., WO 2013/163675, etc.). The compound of Formula 11a can be converted to a compound of Formula 11b via gem-difluoroolefination reaction. The gem-difluoroolefination reaction can be carried out in the presence of a base such as potassium tert-butoxide (tert-BuOK), lithium bis(trimethylsilyl)amide (LiHMDS), or the like using a fluorinated sulfone such as difluoromethyl 2-pyridyl sulfone. The reaction solvent may be an organic solvent such as dimethylformamide, tetrahydrofuran, or the like and the reaction can be carried out at a temperature between −40° C.-0° C. (Yanchuan Zhao; Weizhou Huang; Lingui Zhu; Jinbo Hu, Organic Letters, 12, 1444-1447, 2010), etc.

The compound of Formula 1b can be converted to a compound of Formula 11 via deprotection reaction of a hydroxyl protecting group (TBDMS). The deprotection reaction of a hydroxyl protecting group can be carried out according to known methods (Theodora W. Greene and Peter G. M. Wuts, Protective groups in organic synthesis, 3rd Ed., 1999). For example, the deprotection group of a hydroxyl protecting group (TBDMS) can be carried out in a solvent such as dichloromethane, tetrahydrofuran, or the like, using an organic salt such as tetrabutylamoniumfluoride (TBAF), etc., at room temperature.

The 3,3-difluoroallylamines according to the present technology, i.e., a compound of Formulas X, Y, 1, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, have an inhibitory activity on VAP-1, and thus can be usefully applied in the prevention or treatment of a disease mediated by VAP-1. Preferably, the compound of Formulas X, Y, 1, 12, 13, 14, 15, 16, 17, 18, 19, or 20, according to the present technology, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof can be usefully applied for the prevention of treatment of nonalcoholic steatohepatitis (NASH).

In some embodiments, provided herein is the use of the 3,3-difluoroallylamines according to the present technology, i.e., the compound of Formulas X, Y, 1, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the prophylaxis and/or treatment of lipid and lipoprotein disorders (such as, but not limited to, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis), of conditions and diseases which result from chronic fatty and fibrotic degeneration of organs due to accumulated lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways (such as, but not limited to, NASH and chronic cholestatic conditions in the liver, Glomerulosclerosis and Diabetic Nephropathy in the kidney, Macular Degeneration and Diabetic Retinopathy in the eye and neurodegenerative diseases, such as Alzheimer's Disease in the brain, or Diabetic Neuropathies in the peripheral nervous system), of Type I or Type II Diabetes and clinical complications of Type I and Type II Diabetes (such as, but not limited to, Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathies, or Peripheral Arterial Occlusive Disease (PAOD)), of chronic intrahepatic or some forms of extrahepatic cholestatic conditions, of liver fibrosis, of acute intraheptic cholestatic conditions, of obstructive or chronic inflammatory disorders that arise out of improper bile composition (such as, but not limited to, cholelithiasis also known as cholesterol gallstones), of gastrointestinal conditions with a reduced uptake of dietary fat and fat-soluble dietary vitamins, of inflammatory bowel diseases, of obesity and metabolic syndrome (combined conditions of dyslipidemia, diabetes and abnormally high body-mass index), of persistent infections by intracellular bacteria or parasitic protozoae, of non-malignant hyperproliferative disorders, of malignant hyperproliferative disorders (such as, but not limited to, different forms of cancer, specifically certain forms of breast, liver or colon cancer, or a disorder selected from the group consisting of hepatocellular carcinoma, colon adenoma, and polyposis), of colon adenocarcinoma and hepatocellular carcinoma in particular, of liver steatosis and associated syndromes, of Hepatitis B infection, of Hepatitis C infection and/or of cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis, of liver failure or liver malfunction as an outcome of chronic liver diseases or of surgical liver resection, of acute myocardial infarction, of acute stroke, of thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis, of osteoarthritis, of rheumatoid arthritis, of psoriasis, or of cerebral infarction, individually or of any combination thereof.

In some embodiments, the compounds and/or pharmaceutical compositions disclosed herein are used for prophylaxis and/or treatment of chronic intrahepatic conditions, such as Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), progressive familiar cholestasis (PFIC), alcohol-induced cirrhosis and associated cholestasis, and some forms of extrahepatic cholestatic conditions, or liver fibrosis.

In some embodiments, provided herein is a method to treat chronic intrahepatic conditions and/or some forms of extrahepatic cholestatic conditions in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, the chronic intrahepatic conditions are selected from PBC, PSC, PFIC, and alcohol-induced cirrhosis and associated cholestasis.

In some embodiments, provided herein is a method to treat liver fibrosis in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat a lipid and lipoprotein disorder in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, the lipid and lipoprotein disorder is selected from hypercholesterolemia, hypertriglyceridemia, and atherosclerosis.

In some embodiments, provided herein is a method to treat a condition or disease which results from chronic fatty and fibrotic degeneration of organs due to accumulated lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, the condition or disease which results from chronic fatty and fibrotic degeneration of organs due to accumulated lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways is selected from NASH and chronic cholestatic conditions in the liver, Glomerulosclerosis and Diabetic Nephropathy in the kidney, Macular Degeneration and Diabetic Retinopathy in the eye, and neurodegenerative diseases. In some further embodiments, neurodegenerative diseases are selected from Alzheimer's Disease in the brain, and Diabetic Neuropathies in the peripheral nervous system.

In some embodiments, provided herein is a method to treat Type I or Type II Diabetes and clinical complications of Type I and Type II Diabetes in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, provided herein is a method to treat Type I Diabetes in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, provided herein is a method to treat Type II Diabetes in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, provided herein is a method to treat one or more clinical complications of Type I and Type II Diabetes in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, the clinical complications of Type I and Type II Diabetes are selected from Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathies, and Peripheral Arterial Occlusive Disease (PAOD), or any combination thereof.

In some embodiments, provided herein is a method to treat acute intraheptic cholestatic conditions in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat obstructive or chronic inflammatory disorders that arise out of improper bile composition in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, the obstructive or chronic inflammatory disorders that arise out of improper bile composition is cholelithiasis also known as cholesterol gallstones.

In some embodiments, provided herein is a method to treat gastrointestinal conditions with a reduced uptake of dietary fat and fat-soluble dietary vitamins in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat inflammatory bowel diseases in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat obesity and metabolic syndrome in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat persistent infections by intracellular bacteria or parasitic protozoae in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat non-malignant hyperproliferative disorders in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat malignant hyperproliferative disorders in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein. In some embodiments, malignant hyperproliferative disorders are selected from different forms of cancer, specifically certain forms of breast, liver or colon cancer, or a disorder selected from the group consisting of hepatocellular carcinoma, colon adenoma, and polyposis.

In some embodiments, provided herein is a method to treat colon adenocarcinoma in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat hepatocellular carcinoma in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat liver steatosis and associated syndromes in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat Hepatitis B infection in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat Hepatitis C infection in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat liver failure or liver malfunction as an outcome of chronic liver diseases or of surgical liver resection in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat acute myocardial infarction in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat acute stroke in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat osteoarthritis in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat rheumatoid arthritis in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat psoriasis in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

In some embodiments, provided herein is a method to treat cerebral infarction in a patient in need thereof, the method comprising, consisting essentially of, or consisting of administering to the patient a therapeutically effective amount of a compound or a composition disclosed herein.

Thus, the present technology includes a pharmaceutical composition for inhibiting vascular adhesion protein-1 (VAP-1), comprising a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. In one embodiment, the present technology provides a pharmaceutical composition for preventing or treating nonalcoholic steatohepatitis (NASH), comprising a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. In some embodiments, provided herein is a pharmaceutical composition for preventing or treating NASH comprising, consisting essentially of, or consisting of a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

In another aspect, the present technology provides a pharmaceutical composition for preventing or treating diabetic nephropathy comprising, consisting essentially of, or consisting of a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

In another aspect, the present technology provides a pharmaceutical composition for preventing or treating primary sclerosing cholangitis comprising, consisting essentially of, or consisting of a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

In some embodiments, the compounds of the present disclosure may be combined with one or more additional therapies for the prevention or treatment of a disease or condition amenable to treatment by inhibition of VAP-1.

In some embodiments, the compositions disclosed herein contain at least one additional active agent.

Exemplary additional active agents include, but are not limited, one or more of a(n) ACE inhibitor, Acetyl CoA carboxylase inhibitor, Adenosine A3 receptor agonist, Adiponectin receptor agonist, AKT protein kinase inhibitor, AMP-activated protein kinases (AMPK), Amylin receptor agonist, Angiotensin II AT-1 receptor antagonist, Apoptosis Signaling Kinase 1 inhibitor, Autotaxin inhibitors, Bioactive lipid, Calcitonin agonist, Caspase inhibitor, Caspase-3 stimulator, Cathepsin inhibitor, Caveolin 1 inhibitor, CCR2 chemokine antagonist, CCR3 chemokine antagonist, CCR5 chemokine antagonist, Chloride channel stimulator, CNR1 inhibitor, Cyclin D1 inhibitor, Cytochrome P450 7A1 inhibitor, DGAT1/2 inhibitor, Dipeptidyl peptidase IV inhibitor, Endosialin modulator, Eotaxin ligand inhibitor, Extracellular matrix protein modulator, Farnesoid X receptor agonist, Fatty acid synthase inhibitors, FGF 1 receptor agonist, Fibroblast growth factor (FGF-15, FGF-19, FGF-21) ligands, Galectin-3 inhibitor, Glucagon receptor agonist, Glucagon-like peptide 1 agonist, G-protein coupled bile acid receptor 1 agonist, Hedgehog (Hh) modulator, Hepatitis C virus NS3 protease inhibitor, Hepatocyte nuclear factor 4 alpha modulator (HNF4A), Hepatocyte growth factor modulator, HMG CoA reductase inhibitor, IL-10 agonist, IL-17 antagonist, Ileal sodium bile acid cotransporter inhibitor, Insulin sensitizer, integrin modulator, intereukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, Jak2 tyrosine kinase inhibitor, ketohexokinase inhibitors, Klotho beta stimulator, 5-Lipoxygenase inhibitor, Lipoprotein lipase inhibitor, Liver X receptor, LPL gene stimulator, Lysophosphatidate-1 receptor antagonist, Lysyl oxidase homolog 2 inhibitor, Matrix metalloproteinases (MMPs) inhibitor, MEKK-5 protein kinase inhibitor, Membrane copper amine oxidase (VAP-1) inhibitor, Methionine aminopeptidase-2 inhibitor, Methyl CpG binding protein 2 modulator, MicroRNA-21(miR-21) inhibitor, Mitochondrial uncoupler, Myelin basic protein stimulator, NACHT LRR PYD domain protein 3 (NLRP3) inhibitor, NAD-dependent deacetylase sirtuin stimulator, NADPH oxidase inhibitor (NOX), Nicotinic acid receptor 1 agonist, P2Y13 purinoceptor stimulator, PDE 3 inhibitor, PDE 4 inhibitor, PDE 5 inhibitor, PDGF receptor beta modulator, Phospholipase C inhibitor, PPAR alpha agonist, PPAR delta agonist, PPAR gamma agonist, PPAR gamma modulator, Protease-activated receptor-2 antagonist, Protein kinase modulator, Rho associated protein kinase inhibitor, Sodium glucose transporter-2 inhibitor, SREBP transcription factor inhibitor, STAT-1 inhibitor, Stearoyl CoA desaturase-1 inhibitor, Suppressor of cytokine signalling-1 stimulator, Suppressor of cytokine signalling-3 stimulator, Transforming growth factor β (TGF-β), Transforming growth factor β activated Kinase 1 (TAK1), Thyroid hormone receptor beta agonist, TLR-4 antagonist, Transglutaminase inhibitor, Tyrosine kinase receptor modulator, GPCR modulator, nuclear hormone receptor modulator, WNT modulators, and YAP/TAZ modulator. Examples of JAK inhibitors include, but are not limited to, filgotonib and tofacitinib. A non-limiting example of an apoptosis signal kinase inhibitor is selonsertib.

The compound of Formula 1, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof, and at least one additional active agent may be administered in any order or even simultaneously. The multiple active agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the active agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may vary from more than zero weeks to less than four weeks. In addition, the combination methods, compositions and formulations are not to be limited to the use of only two agents.

The pharmaceutical composition of the present technology may comprise a pharmaceutically acceptable carrier, such as diluents, disintegrants, sweetening agents, glidants, or flavoring agents and may be formulated into an oral dosage form such as tablets, capsules, powders, granules, suspensions, emulsions, or syrups; or a parenteral dosage form such as liquids for external use, suspensions for external use, emulsions for external use, gels (ointments or the like), inhaling agents, spraying agents, injections, etc. Said dosage forms may be formulated in various forms, e.g., a dosage form for single administration or for multiple administrations.

The pharmaceutical composition of the present technology may include excipients such as lactose, corn starch, or the like, glidants such as magnesium stearate, etc., emulsifying agents, suspending agents, stabilizers, and isotonic agents, etc. If desired, a sweetening agent and/or a flavoring agent may be added. Exemplary excipients include, without limitation, polyethylene glycol (PEG), hydrogenated castor oil (HCO), cremophors, carbohydrates, starches (e.g., corn starch), inorganic salts, antimicrobial agents, antioxidants, binders/fillers, surfactants, lubricants (e.g., calcium or magnesium stearate), glidants such as talc, disintegrants, diluents, buffers, acids, bases, film coats, combinations thereof, and the like.

Specific carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like.

Inorganic salt or buffers include, but are not limited to, citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphate dibasic, and combinations thereof.

Suitable antioxidants for use in the present disclosure include, for example, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, and combinations thereof.

Additional exemplary excipients include surfactants such as polysorbates, e.g., “Tween 20” and “Tween 80,” and pluronics such as F68 and F88 (both of which are available from BASF, Mount Olive, N.J.), sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, and phosphatidylethanolamines), fatty acids and fatty esters, steroids such as cholesterol, and chelating agents, such as EDTA, zinc and other such suitable cations.

Further, a composition disclosed herein may optionally include one or more acids or bases. Non-limiting examples of acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof. Non-limiting examples of suitable bases include bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.

The amount of any individual excipient in the composition will vary depending on the role of the excipient, the dosage requirements of the active agent components, and particular needs of the composition.

Generally, however, the excipient will be present in the composition in an amount of about 1% to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15 to about 95% by weight of the excipient. In general, the amount of excipient present in a composition of the disclosure is selected from the following: at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even 95% by weight.

The composition of the present technology can be administered orally or parenterally, including inhalation, intravenous, intraperitoneal, subcutaneous, rectal and topical routes of administration. Therefore, the composition of the present technology can be formulated into various forms such as tablets, capsules, aqueous solutions, suspensions, or the like. In the case of tablets for oral administration, carriers such as lactose, corn starch, and lubricating agents, e.g., magnesium stearate, can be conventionally added thereto. In the case of capsules for oral administration, lactose and/or dried corn starch can be used as a diluent. When an aqueous suspension is required for oral administration, the active ingredient can be combined with emulsifying and/or suspending agents. If desired, certain sweetening agents and/or flavoring agents can be added thereto. For intramuscular, intraperitoneal, subcutaneous and intravenous administration, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous administration, the total concentration of solutes should be controlled in order to render the preparation isotonic. The composition of the present technology may be in the form of an aqueous solution containing pharmaceutically acceptable carriers, e.g., saline having a pH level of 7.4. The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.

Said 3,3-difluoroallylamines, i.e., a compound of Formula 1, or a stereoisomer thereof, or its pharmaceutically acceptable salt can be administered to a patient in an effective amount ranging from about 0.001 mg/kg to about 100 mg/kg per day. This includes 0.001, 0.0025, 0.005, 0.0075, 0.01, 0.025, 0.05, 0.075, 0.1, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg/kg.

Generally, a therapeutically effective amount of the compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, will range from a total daily dosage of about 0.1 mg/day to 1000 mg/day, about 30-720 mg/day, about 60-600 mg/day, or about 100-480 mg/day, or more. In some embodiments, a therapeutically effective amount of the compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, will range from about 1-240 mg/day, about 30-240 mg/day, about 30-200 mg/day, about 30-120 mg/day, about 1-120 mg/day, about 50-150 mg/day, about 60-150 mg/day, about 60-120 mg/day, or about 60-100 mg/day, administered as either a single dosage or as multiple dosages. In some embodiments, multiple dosages include two, three, or four doses per day.

In some embodiments, the therapeutically effective amount of the compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, is at least 0.1 mg/day, at least 0.5 mg/day, at least 1 mg/day, at least 5 mg/day, at least 10 mg/day, at least 20 mg/day, at least 30 mg/day, at least 40 mg/day, at least 50 mg/day, at least 60 mg/day, at least 70 mg/day, at least 80 mg/day, at least 90 mg/day, at least 100 mg/day, at least 110 mg/day, at least 120 mg/day, at least 130 mg/day, at least 140 mg/day, at least 150 mg/day, at least 160 mg/day, at least 170 mg/day, at least 180 mg/day, at least 190 mg/day, at least 200 mg/day, at least 225 mg/day, at least 250 mg/day, at least 275 mg/day, at least 300 mg/day, at least 325 mg/day, at least 350 mg/day, at least 375 mg/day, at least 400 mg/day, at least 425 mg/day, at least 450 mg/day, at least 475 mg/day, at least 500 mg/day, at least 525 mg/day, at least 550 mg/day, at least 575 mg/day, at least 600 mg/day, at least 625 mg/day, at least 650 mg/day, at least 675 mg/day, at least 700 mg/day, at least 725 mg/day, at least 750 mg/day, at least 775 mg/day, at least 800 mg/day, at least 825 mg/day, at least 850 mg/day, at least 875 mg/day, at least 900 mg/day, at least 925 mg/day, at least 950 mg/day, at least 975 mg/day, or at least 1000 mg/day.

Of course, the dosage may be changed according to the patient's age, weight, susceptibility, symptom, or the efficacy of the compound.

In some embodiments, the present technology provides a method of inhibiting vascular adhesion protein (VAP)-1 in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. In one embodiment, the present technology provides a method for treating nonalcoholic hepatosteatosis (NASH), comprising administering to a mammal a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method for treating NASH in a subject in need thereof, the method comprising, consisting essentially of, or consisting of administering to the subject a therapeutically effective amount of a compound of Formula 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Mammals include, but are not limited to, mice, rodents, rats, simians, humans, farm animals, dogs, cats, sport animals, and pets.

In some embodiments, the present technology provides a use of the compound of Formula 1 above, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for inhibiting a vascular adhesion protein-1 (VAP-1) in mammals.

In one embodiment, the present technology provides a use of the compound of Formula 1 above, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for treating or preventing nonalcoholic hepatosteatosis (NASH).

Hereinafter, the present technology is further elaborated through examples and experimental examples. However, the following examples and experimental examples are provided for illustration purposes only, and are not intended to limit the scope of the invention.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present technology. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

EXAMPLES

The analyses of the compounds prepared in the following examples were carried out as follows: Nuclear magnetic resonance (NMR) spectrum analysis was carried out using Bruker 400 MHz spectrometer and Agilent 600 MHz spectrometer and chemical shifts thereof were analyzed in ppm. Further, the indicated molecular weights were measured by using liquid chromatography/mass selective detector (MSD) of Agilent 1260 Infinity series equipped with an electrostatic spray interface (by using Single Quadrupole, it indicates a value of m/z in ESI+ (ESI-MS (cation), which is represented by the [M+H]+peak). Column chromatography was carried out on silica gel (Merck, 70-230 mesh). (W. C. Still, J. Org. Chem., 43, 2923, 1978). Further, the abbreviations used in the following examples are as follows: ‘methyl’ is abbreviated to ‘Me’; ‘ethyl’ is abbreviated to ‘Et’; ‘phenyl’ is abbreviated to ‘Ph, tert-butyloxycarbonyl is abbreviated to ‘Boc’; and tert-butyl dimethylsilyl is abbreviated to TBDMS. Further, the starting materials in each Example are known compounds, which were synthesized according literatures or obtained from Sigma-Aldrich.

Reference Example 1. Tert-butyl N-[3,3-difluoro-2-(hydroxymethyl)allyl]carbamate Step 1: Tert-butyl N-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,3-difluoro-allyl]carbamate

Under nitrogen condition, 2.4 g of tert-butyl N-[3-[tert-butyl(dimethyl)silyl]oxy-2-oxo-propyl]carbamate and 1.0 g of 2-(difluoromethylsulfonyl)pyridine were dissolved in 34.5 mL of N,N-dimethylformamide and then cooled to −70° C. To the reaction mixture, 10.4 mL of a tetrahydrofuran solution of 1.0 M lithium bis(trimethylsilyl)amide was slowly added dropwise. The resulting solution was stirred at −70° C. for 30 minutes and then stirred again by slowly increasing the temperature to −10° C. 20 mL of an ammonium chloride solution was added to the reaction mixture, followed by the addition of 20 mL of a 3 N hydrogen chloride solution. The reaction mixture was extracted with ethyl acetate three times. The extracted organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=20/1) to give 446.0 mg of the title compound as a yellow liquid (yield: 25.5%). ¹H-NMR (CDCl₃, 400 MHz) δ 4.98 (s, 1H), 4.20 (s, 2H), 3.83 (s, 2H), 1.42 (s, 9H), 0.89 (s, 9H), 0.07 (s, 6H)

Step 2: Tert-butyl N-[3,3-difluoro-2-(hydroxymethyl)allyl]carbamate

426 mg of tert-butyl N-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3,3-difluoro-allyl]carbamate was dissolved in 2.0 mL of tetrahydrofuran, followed by the addition of 1.5 mL of a tetrahydrofuran solution of 1.0 M tetrabutylamoniumfluoride (TBAF), and then the resulting solution was stirred at room temperature for 2 hours. Ethyl acetate and water were added to the reaction mixture to separate an organic layer. Ethyl acetate was added to the aqueous layer of the reaction mixture to separate an organic layer again. The organic layers thus obtained were combined and washed with an ammonium chloride solution and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=2/1) to give 285 mg of the title compound as a colorless liquid (yield: 100%). ¹H-NMR (CDCl₃, 400 MHz) δ 4.91 (s, 1H), 4.14 (s, 2H), 3.86 (d, 2H), 3.72 (s, 1H), 1.45 (s, 9H)

Reference Example 2. 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one Step 1: (E)-ethyl 2-(ethoxymethylene)hydrazinecarboxylate

30.0 g of ethyl carbazate was dissolved in 240.2 mL of triethyl orthoformate and then stirred overnight at 110° C. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to give 30.3 g of the title compound as a white solid (yield: 65.6%). ¹H-NMR (DMSO-d₆, 400 MHz) δ 10.09 (s, 1H), 7.94 (s, 1H), 4.03 (t, 4H), 1.24-1.16 (m, 6H)

Step 2: 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one

4.3 g of (E)-ethyl 2-(ethoxymethylene)hydrazinecarboxylate prepared in Step 1 was dissolved in 90 mL of methanol, 3.0 g of 4-fluoroaniline was added thereto, and then the resulting solution was stirred at 80° C. for 5 hours. After the reaction mixture was cooled to room temperature, 7.7 mL of a sodium methoxide solution (<25% in methanol>) was added thereto. The resulting solution was refluxed overnight at 80° C. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Ethyl acetate was added to the resultant residue and then washed with an ammonium chloride solution. The organic layer thereof was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give 948 mg of the title compound as a light grey solid (yield: 19.6%). MS (ESI) m/z=180.1 (M+H)+

Reference Example 3. 4-(3-bromophenyl)-1H-1,2,4-triazol-5-one Step 1: phenyl (3-bromophenyl)carbamate

1.0 g of 3-bromoaniline and 0.98 mL of pyridine were dissolved in 10.0 mL of ethyl acetate. To the resulting solution, 0.77 mL of phenylchloroformate at 0° C. was slowly added, and the solution was stirred at room temperature for 3 hours. To the solution, ethyl acetate was added, and the resulting reaction mixture was washed with 1N hydrochloric acid solution and brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 1.4 g of the title compound as a yellow solid (yield: 80.80%).

Step 2: N-(3-bromophenyl)hydrazine carboxamide

1.4 g of phenyl (3-bromophenyl)carbamate prepared in Step 1 and 480.0 mg of hydrazine hydrate were dissolved in 4.0 mL of tetrahydrofuran and 4.0 mL of ethanol, and the resulting solution was stirred overnight at room temperature. The resulting reaction mixture was concentrated and then washed with ethyl acetate to give 890.0 mg of the title compound as a white solid (yield: 80.0%).

Step 3: 4-(3-bromophenyl)-1H-1,2,4-triazol-5-one

890.0 mg of N-(3-bromophenyl)hydrazine carboxamide prepared in Step 2 and 1.6 g of formamidine acetate were dissolved in 8.9 mL of 1-propanol, and the resulting solution was stirred at room temperature for 30 minutes, and then 1.3 mL of acetic acid was added and stirred at 80° C. for 8 hours. The reaction mixture was cooled to room temperature, distilled water was added to the cooled reaction mixture, and then the reaction mixture was stirred overnight. The resulting crystals were filtered and dried to give 742.8 mg of the title compound as a white solid (yield: 80.2%). MS (ESI) m/z=241.2 (M+H)+

Reference Example 4. 4-(3,4-difluorophenyl)-1H-1,2,4-triazol-5-one

492.0 mg of the title compound (yield: 32.2%) was prepared in the same fashion as Reference Example 2, except that 1.0 g of 3,4-difluoroaniline was used in Step 2 instead of 4-fluoroaniline. ¹H-NMR (MeOD, 400 MHz) δ 8.16 (s, 1H), 7.73 (t, 1H), 7.47-7.42 (m, 2H)

Reference Example 5. 4-(4-bromo-3-fluorophenyl)-1H-1,2,4-triazol-5-one

517.3 mg of the title compound (yield: 38.1%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 4-bromo-3-fluoroaniline was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=259.1 (M+H)+

Reference Example 6. 4-(4-bromo-2-fluorophenyl)-1H-1,2,4-triazol-5-one

443.5 mg of the title compound (yield: 32.7%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 4-bromo-2-fluoroaniline was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=259.2 (M+H)+

Reference Example 7. 4-(4-bromo-2-methylphenyl)-1H-1,2,4-triazol-5-one

450 mg of the title compound (yield: 33.0%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 4-bromo-3-methylaniline was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=255.1 (M+H)+

Reference Example 8. 4-(6-bromo-3-pyridyl)-1H-1,2,4-triazol-5-one

500.7 mg of the title compound (yield: 35.9%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 3-amino-6-bromopyridine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=242.1 (M+H)+

Reference Example 9. 4-(6-bromo-2-pyridyl)-1H-1,2,4-triazol-5-one

6.0 g of the title compound (yield: 86.1%) was prepared in the same fashion as Reference Example 3, except that 5.0 g of 2-amino-6-bromopyridine was used in Step 1 instead of 3-bromoaniline. ¹H-NMR (CDCl₃, 400 MHz) δ 9.79 (s, 1H), 8.44 (s, 1H), 8.33 (d, 1H), 7.71 (t, 1H), 7.43 (d, 1H)

Reference Example 10. 4-(4-bromo-2-pyridyl)-1H-1,2,4-triazol-5-one

902.2 mg of the title compound (yield: 64.8%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 2-amino-4-bromopyridine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=242.1 (M+H)+

Reference Example 11. 4-(2-bromo-4-pyridyl)-1H-1,2,4-triazol-5-one

2.0 g of the title compound (yield: 28.7%) was prepared in the same fashion as Reference Example 3, except that 5.0 g of 4-amino-2-bromopyridine was used in Step 1 instead of 3-bromoaniline. ¹H-NMR (DMSO-d₆, 600 MHz) δ 8.65 (s, 1H), 8.45 (d, 1H), 8.17 (s, 1H), 8.12 (d, 1H), 7.97 (dd, 1H)

Reference Example 12. 4-(5-bromo-3-methyl-2-pyridyl)-1H-1,2,4-triazol-5-one

1.9 g of the title compound (yield: 69.6%) was prepared in the same fashion as Reference Example 3, except that 2.0 g of 2-amino-5-bromo-3-methylpyridine was used in Step 1 instead of 3-bromoaniline. ¹H-NMR (DMSO-d₆, 400 MHz) δ 8.55 (d, 1H), 8.21 (s, 1H), 8.13 (s, 1H), 2.27 (s, 3H)

Reference Example 13. 4-(6-bromo-4-methyl-3-pyridyl)-1H-1,2,4-triazol-5-one

4.5 g of the title compound (yield: 66.1, %) was prepared in the same fashion as Reference Example 3, except that 5.0 g of 2-bromo-4-methyl-5-aminopyridine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=256.0 (M+H)+

Reference Example 14. 4-(6-bromo-5-methyl-3-pyridyl)-1H-1,2,4-triazol-5-one

362.1 mg of the title compound (yield: 26.5%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 5-amino-2-bromo-3-picoline was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=256.1 (M+H)+

Reference Example 15. 4-(5-bromo-3-fluoro-2-pyridyl)-1H-1,2,4-triazol-5-one

715.0 mg of the title compound (yield: 52.7%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 2-amino-5-bromo-3-fluoropyridine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=260.2 (M+H)+

Reference Example 16. 4-(6-bromo-3-methyl-2-pyridyl)-1H-1,2,4-triazol-5-one

1.8 g of the title compound (yield: 65.9%) was prepared in the same fashion as Reference Example 3, except that 2.0 g of 2-amino-6-bromo-3-methylpyridine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=256.1 (M+H)+

Reference Example 17. 4-(5-bromopyrazin-2-yl)-1H-1,2,4-triazol-5-one

4.3 g of the title compound (yield: 61.9%) was prepared in the same fashion as Reference Example 3, except that 5.0 g of 2-amino-5-bromopyrazine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=243.2 (M+H)+

Reference Example 18. 4-[(4-benzyloxyphenyl)methyl]-1H-1,2,4-triazol-5-one

570 mg of the title compound (yield: 43.2%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of (4-(benzyloxy)phenyl)methylamine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=282.2 (M+H)+

Reference Example 19. 4-[(5-bromo-2-thienyl)methyl]-1H-1,2,4-triazol-5-one

742.8 mg of the white solid title compound (yield: 80.3%) was prepared in the same fashion as Reference Example 2, except that 1.0 g of (5-bromothiophen-2-yl)methylamine was used in Step 2 instead of 4-fluoroaniline. ¹H-NMR (MeOD, 400 MHz) δ 7.83 (s, 1H), 7.01 (s, 1H), 6.94 (s, 1H), 5.04 (s, 2H).

Reference Example 20. 4-[(4-bromo-2-thienyl)methyl]-1H-1,2,4-triazol-5-one

3.9 g of the title compound (yield: 57.6%) was prepared in the same fashion as Reference Example 2, except that 5.0 g of (4-bromothiophen-2-yl)methylamine was used in Step 2 instead of 4-fluoroaniline. ¹H-NMR (DMSO-d₆, 400 MHz) δ 11.74 (s, 1H), 7.97 (s, 1H), 7.61 (s, 1H), 7.10 (s, 1H), 4.92 (s, 2H)

Reference Example 21. 4-[(5-bromo-3-methyl-2-thienyl)methyl]-1H-1,2,4-triazol-5-one

1.4 g of the title compound (yield: 41.2%) was prepared in the same fashion as Reference Example 3, except that 2.6 g of (5-bromo-3-methylthiophen-2-yl)methylamine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=275.1 (M+H)+

Reference Example 22. 4-[2-(2-thienyl)ethyl]-1H-1,2,4-triazol-5-one

569 mg of the white solid title compound (yield: 72.0%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 2-thiophenethylamine was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=196.2 (M+H)+

Reference Example 23. 4-[2-(5-bromo-2-thienyl)ethyl]-1H-1,2,4-triazol-5-one

2.1 g of the title compound (yield: 68.6%) was prepared in the same fashion as Reference Example 2, except that 2.3 g of 2-(5-bromothiophen-2-yl)ethan-1-amine was used in Step 2 instead of 4-fluoroaniline. MS (ESI) m/z=275.2 (M+H)+

Reference Example 24. Tert-butyl N-[3,3-difluoro-2-[[4-(4-fluorophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate

321 mg of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one prepared in Step 2 of Reference Example 2, 400 mg of tert-butyl N-[3,3-difluoro-2-(hydroxymethyl)allyl]carbamate prepared in Step 2 of Reference Example 1, and 940 mg of triphenylphosphine were dissolved in 4.5 mL of tetrahydrofuran, and the resulting solution was stirred and cooled to 0° C. To the reaction mixture, 706 uL of diisopropyl azodicarboxylate (DIAD) was slowly added dropwise and stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=2/1) to give 222 mg of the title compound as a colorless liquid (yield: 32.3%). ¹H-NMR (CDCl₃, 400 MHz) δ 7.68 (s, 1H), 7.52 (s, 2H), 7.19 (t, 2H), 5.37 (s, 1H), 4.54 (s, 2H), 3.79 (s, 2H), 1.41 (s, 9H)

Reference Example 25. Tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

30 mg of the title compound (yield: 10.0%) was prepared in the same fashion as Reference Example 24, except that 161 mg of 4-(3-bromophenyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 3 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=346.2 (M+H)+

Reference Example 26. Tert-butyl N-[2-[[4-(3,4-difluorophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

1.8 g of the title compound (yield: 100%) was prepared in the same fashion as Reference Example 24, except that 883 mg of 4-(3,4-difluorophenyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 4 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=303.1 (M+H)+

Reference Example 27. Tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

19 mg of the title compound (yield: 9.3%) was prepared in the same fashion as Reference Example 24, except that 150 mg of 4-(4-bromo-3-fluorophenyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 5 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=(M+H)+

Reference Example 28. Tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

448 mg of the title compound (yield: 8.3%) was prepared in the same fashion as Reference Example 24, except that 3.0 g of 4-(4-bromo-2-fluorophenyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 6 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=364.2 (M+H)+

Reference Example 29. Tert-butyl N-[2-[[4-(4-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

35 mg of the title compound (yield: 24.2%) was prepared in the same fashion as Reference Example 24, except that 80 mg of 4-(4-bromo-2-methylphenyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 7 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=360.1 (M+H)+

Reference Example 30. Tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

1.3 g of the title compound (yield: 41.3%) was prepared in the same fashion as Reference Example 24, except that 1.7 g of 4-(6-bromo-3-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 8 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=347.2 (M+H)+

Reference Example 31. Tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

1.8 g of the title compound (yield: 100%) was prepared in the same fashion as Reference Example 24, except that 972 mg of 4-(6-bromo-2-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 9 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 8.42 (s, 1H), 8.32 (d, 1H), 7.70 (t, 1H), 7.43 (d, 1H), 4.53 (s, 2H), 3.78 (s, 2H), 1.40 (s, 9H)

Reference Example 32. Tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

499 mg of the title compound (yield: 49.9%) was prepared in the same fashion as Reference Example 24, except that 540 mg of 4-(4-bromo-2-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 10 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=347.2 (M+H)+

Reference Example 33. Tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

1.2 g of the title compound (yield: 90.0%) was prepared in the same fashion as Reference Example 24, except that 702 mg of 4-(2-bromo-4-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 11 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=347.1 (M+H)+

Reference Example 34. Tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

1.8 g of the title compound (yield: 97.0%) was prepared in the same fashion as Reference Example 24, except that 1.0 g of 4-(5-bromo-3-methyl-2-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 12 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 8.42 (s, 1H), 7.87 (s, 1H), 7.74 (s, 1H), 5.36 (s, 1H), 4.53 (s, 2H), 3.78 (s, 2H), 2.40 (s, 3H), 1.42 (s, 9H)

Reference Example 35. Tert-butyl N-[2-[[4-(6-bromo-4-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

56 mg of the title compound (yield: 34.4%) was prepared in the same fashion as Reference Example 24, except that 89 mg of 4-(6-bromo-4-methyl-3-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 13 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=361.1 (M+H)+

Reference Example 36. Tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

405 mg of the title compound (yield: 39.3%) was prepared in the same fashion as Reference Example 24, except that 571 mg of 4-(6-bromo-5-methyl-3-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 14 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=361.1 (M+H)+

Reference Example 37. Tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

780 mg of the title compound (yield: 33.5%) was prepared in the same fashion as Reference Example 24, except that 1.3 g of 4-(5-bromo-3-fluoro-2-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 15 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=365.2 (M+H)+

Reference Example 38. Tert-butyl N-[2-[[4-(6-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

521 mg of the title compound (yield: 50.5%) was prepared in the same fashion as Reference Example 24, except that 571 mg of 4-(6-bromo-3-methyl-2-pyridyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 14 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=361.2 (M+H)+

Reference Example 39. Tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

110 mg of the title compound (yield: 43.1%) was prepared in the same fashion as Reference Example 24, except that 138 mg of 4-(5-bromopyrazin-2-yl)-1H-1,2,4-triazol-5-one prepared in Reference Example 17 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=348.1 (M+H)+

Reference Example 40. Tert-butyl N-[2-[[4-[(4-benzyloxyphenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

20 mg of the title compound (yield: 4.6%) was prepared in the same fashion as Reference Example 24, except that 126 mg of 4-[(4-benzyloxyphenyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 18 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=387.1 (M+H)+

Reference Example 41. Tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

3.3 g of the title compound (yield: 87.2%) was prepared in the same fashion as Reference Example 24, except that 2.0 g of 4-[(5-bromo-2-thienyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 19 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 7.38 (s, 1H), 6.95 (s, 1H), 6.85 (s, 1H), 5.40 (s, 1H), 4.88 (s, 2H), 4.47 (s, 2H), 3.71 (s, 2H), 1.44 (s, 9H)

Reference Example 42. Tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

2.9 g of the title compound (yield: 64.9%) was prepared in the same fashion as Reference Example 24, except that 2.3 g of 4-[(4-bromo-2-thienyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 20 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 7.41 (s, 1H), 7.22 (s, 1H), 7.02 (s, 1H), 5.38 (s, 1H), 4.93 (s, 2H), 4.48 (s, 2H), 3.72 (s, 2H), 1.44 (s, 9H)

Reference Example 43. Tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

546 mg of the title compound (yield: 33.0%) was prepared in the same fashion as Reference Example 24, except that 946 mg of 4-[(5-bromo-3-methyl-2-thienyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 21 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=380.2 (M+H)+

Reference Example 44. Tert-butyl N-[3,3-difluoro-2-[[5-oxo-4-[2-(2-thienyl)ethyl]-1,2,4-triazol-1-yl]methyl]allyl]carbamate

44 mg of the title compound (yield: 14.3%) was prepared in the same fashion as Reference Example 24, except that 87 mg of 4-[2-(2-thienyl)ethyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 22 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=387.2 (M+H)+

Reference Example 45. Tert-butyl N-[2-[[4-(5-bromo-2-thienyl)ethyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

780 mg of the title compound (yield: 22.3%) was prepared in the same fashion as Reference Example 24, except that 2.0 g of 4-[2-(5-bromo-2-thienyl)ethyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 23 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=380.1 (M+H)+

Reference Example 46. 4-(3-bromo-2-methyl-phenyl)-1H-1,2,4-triazol-5-one

528 mg of the title compound (yield: 38.7%) was prepared in the same fashion as Reference Example 3, except that 1.0 g of 3-bromo-2-methylaniline was used in Step 1 instead of 3-bromoaniline. MS (ESI) m/z=255.2 (M+H)+

Reference Example 47. 4-[(4-bromophenyl)methyl]-1H-1,2,4-triazol-5-one

1.0 g of 1,4-dihydro-1,2,4-triazol-5-one and 3.2 g of potassium carbonate were dissolved in 100.0 mL of N,N-dimethylformamide, and the solution was stirred at RT for 10 min. 2.9 g of 4-bromobenzyl bromide was added to the resulting solution, and then the solution was stirred at RT for 16 hours. After addition of distilled water, the reaction mixture was extracted with ethyl acetate three times. The combined organic extracts were dried over anhydrous magnesium sulfate and then concentrated under reduced pressure to give a residue as a yellow liquid. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=1/2) to give 715 mg of the title compound as a white solid (yield: 23.9%). ¹H-NMR (DMSO-d₆, 400 MHz) δ 11.7 (s, 1H), 7.96 (s, 1H), 7.56 (d, 2H), 7.24 (d, 2H), 4.73 (s, 2H)

Reference Example 48. 4-[(3-bromophenyl)methyl]-1H-1,2,4-triazol-5-one

944 mg of the title compound (yield: 31.6%) was prepared as a white solid in the same fashion as Reference Example 47, except that 2.9 g of 3-bromobenzyl bromide was used instead of 4-bromobenzyl bromide. ¹H-NMR (DMSO-d₆, 400 MHz) δ 11.8 (s, 1H), 8.00 (s, 1H), 7.51 (d, 2H), 7.35-7.28 (m, 2H), 4.76 (s, 2H)

Reference Example 49. 4-[(2-bromophenyl)methyl]-1H-1,2,4-triazol-5-one

1.4 g of the title compound (yield: 48.4%) was prepared as a white solid in the same fashion as Reference Example 47, except that 2.9 g of 2-bromobenzyl bromide was used instead of 4-bromobenzyl bromide. ¹H-NMR (DMSO-d₆, 400 MHz) δ 11.80 (s, 1H), 7.91 (s, 1H), 7.67 (d, 1H), 7.40 (t, 1H), 7.28 (t, 1H), 7.09 (d, 1H), 4.81 (s, 2H)

Reference Example 50. 4-[(6-bromobenzothiophen-2-yl)methyl]-1H-1,2,4-triazol-5-one

1.5 g of the title compound (yield: 66.8%) was prepared as a pale pink solid in the same fashion as Reference Example 2, except that 1.8 g of (6-bromo-1-benzothiophen-2-yl)methanamine was used in Step 2 instead of 4-fluoroaniline. MS (ESI) m/z=311.2 (M+H)+

Reference Example 51. 4-[(5-bromobenzothiophen-2-yl)methyl]-1H-1,2,4-triazol-5-one

1.5 g of the title compound (yield: 57.5%) was prepared as a pale brown solid in the same fashion as Reference Example 2, except that 2.0 g of (5-bromo-1-benzothiophen-2-yl)methanamine was used in Step 2 instead of 4-fluoroaniline. ¹H-NMR (DMSO-d₆, 400 MHz) δ 11.8 (s, 1H), 8.24 (s, 1H), 8.00 (s, 1H), 7.78 (d, 1H), 7.52 (d, 1H), 7.36 (s, 1H), 5.04 (s, 2H)

Reference Example 52. 4-[(5-bromo-3-fluoro-2-thienyl)methyl]-1H-1,2,4-triazol-5-one

689 mg of the title compound (yield: 66.0%) was prepared as a pale yellow liquid in the same fashion as Reference Example 47, except that 1.1 g of (5-bromo-3-fluoro-2-thienyl)methyl methanesulfonate was used instead of 4-bromobenzyl bromide. ¹H-NMR (MeOD, 400 MHz) δ 7.84 (s, 1H), 7.02 (s, 1H), 4.93 (s, 2H)

Reference Example 53. Tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

4.7 g of the title compound (yield: 86.1%) was prepared in the same fashion as Reference Example 24, except that 3.0 g of 4-(3-bromo-2-methyl-phenyl)-1H-1,2,4-triazol-5-one prepared in Reference Example 46 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 7.70 (d, 1H), 7.49 (s, 1H), 7.24-7.18 (m, 2H), 5.41 (bs, 1H), 4.57 (s, 2H), 3.81 (d, 2H), 2.33 (s, 3H), 1.44 (s, 9H)

Reference Example 54. Tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

624 mg of the title compound (yield: 48.3%) was prepared in the same fashion as Reference Example 24, except that 715 mg of 4-[(4-bromophenyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 47 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 7.60 (s, 1H), 7.55 (d, 2H), 7.43 (d, 2H), 5.18 (s, 2H), 4.66 (s, 2H), 4.37 (s, 2H), 1.33 (s, 9H)

Reference Example 55. Tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

790 mg of the title compound (yield: 64.0%) was prepared in the same fashion as Reference Example 24, except that 683 mg of 4-[(3-bromophenyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 48 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=459.1 (M+H)+

Reference Example 56. Tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

692 mg of the title compound (yield: 56.2%) was prepared in the same fashion as Reference Example 24, except that 683 mg of 4-[(2-bromophenyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 49 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. MS (ESI) m/z=460.1 (M+H)+

Reference Example 57. Tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

368 mg of the title compound (yield: 37.0%) was prepared in the same fashion as Reference Example 24, except that 600 mg of 4-[(6-bromobenzothiophen-2-yl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 50 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 7.92 (s, 1H), 7.60 (d, 1H), 7.48-7.43 (m, 2H), 7.26 (s, 1H), 5.34 (s, 1H), 5.02 (s, 2H), 4.48 (s, 2H), 3.73 (s, 2H), 1.42 (s, 9H)

Reference Example 58. Tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

344 mg of the title compound (yield: 44.5%) was prepared in the same fashion as Reference Example 24, except that 464 mg of 4-[(5-bromobenzothiophen-2-yl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 51 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 7.91 (s, 1H), 7.66 (d, 1H), 7.46 (d, 2H), 7.28 (s, 1H), 5.41 (bs, 1H), 5.06 (s, 2H), 4.51 (s, 2H), 3.75 (s, 2H), 1.45 (s, 9H)

Reference Example 59. Tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

581 mg of the title compound (yield: 48.6%) was prepared as a yellow liquid in the same fashion as Reference Example 24, except that 689 mg of 4-[(5-bromo-3-fluoro-2-thienyl)methyl]-1H-1,2,4-triazol-5-one prepared in Reference Example 52 was used instead of 4-(4-fluorophenyl)-1H-1,2,4-triazol-5-one. ¹H-NMR (CDCl₃, 400 MHz) δ 7.44 (s, 1H), 6.85 (s, 1H), 6.37 (s, 1H), 4.83 (s, 2H), 4.47 (s, 2H), 3.73 (s, 2H), 1.45 (s, 9H)

Example 1. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-fluorophenyl)-1,2,4-triazol-3-one Trifluoroacetate

287 mg of tert-butyl N-[3,3-difluoro-2-[[4-(4-fluorophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate prepared in Reference Example 24 was dissolved in 10.0 mL of dichloromethane and 1.1 mL of trifluoroacetic acid was added thereto. The resulting solution was stirred at room temperature for 2.5 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. The solution was concentrated under reduced pressure and then dried in vacuo to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 262 mg of the title compound as a white solid (yield: 100%). ¹H-NMR (MeOD, 400 MHz) δ 8.23 (s, 1H), 7.65 (s, 2H), 7.27 (t, 2H), 4.64 (s, 2H), 3.73 (s, 2H).

Example 2. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(3-bromophenyl)-1,2,4-triazol-3-one Trifluoroacetate

31 mg of the title compound (yield: 40.1%) was prepared in the same fashion as Example 1, except that 96 mg of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.30 (s, 1H), 7.95 (s, 1H), 7.65-7.56 (m, 2H), 7.44 (t, 1H), 4.63 (s, 2H), 3.72 (s, 2H)

Example 3. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(3,4-difluorophenyl)-1,2,4-triazol-3-one Trifluoroacetate

143 mg of the title compound as a colorless liquid (yield: 100%) was prepared in the same fashion as Example 1, except that 189 mg of tert-butyl N-[2-[[4-(3,4-difluorophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 26 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.29 (s, 1H), 7.74 (t, 3H), 7.48 (s, 1H), 7.42 (t, 1H), 4.65 (s, 2H), 3.75 (s, 2H)

Example 4. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-3-fluoro-phenyl)-1,2,4-triazol-3-one Trifluoroacetate

56 mg of the title compound (yield: 58.0%) was prepared in the same fashion as Example 1, except that 123 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.34 (s, 1H), 7.79-7.69 (m, 2H), 7.47 (d, 2H), 4.63 (s, 2H), 3.72 (s, 2H)

Example 5. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-fluoro-phenyl)-1,2,4-triazol-3-one Trifluoroacetate

51 mg of the title compound (yield: 57.7%) was prepared in the same fashion as Example 1, except that 113 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.11 (s, 1H), 7.65-7.53 (m, 3H), 4.64 (s, 2H), 3.73 (s, 2H)

Example 6. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-methyl-phenyl)-1,2,4-triazol-3-one trifluoroacetate

27 mg of the title compound (yield: 69.0%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 29 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (s, 1H), 7.58-7.55 (m, 2H), 7.34 (d, 2H), 4.64 (s, 2H), 3.73 (s, 2H), 2.20 (s, 3H)

Example 7. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-3-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 87.7%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.73 (s, 1H), 8.35 (s, 1H), 8.06 (d, 1H), 7.76 (d, 1H), 5.49 (s, 2H), 4.62 (s, 2H), 3.54 (s, 2H)

Example 8. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-2-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

325 mg of the title compound (yield: 98.4%) was prepared in the same fashion as Example 1, except that 369 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.58 (s, 1H), 8.26 (d, 1H), 7.87 (t, 1H), 7.58 (d, 1H), 4.65 (s, 2H), 3.74 (s, 2H)

Example 9. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 98.0%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.62 (s, 1H), 8.48 (s, 1H), 8.32 (d, 1H), 7.56 (d, 1H), 4.66 (s, 2H), 3.75 (s, 2H)

Example 10. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(2-bromo-4-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 88.4%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.69 (s, 1H), 8.44 (d, 2H), 8.21 (s, 1H), 7.89 (d, 1H), 4.65 (s, 2H), 3.73 (s, 2H)

Example 11. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromo-3-methyl-2-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

260 mg of the title compound (yield: 73.0%) was prepared in the same fashion as Example 1, except that 455 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.50 (s, 1H), 8.13 (s, 2H), 4.64 (s, 2H), 3.73 (s, 2H), 2.34 (s, 3H)

Example 12. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-4-methyl-3-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 89.2%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(6-bromo-4-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 35 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.31 (s, 1H), 8.08 (s, 1H), 7.72 (s, 1H), 4.65 (s, 2H), 3.74 (s, 2H), 2.29 (s, 3H)

Example 13. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-5-methyl-3-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

22 mg of the title compound (yield: 56.0%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 36 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.57 (s, 1H), 8.35 (s, 1H), 8.06 (d, 1H), 4.64 (s, 2H), 3.67 (s, 2H), 2.46 (s, 3H)

Example 14. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromo-3-fluoro-2-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

19 mg of the title compound (yield: 48.3%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.54 (s, 1H), 8.24 (d, 1H), 8.20 (s, 1H), 4.65 (s, 2H), 3.74 (s, 2H)

Example 15. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-3-methyl-2-pyridyl)-1,2,4-triazol-3-one Trifluoroacetate

28 mg of the title compound (yield: 71.3%) was prepared in the same fashion as Example 1, except that 50 mg of tert-butyl N-[2-[[4-(6-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 38 was used. ¹H-NMR (MeOD, 400 MHz) δ 8.15 (s, 1H), 7.79 (d, 1H), 7.66 (d, 1H), 4.65 (s, 2H), 3.72 (s, 2H), 2.31 (s, 3H)

Example 16. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromopyrazin-2-yl)-1,2,4-triazol-3-one Trifluoroacetate

56 mg of the title compound (yield: 65.6%) was prepared in the same fashion as Example 1, except that 110 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used. ¹H-NMR (MeOD, 400 MHz) δ 9.31 (s, 1H), 8.67 (s, 1H), 8.58 (s, 1H), 4.65 (s, 2H), 3.73 (s, 2H)

Example 17. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one Trifluoroacetate Step 1: tert-butyl N-[3,3-difluoro-2-[[4-[3-(4-methylsulfonylphenyl)phenyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate

70 mg of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 31 mg of 4-(methanesulfonyl)phenylboronic acid were dissolved in 1.0 mL of 1,4-dioxane, followed by the addition of 785 uL of 1 M potassium carbonate and 6 mg of palladiumdi[1,1′-bis(diphenylphospino)ferrocene]dichloride (PdCl₂(dppf)), and the resulting solution was stirred overnight at 90° C. The resulting reaction mixture was filtered through a celite pad and concentrated under reduced pressure to give a residue. The residue thus obtained was dissolved in ethylacetate, washed with distilled water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=1/1) to give 53 mg of the title compound (yield: 64.8%). MS (ESI) m/z=421.1 (M+H)+

Step 2: 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one

53 mg of tert-butyl N-[3,3-difluoro-2-[[4-[3-(4-methyl sulfonylphenyl)phenyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate prepared in Step 1 was dissolved in 1.0 mL of dichloromethane, followed by the addition of 0.1 mL of trifluoroacetic acid, the resulting solution was stirred at room temperature for 2 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. The solution was concentrated under reduced pressure and then dried in vacuo to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 40 mg of the title compound as a white solid (yield: 93.1%). ¹H-NMR (MeOD, 400 MHz) δ 8.36 (s, 1H), 8.07-7.95 (m, 4H), 7.76-7.66 (m, 4H), 4.66 (s, 2H), 3.50 (s, 2H), 2.22 (s, 3H)

Example 18. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one Ditrifluoroacetate

35 mg of the title compound (yield: 35.6%) was prepared in the same fashion as Example 17, except that in Step 1, 61 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.33 (s, 1H), 7.88 (s, 1H), 7.66-7.55 (m, 5H), 7.14 (d, 2H), 4.67 (s, 2H), 3.71 (s, 2H), 3.49-3.46 (m, 4H), 3.40-3.37 (m, 4H)

Example 19. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one Trifluoroacetate

36 mg of the title compound (yield: 44.8%) was prepared in the same fashion as Example 17, except that 43 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid in Step 1. ¹H-NMR (MeOD, 400 MHz) δ 9.05 (s, 1H), 8.41 (s, 1H), 8.36 (d, 1H), 8.06 (s, 1H), 7.94 (d, 1H), 7.83-7.72 (m, 3H), 4.68 (s, 2H), 3.74 (s, 2H)

Example 20. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(dimethylamino)-3-pyridyl]phenyl]-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 49.7%) was prepared in the same fashion as Example 17, except that 39 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid in Step 1. ¹H-NMR (MeOD, 400 MHz) δ 8.37 (s, 1H), 8.28 (d, 2H), 7.93 (s, 1H), 7.70-7.65 (m, 3H), 7.26 (d, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.32 (s, 6H)

Example 21. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1,3-benzodioxol-5-yl)phenyl]-1,2,4-triazol-3-one Trifluoroacetate

62 mg of the title compound (yield: 81.2%) was prepared in the same fashion as Example 17, except that 39 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid in Step 1. ¹H-NMR (MeOD, 400 MHz) δ 8.33 (s, 1H), 7.83 (s, 1H), 7.57-7.55 (m, 3H), 7.18 (s, 1H), 6.91 (s, 2H), 6.01 (s, 2H), 4.66 (s, 2H), 3.67 (s, 2H)

Example 22. 6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

33 mg of the title compound (yield: 40.0%) was prepared in the same fashion as Example 17, except that 45 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid in Step 1. ¹H-NMR (MeOD, 400 MHz) δ 8.34 (s, 1H), 7.87 (s, 1H), 7.65 (t, 1H), 7.59-7.56 (m, 2H), 7.39 (s, 2H), 4.66 (s, 2H), 3.64 (s, 2H), 3.02 (t, 2H), 2.60 (t, 2H)

Example 23. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-ethylpyrazol-4-yl)phenyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 48.4%) was prepared in the same fashion as Example 17, except that X mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid in Step 1. ¹H-NMR (MeOD, 400 MHz) δ 8.32 (s, 1H), 8.11 (s, 1H), 7.91 (s, 1H), 7.83 (s, 1H), 7.62 (d, 1H), 7.54-7.47 (m, 2H), 4.67 (d, 2H), 4.23 (q, 2H), 3.75 (s, 2H), 1.50 (t, 3H)

Example 24. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 52.8%) was prepared in the same fashion as Example 17, except that 50 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used in Step 1, instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.38 (s, 1H), 8.08 (d, 1H), 7.86 (d, 1H), 7.79-7.67 (m, 3H), 4.63 (s, 2H), 3.18 (s, 3H)

Example 25. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one Ditrifluoroacetate

21 mg of the title compound (yield: 43.7%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 54 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.36 (s, 1H), 7.67-7.53 (m, 5H), 7.14 (d, 2H), 4.66 (s, 2H), 3.71 (s, 2H), 3.51-3.39 (m, 8H)

Example 26. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one Trifluoroacetate

33 mg of the title compound (yield: 71.2%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 38 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.94 (s, 1H), 8.40 (s, 1H), 8.28 (d, 1H), 7.95 (d, 1H), 7.85-7.72 (m, 3H), 4.64 (s, 2H), 3.39 (s, 2H)

Example 27. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-3-fluoro-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

24 mg of the title compound (yield: 55.0%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 35 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.40 (s, 1H), 8.19 (s, 1H), 8.12 (d, 1H), 7.78-7.64 (m, 3H), 7.21 (d, 1H), 4.67 (s, 2H), 3.75 (s, 2H), 3.32 (s, 6H)

Example 28. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-3-fluoro-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

31 mg of the title compound (yield: 71.0%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 35 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.36 (s, 1H), 7.67-7.54 (m, 3H), 7.06 (s, 2H), 6.94 (d, 1H), 6.02 (s, 2H), 4.65 (s, 2H), 3.66 (s, 2H)

Example 29. 6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-fluoro-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

27 mg of the title compound (yield: 56.4%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 40 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.36 (s, 1H), 7.67-7.54 (m, 3H), 7.26 (s, 2H), 4.67 (s, 2H), 3.75 (s, 2H), 3.00 (t, 2H), 2.60 (t, 2H), 2.32 (s, 3H)

Example 30. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-3-fluoro-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

28 mg of the title compound (yield: 81.4%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-3-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 27 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 31 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.33 (s, 1H), 8.13 (s, 1H), 7.95 (s, 1H), 7.83 (t, 1H), 7.64 (d, 1H), 7.51 (d, 1H), 4.64 (s, 2H), 4.26 (q, 2H), 3.62 (s, 2H), 1.51 (t, 3H)

Example 31. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 61.2%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.19 (s, 1H), 8.08 (d, 2H), 7.97 (d, 2H), 7.81-7.72 (m, 3H), 4.68 (s, 2H), 3.76 (s, 2H), 3.18 (s, 3H)

Example 32. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one Ditrifluoroacetate

22 mg of the title compound (yield: 45.8%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 54 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.14 (s, 1H), 7.64-7.60 (m, 5H), 7.14 (d, 2H), 4.67 (s, 2H), 3.73 (s, 2H), 3.50-3.40 (m, 8H)

Example 33. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 53.9%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25, and 38 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.19 (s, 1H), 8.08 (d, 2H), 7.97 (d, 2H), 7.81-7.72 (m, 3H), 4.68 (s, 2H), 3.76 (s, 2H), 3.18 (s, 3H)

Example 34. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-2-fluoro-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 80.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 35 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.30-8.16 (m, 3H), 7.74-7.62 (m, 3H), 7.20 (d, 1H), 4.67 (s, 2H), 3.73 (s, 2H), 1.87 (s, 6H)

Example 35. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-2-fluoro-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

30 mg of the title compound (yield: 68.7%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 35 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.13 (s, 1H), 7.64-7.53 (m, 3H), 7.18 (s, 2H), 6.94 (s, 1H), 6.02 (d, 2H), 4.67 (s, 2H), 3.73 (s, 2H)

Example 36. 6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-fluoro-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

33 mg of the title compound (yield: 68.9%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 40 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.06 (s, 1H), 8.36 (s, 1H), 8.17 (s, 1H), 7.95-7.76 (m, 4H), 4.65 (s, 2H), 3.49 (s, 2H)

Example 37. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-2-fluoro-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 61.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-fluoro-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 28 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 31 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.16 (s, 1H), 8.11 (s, 1H), 7.93 (s, 1H), 7.61-7.56 (m, 3H), 4.65 (s, 2H), 4.23 (q, 2H), 3.63 (s, 2H), 1.50 (t, 3H)

Example 38. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-methylsulfonylphenyl)-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 44.0%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 9.04 (s, 1H), 8.44 (s, 1H), 8.30 (d, 2H), 8.24 (d, 1H), 8.13 (d, 1H), 8.06 (d, 2H), 4.69 (s, 2H), 3.77 (s, 2H), 3.18 (s, 3H)

Example 39. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-piperazin-1-ylphenyl)-3-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

32 mg of the title compound (yield: 55.9%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 52 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.37 (s, 1H), 8.12 (d, 1H), 8.00-7.95 (m, 3H), 7.14 (d, 2H) 4.67 (s, 2H), 3.73 (s, 2H), 3.53 (t, 4H), 3.39 (t, 4H)

Example 40. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(trifluoromethyl)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

17 mg of the title compound (yield: 29.8%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 37 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.41 (s, 1H), 9.10 (s, 1H), 8.71 (d, 1H), 8.46 (s, 1H), 8.31 (d, 1H), 8.23 (d, 1H), 7.96 (d, 1H), 4.69 (s, 2H), 3.77 (s, 2H)

Example 41. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

19 mg of the title compound (yield: 37.3%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 33 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.00 (s, 1H), 8.68 (d, 1H), 8.65 (s, 1H), 8.42 (s, 1H), 8.23 (d, 1H), 8.07 (d, 1H), 7.35 (d, 1H), 4.68 (s, 2H), 3.36 (s, 3H)

Example 42. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

26 mg of the title compound (yield: 50.0%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 33 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.37 (s, 1H), 8.11 (d, 1H), 7.93 (d, 1H), 7.57 (d, 1H), 7.55 (s, 1H), 6.94 (d, 1H), 6.04 (s, 2H), 4.67 (s, 2H), 3.76 (s, 2H)

Example 43. 6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

17 mg of the title compound (yield: 29.8%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 39 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.89 (s, 1H), 8.38 (s, 1H), 8.11 (d, 1H), 7.94 (d, 1H), 7.71 (s, 2H), 4.68 (s, 2H), 3.77 (s, 2H), 3.01 (t, 2H), 2.60 (t, 4H), 2.33 (s, 3H)

Example 44. 6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

22 mg of the title compound (yield: 39.6%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 39 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.90 (s, 1H), 8.38 (s, 1H), 8.11 (d, 1H), 7.96-7.86 (m, 3H), 7.17 (d, 1H), 4.68 (s, 2H), 3.34 (s, 3H), 2.96 (t, 2H), 2.64 (t, 2H)

Example 45. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1-ethylpyrazol-4-yl)-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

22 mg of the title compound (yield: 45.4%) was prepared in the same fashion as Example 17, except that in Step 1, 60 mg of tert-butyl N-[2-[[4-(6-bromo-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 30 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 30 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.35 (s, 1H), 8.26 (s, 1H), 8.07 (s, 2H), 7.80 (d, 1H) 4.67 (s, 2H), 4.27 (q, 2H), 3.75 (s, 2H), 1.52 (t, 3H)

Example 46. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 74.2%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.85 (s, 1H), 8.37 (d, 2H), 8.28 (d, 1H), 8.07 (t, 3H), 7.99 (d, 1H), 4.68 (s, 2H), 3.77 (s, 2H), 3.18 (s, 3H)

Example 47. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

33 mg of the title compound (yield: 68.9%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 52 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.79 (s, 1H), 8.07 (d, 3H), 7.95 (t, 1H), 7.80 (d, 1H), 7.13 (d, 2H), 4.67 (s, 2H), 3.72 (s, 2H), 3.53 (s, 4H), 3.39 (s, 4H)

Example 48. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

28 mg of the title compound (yield: 60.6%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 26 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.44 (s, 1H), 8.88 (s, 1H), 8.75 (d, 1H), 8.33 (d, 1H), 8.13 (t, 1H), 8.05 (d, 1H), 7.95 (d, 1H), 4.69 (s, 2H), 3.77 (s, 2H)

Example 49. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 57.6%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 33 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.83 (s, 1H), 8.70 (s, 1H), 8.63 (d, 1H), 8.21 (d, 1H), 8.05 (t, 1H), 7.86 (d, 1H), 7.24 (d, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.34 (s, 6H)

Example 50. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

36 mg of the title compound (yield: 83.0%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.76 (s, 1H), 8.07 (d, 1H), 7.93 (t, 1H), 7.73 (d, 1H), 7.61 (d, 2H), 6.90 (d, 1H), 6.02 (s, 2H), 4.66 (s, 2H), 3.75 (s, 2H)

Example 51. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

29 mg of the title compound (yield: 60.7%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 39 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.81 (s, 1H), 8.10 (d, 1H), 7.96 (t, 1H), 7.80 (s, 3H), 4.68 (s, 2H), 3.76 (s, 2H), 3.03 (t, 2H), 2.61 (t, 2H), 2.34 (s, 3H)

Example 52. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

36 mg of the title compound (yield: 75.4%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 39 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.82 (s, 1H), 8.12 (d, 1H), 8.01-7.96 (m, 3H), 7.83 (d, 1H), 7.18 (d, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.36 (s, 3H), 3.00 (t, 2H), 2.66 (t, 2H)

Example 53. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

24 mg of the title compound (yield: 59.3%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 30 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.81 (s, 1H), 8.32 (s, 1H), 8.09 (s, 1H), 8.02 (d, 1H), 7.89 (t, 1H), 7.58 (d, 1H), 4.66 (s, 3H), 4.25 (q, 2H), 3.75 (s, 2H), 1.51 (t, 3H)

Example 54. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 72.0%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.68 (s, 1H), 8.58 (d, 2H), 8.12 (d, 2H), 8.04 (d, 2H), 7.72 (s, 1H), 4.66 (s, 2H), 3.66 (s, 2H), 3.20 (s, 3H)

Example 55. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

25 mg of the title compound (yield: 52.2%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 52 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.65 (s, 1H), 8.47 (d, 2H), 7.76 (d, 2H), 7.62 (s, 1H), 7.16 (d, 2H), 4.67 (s, 2H), 3.67 (s, 2H), 3.51 (d, 4H), 3.36 (d, 4H)

Example 56. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 62.8%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 31 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.11 (s, 1H), 8.68 (s, 1H), 8.59 (s, 2H), 8.42 (d, 1H), 7.99 (d, 1H), 7.75 (d, 1H), 4.67 (s, 2H), 3.63 (s, 2H)

Example 57. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

30 mg of the title compound (yield: 69.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 28 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.68 (s, 1H), 8.52 (s, 1H), 8.46 (d, 2H), 8.25 (d, 1H), 7.65 (s, 1H), 7.19 (d, 1H), 4.69 (s, 2H), 3.76 (s, 2H), 3.31 (s, 3H)

Example 58. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

26 mg of the title compound (yield: 59.9%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 28 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.63 (s, 1H), 8.42 (d, 2H), 7.56 (s, 1H), 7.32-7.28 (m, 2H), 6.97 (d, 1H), 6.06 (s, 2H), 4.66 (s, 2H), 3.54 (s, 2H)

Example 59. 6-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-4-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

25 mg of the title compound (yield: 52.3%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 33 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.61 (s, 1H), 8.44 (d, 2H), 7.60 (d, 1H), 7.50 (d, 2H), 4.64 (s, 2H), 3.36 (s, 2H), 3.04 (d, 2H), 2.62 (d, 2H)

Example 60. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

24 mg of the title compound (yield: 59.3%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 32 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 26 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.62 (s, 1H), 8.37-8.29 (m, 3H), 8.02 (s, 1H), 7.53 (s, 1H), 4.68 (s, 2H), 4.26 (q, 2H), 3.76 (s, 2H), 1.52 (t, 3H)

Example 61. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(4-methylsulfonylphenyl)-4-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

45 mg of the title compound (yield: 47.7%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.78 (s, 1H), 8.63 (s, 1H), 8.41 (s, 1H), 8.29 (s, 1H), 8.07 (d, 2H), 7.91 (s, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.18 (s, 3H)

Example 62. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(4-piperazin-1-ylphenyl)-4-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

50 mg of the title compound (yield: 52.2%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 87 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.67 (d, 1H), 8.61 (s, 1H), 8.27 (s, 2H), 7.99 (d, 2H), 7.75 (d, 1H), 7.16 (d, 2H), 4.68 (s, 2H), 3.75 (s, 2H), 3.55 (t, 4H), 3.40 (t, 4H)

Example 63. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[6-(dimethylamino)-3-pyridyl]-4-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

40 mg of the title compound (yield: 46.1%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 56 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.75 (d, 1H), 8.65 (d, 3H), 8.34 (s, 1H), 7.90 (d, 1H), 7.36 (d, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.37 (s, 6H)

Example 64. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(1,3-benzodioxol-5-yl)-4-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 43.8%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 67 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.63 (d, 1H), 8.59 (s, 1H), 8.19 (s, 1H), 7.78 (d, 1H), 7.52 (d, 1H), 7.49 (s, 1H), 6.93 (d, 1H), 4.67 (s, 2H), 3.75 (s, 2H)

Example 65. 6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

42 mg of the title compound (yield: 44.0%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 64 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.66 (d, 1H), 8.64 (s, 1H), 8.27 (s, 1H), 7.82 (d, 1H), 7.71 (s, 2H), 3.03 (t, 2H), 2.61 (t, 2H), 2.29 (s, 3H)

Example 66. 6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

46 mg of the title compound (yield: 48.2%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 64 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.76 (d, 1H), 8.74 (s, 1H), 8.52 (s, 1H), 8.13 (s, 1H), 7.95 (d, 1H), 7.90 (s, 1H), 7.32 (d, 1H), 4.69 (s, 2H), 3.76 (s, 2H), 3.41 (s, 3H), 3.05 (t, 2H), 2.70 (t, 2H)

Example 67. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(1-ethylpyrazol-4-yl)-4-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

42 mg of the title compound (yield: 51.9%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(2-bromo-4-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 33 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 50 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.60 (s, 1H), 8.58 (d, 1H), 8.28 (s, 1H), 8.10 (d, 2H), 7.76 (d, 1H), 4.67 (s, 2H), 4.26 (q, 2H), 3.75 (s, 2H), 1.52 (t, 3H)

Example 68. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-methyl sulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 80.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.74 (s, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 8.09 (d, 2H), 7.99 (d, 2H), 4.69 (s, 2H), 3.77 (s, 2H), 3.19 (s, 3H), 2.45 (s, 3H)

Example 69. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

39 mg of the title compound (yield: 81.0%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 51 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.63 (s, 1H), 8.16 (s, 1H), 8.11 (s, 1H), 7.68 (d, 2H), 7.17 (d, 2H), 4.68 (s, 2H), 3.73 (s, 2H), 3.51 (s, 4H), 3.40 (s, 4H), 2.40 (s, 3H)

Example 70. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 75.3%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.09 (s, 1H), 8.80 (s, 1H), 8.41 (d, 1H), 8.32 (s, 1H), 8.22 (s, 1H), 7.98 (d, 1H), 4.69 (s, 2H), 3.77 (s, 2H), 2.47 (s, 3H)

Example 71. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(dimethylamino)-3-pyridyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

30 mg of the title compound (yield: 68.6%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 32 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.68 (s, 1H), 8.35 (s, 1H), 8.24 (d, 1H), 8.18 (s, 2H), 7.21 (d, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.31 (s, 6H), 2.43 (s, 3H)

Example 72. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 73.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 3,4-(methylenedioxy)phenyl boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.59 (s, 1H), 8.16 (s, 1H), 8.07 (s, 1H), 7.21 (s, 1H), 7.20 (d, 1H), 6.96 (d, 1H), 6.03 (s, 2H), 4.68 (s, 2H), 3.76 (s, 2H), 2.40 (s, 3H)

Example 73. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

40 mg of the title compound (yield: 83.3%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 37 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.54 (s, 1H), 8.16 (s, 1H), 8.06 (s, 1H), 7.36 (d, 2H), 4.70 (s, 2H), 3.78 (s, 2H), 3.01 (t, 2H), 2.59 (t, 2H), 2.40 (s, 3H), 2.29 (s, 3H)

Example 74. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

42 mg of the title compound (yield: 87.5%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 37 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.65 (s, 1H), 8.16 (d, 2H), 7.64 (d, 1H), 7.60 (s, 1H), 7.25 (d, 1H), 4.69 (s, 2H), 3.77 (s, 2H), 3.39 (s, 3H), 3.01 (t, 2H), 2.67 (t, 2H), 2.42 (s, 3H)

Example 75. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 78.2%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 29 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.63 (s, 1H), 8.23 (s, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 7.99 (s, 1H), 4.68 (s, 2H), 4.25 (q, 2H), 3.75 (s, 2H), 2.36 (s, 3H), 1.51 (t, 3H)

Example 76. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-methyl-6-(4-methyl sulfonylphenyl)-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 52.3%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 36 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.87 (s, 1H), 8.43 (s, 1H), 8.15-8.08 (m, 3H), 7.81 (d, 2H), 4.69 (s, 2H), 3.77 (s, 2H), 3.20 (s, 3H), 2.44 (s, 3H)

Example 77. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-methyl-6-[6-(trifluoromethyl)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

17 mg of the title compound (yield: 35.8%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 36 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 30 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.93 (s, 2H), 8.45 (s, 1H), 8.27 (s, 1H), 8.19 (s, 1H), 7.97 (s, 1H), 4.68 (s, 2H), 3.77 (s, 2H), 2.49 (s, 3H)

Example 78. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-5-methyl-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

19 mg of the title compound (yield: 44.0%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 36 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 27 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.83 (s, 1H), 8.40 (s, 1H), 8.23 (s, 1H), 8.10 (s, 1H), 8.02 (s, 1H), 7.06 (s, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.26 (s, 6H), 2.50 (s, 3H)

Example 79. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-5-methyl-3-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

26 mg of the title compound (yield: 59.6%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 36 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 27 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.76 (s, 1H), 8.39 (s, 1H), 8.07 (s, 1H), 7.01-6.96 (m, 3H), 6.04 (s, 2H), 4.67 (s, 2H), 3.76 (s, 2H), 2.43 (s, 3H)

Example 80. 6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

17 mg of the title compound (yield: 35.8%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 36 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 32 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.77 (s, 1H), 8.40 (s, 1H), 8.07 (s, 1H), 7.23 (s, 2H), 4.68 (s, 2H), 3.77 (s, 2H), 3.02 (t, 2H), 2.62 (t, 2H), 2.44 (s, 3H), 2.34 (s, 3H)

Example 81. 6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

22 mg of the title compound (yield: 46.8%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-5-methyl-3-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 36 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 32 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.80 (s, 1H), 8.41 (s, 1H), 8.09 (s, 1H), 7.46 (d, 1H), 7.42 (s, 1H), 7.25 (d, 1H), 4.68 (s, 2H), 3.77 (s, 2H), 3.42 (s, 3H), 3.01 (t, 2H), 2.69 (t, 2H), 2.45 (s, 3H)

Example 82. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-(4-methyl sulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

23 mg of the title compound (yield: 48.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.77 (s, 1H), 8.31 (s, 1H), 8.28 (s, 1H), 8.11 (d, 2H), 8.02 (d, 2H), 4.69 (s, 2H), 3.77 (s, 2H), 3.19 (s, 3H)

Example 83. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

18 mg of the title compound (yield: 38.9%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 42 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.67 (s, 1H), 8.24 (s, 1H), 8.12 (d, 1H), 7.72 (d, 2H), 7.18 (d, 2H), 4.68 (s, 2H), 3.76 (s, 2H), 3.54 (t, 4H), 3.41 (t, 4H)

Example 84. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 44.4%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 29 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.13 (s, 1H), 8.83 (s, 1H), 8.44 (d, 2H), 8.29 (s, 1H), 8.00 (s, 1H), 4.69 (s, 2H), 3.77 (s, 2H)

Example 85. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)-3-fluoro-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 74.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 27 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.60 (s, 1H), 8.22 (s, 1H), 8.07 (d, 1H), 7.24 (s, 1H), 7.22 (s, 1H), 6.96 (d, 1H), 6.04 (s, 2H), 4.68 (s, 2H), 3.74 (s, 2H)

Example 86. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-fluoro-3-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

17 mg of the title compound (yield: 35.2%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 31 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.58 (s, 1H), 8.23 (s, 1H), 8.07 (d, 1H), 7.41 (s, 1H), 4.69 (s, 2H), 3.78 (s, 2H), 3.01 (t, 2H), 2.59 (t, 2H), 2.31 (s, 3H)

Example 87. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-fluoro-3-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

18 mg of the title compound (yield: 38.9%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 31 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.68 (s, 1H), 8.25 (s, 1H), 8.17 (d, 1H), 7.68 (d, 1H), 7.64 (s, 1H), 7.27 (d, 1H), 4.68 (s, 2H), 3.77 (s, 2H), 3.39 (s, 3H), 3.02 (t, 2H), 2.66 (t, 2H)

Example 88. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)-3-fluoro-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

18 mg of the title compound (yield: 45.4%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-fluoro-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 37 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 37 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.65 (s, 1H), 8.28 (s, 1H), 8.21 (s, 1H), 8.10 (d, 1H), 8.03 (s, 1H), 4.67 (s, 2H), 4.26 (q, 2H), 3.75 (s, 2H), 1.50 (t, 3H)

Example 89. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(4-methylsulfonylphenyl)-pyrazin-2-yl]-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 57.3%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 9.53 (s, 1H), 9.04 (s, 1H), 8.63 (s, 1H), 8.30 (d, 2H), 8.03 (d, 2H), 4.69 (s, 2H), 3.78 (s, 2H), 3.17 (s, 3H)

Example 90. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(4-piperazin-1-ylphenyl)pyrazin-2-yl]-1,2,4-triazol-3-one Ditrifluoroacetate

30 mg of the title compound (yield: 44.6%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 61 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.45 (s, 1H), 8.98 (s, 1H), 8.63 (s, 1H), 8.07 (d, 2H), 7.18 (d, 2H), 4.68 (s, 2H), 3.76 (s, 2H), 3.56 (t, 4H), 3.41 (t, 4H)

Example 91. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(trifluoromethyl)-3-pyridyl]pyrazin-2-yl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 49.3%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 43 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.64 (s, 1H), 9.43 (s, 1H), 9.20 (s, 1H), 8.75 (d, 1H), 8.68 (s, 2H), 7.98 (d, 1H), 4.69 (s, 2H), 3.78 (s, 2H)

Example 92. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(dimethylamino)-3-pyridyl]pyrazin-2-yl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 47.6%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 39 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.48 (s, 1H), 8.97 (s, 1H), 8.76 (s, 1H), 8.63 (s, 1H), 8.44 (d, 1H), 7.05 (d, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.32 (s, 6H)

Example 93. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)pyrazin-2-yl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 57.4%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 39 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.44 (s, 1H), 8.91 (s, 1H), 8.61 (s, 1H), 7.64 (d, 1H), 7.60 (s, 1H), 6.96 (d, 1H), 6.05 (s, 2H), 4.67 (s, 2H), 3.69 (s, 2H)

Example 94. 6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]pyrazin-2-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

41 mg of the title compound (yield: 61.1%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 45 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.47 (s, 1H), 8.98 (s, 1H), 8.64 (s, 1H), 8.03 (d, 1H), 7.99 (s, 1H), 7.25 (d, 1H), 4.68 (s, 2H), 3.77 (s, 2H), 3.39 (s, 3H), 3.03 (t. 2H), 2.68 (t, 2H)

Example 95. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)pyrazin-2-yl]-1,2,4-triazol-3-one Trifluoroacetate

39 mg of the title compound (yield: 68.6%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromopyrazin-2-yl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 39 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 35 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.37 (s, 1H), 8.79 (s, 1H), 8.60 (s, 1H), 8.34 (s, 1H), 8.12 (s, 1H), 4.67 (s, 1H), 4.27 (q, 2H), 3.92 (s, 2H), 1.52 (t, 3H)

Example 96. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(4-benzyloxyphenyl)methyl]-1,2,4-triazol-3-one Trifluoroacetate

17 mg of the title compound (yield: 8.5%) as a colorless liquid was prepared in the same fashion as Example 1, except that 126 mg of tert-butyl N-[2-[[4-[(4-benzyloxyphenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 40 was used. ¹H-NMR (MeOD, 400 MHz) δ 7.88 (s, 1H), 7.41-7.36 (m, 4H), 7.29 (d, 3H), 6.99 (d, 2H), 5.08 (s, 2H), 4.79 (s, 2H), 4.57 (s, 2H), 3.66 (s, 2H)

Example 97. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(5-bromo-2-thienyl)methyl]-1,2,4-triazol-3-one Trifluoroacetate

92 mg of the title compound (yield: 1.0%) was prepared in the same fashion as Example 1, except that 116 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used. ¹H-NMR (MeOD, 400 MHz) δ 7.96 (s, 1H), 6.98 (d, 2H), 5.00 (s, 2H), 4.58 (s, 2H), 3.67 (s, 2H)

Example 98. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(4-bromo-2-thienyl)methyl]-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 76.0%) was prepared in the same fashion as Example 1, except that 57 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.40 (s, 1H), 7.12 (s, 1H), 5.04 (s, 2H), 4.57 (s, 2H), 3.66 (s, 2H).

Example 99. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(5-bromo-3-methyl-2-thienyl)methyl]-1,2,4-triazol-3-one Trifluoroacetate

16 mg of the title compound (yield: 3.7%) was prepared in the same fashion as Example 1, except that 546 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 43 was used. ¹H-NMR (MeOD, 400 MHz) δ 7.90 (s, 1H), 6.90 (s, 1H), 4.94 (s, 2H), 4.57 (s, 2H), 3.67 (s, 2H), 2.27 (s, 3H)

Example 100. 4-[[5-(4-acetylphenyl)-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one trifluoroacetate Step 1: tert-butyl N-[2-[[4-[[5-(4-acetylphenyl)-2-thienyl]methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate

80 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 28 m of 4-acetylphenylboronicacid 28 were dissolved in 1.6 mL of 1,4-dioxane, followed by the addition of 0.9 mL of 1 M potassium carbonate and 7 mg of palladiumdi[1,1′-bis(diphenylphospino)ferrocene]dichloride (PdCl₂(dppf)), and the resulting solution was stirred overnight at 90° C. The resulting reaction mixture was filtered through a celite pad and concentrated under reduced pressure to give a residue. The residue thus obtained was dissolved in ethylacetate, washed with distilled water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=1/1) to give 47 mg of the title compound (yield: 54.2%). MS (ESI) m/z=405.2 (M+H)+

Step 2: 4-[[5-(4-acetylphenyl)-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one

47 mg of tert-butyl N-[2-[[4-[[5-(4-acetylphenyl)-2-thienyl]methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Step 1 was dissolved in 1.0 mL of dichloromethane, followed by the addition of 0.1 mL of trifluoroacetic acid, and the resulting solution was stirred at room temperature for 2 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. The solution was concentrated under reduced pressure and then dried in vacuo to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 4 mg of the title compound as a white solid (yield: 12.0%). ¹H-NMR (MeOD, 400 MHz) δ 8.00 (s, 1H), 7.99 (d, 2H), 7.72 (d, 2H), 7.43 (s, 1H), 7.18 (s, 1H), 5.09 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 2.60 (s, 3H)

Example 101. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methylsulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

42 mg of the title compound (yield: 82.2%) was prepared in the same fashion as Example 100, except that in Step 1, 26 mg of 4-(methanesulfonyl)phenylboronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (s, 1H), 7.94 (d, 2H), 7.84 (d, 2H), 7.48 (s, 1H), 7.19 (s, 1H), 5.10 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.14 (s, 3H)

Example 102. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3-methyl sulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

8 mg of the title compound (yield: 11.0%) was prepared in the same fashion as Example 100, except that in Step 1, 34 mg of 3-(methanesulfonyl)phenylboronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.11 (s, 1H), 8.00 (s, 1H), 7.92-7.86 (m, 2H), 7.64 (t, 1H), 7.42 (s, 1H), 7.17 (s, 1H), 5.09 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 3.17 (s, 3H)

Example 103. 3-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N,N-dimethyl-benzenesulfonamide trifluoroacetate

16 mg of the title compound (yield: 17.6%) was prepared in the same fashion as Example 100, except that in Step 1, 54 mg of 3-(N,N-dimethylaminosulfonyl)phenylboronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.00 (s, 1H), 7.92 (s, 2H), 7.72-7.63 (m, 2H), 7.42 (s, 1H), 7.19 (s, 1H), 5.10 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H), 2.72 (s, 6H)

Example 104. 4-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N-methyl-benzamide trifluoroacetate

22 mg of the title compound (yield: 29.4%) was prepared in the same fashion as Example 100, except that in Step 1, 36 mg of (4-(methylcarbamoyl)phenyl)boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.00 (s, 1H), 7.83 (d, 2H), 7.69 (d, 2H), 7.39 (s, 1H), 7.16 (s, 1H), 5.08 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 2.93 (s, 3H)

Example 105. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3,4,5-trimethoxyphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

22 mg of the title compound (yield: 45.4%) was prepared in the same fashion as Example 100, except that in Step 1, 23 mg of 3,4,5-trimethoxyphenylboronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.24 (s, 1H), 7.12 (s, 1H), 6.85 (s, 2H), 5.05 (s, 2H), 4.59 (s, 2H), 3.88 (s, 6H), 3.78 (s, 3H), 3.67 (s, 2H)

Example 106. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

40 mg of the title compound (yield: 81.8%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.52 (d, 2H), 7.15 (s, 1H), 7.09 (s, 1H), 7.03 (d, 2H), 5.04 (s, 2H), 4.59 (s, 2H), 3.66 (s, 2H), 3.45 (s, 4H), 3.38 (s, 4H)

Example 107. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

11 mg of the title compound (yield: 18.2%) was prepared in the same fashion as Example 100, except that in Step 1, 51 mg of tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.33-7.29 (m, 2H), 7.22 (s, 1H), 7.18-7.13 (m, 2H), 6.99 (d, 1H), 5.06 (s, 2H), 4.59 (s, 2H), 3.64 (s, 2H), 3.45 (t, 4H), 3.38 (t, 4H)

Example 108. 4-[[5-[4-(4-acetylpiperazin-1-yl)phenyl]-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one Trifluoroacetate

695 mg of the title compound (yield: 66.0%) was prepared in the same fashion as Example 100, except that in Step 1, 923 mg of 4-(4-acetyl-1-piperazinyl)phenylboronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.49 (d, 2H), 7.14 (d, 1H), 7.09 (d, 1H), 7.00 (d, 2H), 5.03 (s, 2H), 4.59 (s, 2H), 3.74 (t, 2H), 3.71 (t, 2H), 3.66 (s, 2H), 3.26 (t, 2H), 3.21 (t, 2H), 2.16 (s, 3H)

Example 109. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-morpholine-4-carbonyl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one trifluoroacetate

23 mg of the title compound (yield: 29.4%) was prepared in the same fashion as Example 100, except that in Step 1, 54 mg of 4-(morpholine-4-carbonyl)phenylboronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.00 (s, 1H), 7.71 (d, 2H), 7.47 (d, 2H), 7.38 (s, 1H), 7.16 (s, 1H), 5.08 (s, 2H), 4.59 (s, 2H), 3.75-3.50 (m, 8H), 3.68 (s, 2H)

Example 110. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1H-pyrazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

6 mg of the title compound (yield: 5.9%) was prepared in the same fashion as Example 100, except that in Step 1, 32 mg of [3-(1H-pyrazol-3-yl)phenyl]boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.04 (s, 1H), 8.00 (s, 1H), 7.70 (s, 2H), 7.56 (d, 1H), 7.46 (t, 1H), 7.37 (s, 1H), 7.17 (s, 1H), 6.73 (s, 1H), 5.09 (s, 2H), 4.60 (s, 2H), 3.65 (s, 2H)

Example 111. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

7 mg of the title compound (yield: 9.1%) was prepared in the same fashion as Example 100, except that in Step 1, 25 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.97 (s, 1H), 8.24 (d, 1H), 8.02 (s, 1H), 7.84 (d, 1H), 7.57 (s, 1H), 7.24 (s, 1H), 5.12 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H)

Example 112. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

45 mg of the title compound (yield: 1.0%) was prepared in the same fashion as Example 100, except that in Step 1, 32 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.11 (d, 2H), 7.99 (s, 1H), 7.28 (s, 1H), 7.17 (s, 2H), 5.08 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.28 (s, 6H)

Example 113. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(6-methoxy-3-pyridyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 41.2%) was prepared in the same fashion as Example 100, except that in Step 1, 40 mg of 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.34 (s, 1H), 7.99 (s, 1H), 7.88 (d, 1H), 7.21 (s, 1H), 7.14 (s, 1H), 6.83 (d, 1H), 5.06 (s, 2H), 4.59 (s, 2H), 3.93 (s, 3H), 3.68 (s, 2H)

Example 114. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(6-piperazin-1-yl-3-pyridyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

35 mg of the title compound (yield: 72.7%) was prepared in the same fashion as Example 100, except that in Step 1, 54 mg of tert-butyl 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]piperazine-1-carboxylate was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.41 (s, 1H), 7.98 (s, 1H), 7.83 (d, 1H), 7.15 (d, 2H), 6.96 (d, 1H), 5.06 (s, 2H), 4.59 (s, 2H), 3.85 (s, 4H), 3.68 (s, 2H), 3.32 (s, 4H)

Example 115. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-5-fluoro-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

26 mg of the title compound (yield: 35.3%) was prepared in the same fashion as Example 100, except that in Step 1, 46 mg of 3-fluoro-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-amine was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.13 (s, 1H), 7.98 (s, 1H), 7.54 (d, 1H), 7.17 (s, 1H), 7.11 (s, 1H), 5.05 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.11 (s, 6H)

Example 116. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-aminopyrimidin-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 41.2%) was prepared in the same fashion as Example 100, except that in Step 1, 55 mg of 2-(tert-butoxycarbonylamino)pyrimidine-5-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.47 (s, 2H), 7.98 (s, 1H), 7.15 (d, 2H), 5.06 (s, 2H), 4.59 (s, 2H), 3.66 (s, 2H)

Example 117. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-ethoxypyrimidin-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 29.4%) was prepared in the same fashion as Example 100, except that in Step 1, 29 mg of 2-ethoxypyrimidin-5-boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.76 (s, 2H), 8.00 (s, 1H), 7.33 (s, 1H), 7.19 (s, 1H), 5.09 (s, 2H), 4.59 (s, 2H), 4.48 (q, 2H), 3.68 (s, 2H), 1.42 (t, 3H)

Example 118. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2-methoxyethylamino)pyrimidin-5-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 43.6%) was prepared in the same fashion as Example 100, except that in Step 1, 30 mg of N-(2-methoxyethyl)-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine-2-amine was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.49 (s, 2H), 7.94 (s, 1H), 7.14 (d, 1H), 5.50 (s, 4H), 5.05 (s, 2H), 4.55 (s, 2H), 3.38-3.28 (m, 7H)

Example 119. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

48 mg of the title compound (yield: 51.6%) was prepared in the same fashion as Example 100, except that in Step 1, 62 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.96 (s, 1H), 7.89 (s, 1H), 7.66 (s, 1H), 7.06 (s, 1H), 7.01 (s, 1H), 5.02 (s, 2H), 4.58 (s, 2H), 4.18 (q, 2H), 3.67 (s, 2H), 1.47 (t, 3H)

Example 120. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-chloro-3-methyl-imidazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

17 mg of the title compound (yield: 24.9%) was prepared in the same fashion as Example 100, except that in Step 1, 42 mg of 2-chloro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.20 (S, 1H), 7.14 (d, 1H), 7.05 (s, 1H), 5.09 (s, 2H), 4.57 (s, 2H), 3.68 (s, 2H), 3.65 (s, 3H)

Example 121. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-methyl-pyridin-2-one Trifluoroacetate

8 mg of the title compound (yield: 11.8%) was prepared in the same fashion as Example 100, except that in Step 1, 40 mg of 1-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 2H), 7.77 (d, 1H), 7.12 (d, 2H), 6.58 (d, 1H), 5.04 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.60 (s, 3H)

Example 122. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-ethyl-pyridin-2-one Trifluoroacetate

46 mg of the title compound (yield: 52.4%) was prepared in the same fashion as Example 100, except that in Step 1, 70 mg of 1-ethyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 2H), 7.77 (d, 1H), 7.13 (d, 2H), 6.59 (d, 1H), 5.05 (s, 2H), 4.59 (s, 2H), 4.08 (q, 2H), 3.68 (s, 2H), 1.36 (t, 3H)

Example 123. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-isopropyl-pyridin-2-one Trifluoroacetate

14 mg of the title compound (yield: 33.3%) was prepared in the same fashion as Example 100, except that in Step 1, 27 mg of 1-isopropyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.86 (s, 1H), 7.74 (d, 1H), 7.15 (d, 2H), 6.60 (d, 1H), 5.20 (m, 1H), 5.06 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H), 1.44 (d, 6H)

Example 124. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

14 mg of the title compound (yield: 27.3%) was prepared in the same fashion as Example 100, except that in Step 1, 31 mg of 1-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.95 (s, 1H), 7.06 (s, 2H), 6.08 (s, 1H), 5.02 (s, 2H), 4.58 (s, 2H), 3.85 (s, 2H), 3.67 (s, 2H), 3.59 (s, 2H), 2.96 (s, 3H), 2.86 (s, 2H)

Example 125. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

11 mg of the title compound (yield: 18.2%) was prepared in the same fashion as Example 100, except that in Step 1, 35 mg of 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-yl)ethanone was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.94 (s, 1H), 7.03 (s, 1H), 6.95 (d, 1H), 6.09 (s, 1H), 5.00 (s, 2H), 4.58 (s, 2H), 4.16 (d, 2H), 3.75 (d, 2H), 3.66 (s, 2H), 2.56 (d, 2H), 2.15 (s, 3H)

Example 126. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

42 mg of the title compound (yield: 90.9%) was prepared in the same fashion as Example 100, except that in Step 1, 21 mg of 3,4-(methylenedioxy)phenyl boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.96 (s, 1H), 7.11 (s, 1H), 7.06 (s, 3H), 6.81 (d, 1H), 5.97 (s, 2H), 5.02 (s, 2H), 4.58 (s, 2H), 3.67 (s, 2H).

Example 127. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1H-indazol-6-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

27 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 100, except that in Step 1, 34 mg of 1H-indazole-6-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (d, 2H), 7.78 (d, 1H), 7.73 (s, 1H), 7.42 (d, 1H), 7.36 (s, 1H), 7.16 (s, 1H), 5.08 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H)

Example 128. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

40 mg of the title compound (yield: 90.9%) was prepared in the same fashion as Example 100, except that in Step 1, 34 mg of 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.74 (d, 1H), 8.40 (s, 1H), 8.03 (s, 1H), 7.87 (s, 1H), 7.57 (s, 1H), 7.47 (d, 1H), 7.21 (s, 1H), 5.12 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H)

Example 129. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2,1,3-benzoxadiazol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 72.7%) was prepared in the same fashion as Example 100, except that in Step 1, 26 mg of benzo[c][1,2,5]oxadiazole-5-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (d, 2H), 7.94 (d, 1H), 7.86 (d, 1H), 7.57 (d, 1H), 7.21 (d, 1H), 5.12 (s, 2H), 4.60 (s, 2H), 3.67 (s, 2H)

Example 130. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-7-fluoro-indolin-2-one Trifluoroacetate

14 mg of the title compound (yield: 27.3%) was prepared in the same fashion as Example 100, except that in Step 1, 7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one 39 mg was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.35 (s, 1H), 7.29 (d, 1H), 7.22 (s, 1H), 7.11 (s, 1H), 5.05 (s, 2H), 4.58 (s, 2H), 3.65 (d, 2H), 3.59 (s, 2H)

Example 131. N-[6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,3-benzothiazol-2-yl]acetamide trifluoroacetate

28 mg of the title compound (yield: 54.5%) was prepared in the same fashion as Example 100, except that in Step 1, 44 mg of N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.07 (s, 1H), 8.00 (s, 1H), 7.71 (d, 1H), 7.64 (d, 1H), 7.30 (d, 1H), 7.14 (d, 1H), 5.07 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H), 2.27 (s, 3H)

Example 132. 7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3,4-dihydro-2H-isoquinolin-1-one Trifluoroacetate

33 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 100, except that in Step 1, 38 mg of (1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.14 (s, 1H), 8.00 (s, 1H), 7.74 (d, 1H), 7.35 (d, 1H), 7.34 (s, 1H), 7.15 (s, 1H), 5.08 (s, 2H), 4.59 (s, 2H), 3.65 (s, 2H), 3.53 (t, 2H), 3.01 (t, 2H)

Example 133. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

26 mg of the title compound (yield: 54.5%) was prepared in the same fashion as Example 100, except that in Step 1, 38 mg of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.43 (s, 1H), 7.40 (d, 1H), 7.20 (d, 1H), 7.10 (d, 1H), 6.87 (d, 1H), 5.05 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 2.98 (t, 2H), 2.58 (t, 2H)

Example 134. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

34 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 100, except that in Step 1, 37 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.26 (s, 2H), 7.17 (s, 1H), 7.09 (s, 1H), 5.04 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 2.94 (t, 2H), 2.55 (t, 2H), 2.27 (s, 3H)

Example 135. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-methyl-1H-quinolin-2-one Trifluoroacetate

33 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 100, except that in Step 1, 40 mg of 8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-quinolin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (s, 1H), 7.90 (d, 1H), 7.61 (d, 2H), 7.25 (s, 1H), 7.12 (s, 1H), 6.59 (d, 1H), 5.07 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 2.47 (s, 3H)

Example 136. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-fluoro-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

29 mg of the title compound (yield: 54.5%) was prepared in the same fashion as Example 100, except that in Step 1, 41 mg of 8-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1H-quinolin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.26-7.24 (m, 3H), 7.11 (s, 1H), 5.05 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.01 (t, 2H), 2.60 (t, 2H)

Example 137. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-fluoro-1H-quinolin-2-one Trifluoroacetate

30 mg of the title compound (yield: 54.5%) was prepared in the same fashion as Example 100, except that in Step 1, 40 mg of 8-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-quinolin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (s, 1H), 7.95 (d, 1H), 7.65 (s, 1H), 7.60 (d, 1H), 7.31 (s, 1H), 7.13 (s, 1H), 6.65 (d, 1H), 5.08 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H)

Example 138. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

41 mg of the title compound (yield: 81.8%) was prepared in the same fashion as Example 100, except that in Step 1, 37 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (s, 1H), 7.48 (d, 1H), 7.44 (s, 1H), 7.22 (s, 1H), 7.12 (s, 2H), 5.05 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.34 (s, 3H), 2.93 (t, 2H), 2.62 (t, 2H)

Example 139. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(5-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 100, except that in Step 1, 38 mg of (5-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.09 (d, 1H), 6.78 (d, 1H), 6.58 (s, 2H), 5.05 (s, 2H), 4.59 (s, 2H), 4.17 (t, 2H), 3.68 (s, 2H), 3.43 (t, 2H), 2.10 (s, 3H).

Example 140. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

27 mg of the title compound (yield: 54.5%) was prepared in the same fashion as Example 100, except that in Step 1, 38 mg of 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1,4-benzoxazine was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.95 (s, 1H), 7.04 (s, 3H), 6.91 (s, 1H), 6.68 (d, 1H), 5.01 (s, 2H), 4.58 (s, 2H), 4.27 (s, 2H), 3.66 (s, 2H), 3.36-3.27 (m, 6H), 2.90 (s, 3H)

Example 141. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-4H-1,4-benzoxazin-3-one Trifluoroacetate

11 mg of the title compound (yield: 27.3%) was prepared in the same fashion as Example 100, except that in Step 1, 30 mg of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazine-3(4H)-ones was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.21-7.12 (m, 4H), 6.96 (d, 1H), 5.05 (s, 2H), 4.59 (d, 4H), 3.59 (s, 2H)

Example 142. 7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one Trifluoroacetate

35 mg of the title compound (yield: 72.7%) was prepared in the same fashion as Example 100, except that in Step 1, 41 mg of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (s, 1H), 7.28 (s, 1H), 7.26 (d, 1H), 7.18 (d, 1H), 7.13 (d, 1H), 7.09 (s, 1H), 5.31 (s, 2H), 5.06 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H)

Example 143. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one Trifluoroacetate

31 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 100, except that in Step 1, 38 mg of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.49 (d, 1H), 7.43 (s, 1H), 7.21 (d, 1H), 7.11 (d, 1H), 6.89 (d, 1H), 5.33 (s, 2H), 5.05 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H)

Example 144. 7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-4-methyl-1,4-benzoxazin-3-one Trifluoroacetate

34 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 100, except that in Step 1, 43 mg of 4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzo[b][1,4]oxazine-7-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.28 (d, 1H), 7.20 (d, 2H), 7.12 (d, 2H), 5.05 (s, 2H), 4.62 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.34 (s, 3H)

Example 145. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

6 mg of the title compound (yield: 18.2%) was prepared in the same fashion as Example 100, except that in Step 1, 36 mg of (5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.92 (s, 1H), 7.69 (s, 1H), 7.17 (s, 1H), 7.12 (s, 1H), 5.05 (s, 2H), 4.58 (s, 2H), 3.67 (s, 2H), 3.50 (d, 2H), 2.86 (m, 2H), 1.95 (m, 2H)

Example 146. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-methyl sulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

83 mg of the title compound (yield: 87.0%) was prepared in the same fashion as Example 100, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 60 mg of 4-(methanesulfonyl)phenylboronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.02-7.97 (m, 3H), 7.92-7.86 (m, 3H), 7.62 (s, 1H), 5.12 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.15 (s, 3H)

Example 147. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

45 mg of the title compound (yield: 56.3%) was prepared in the same fashion as Example 100, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 83 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (s, 1H), 7.58-7.48 (m, 4H), 7.06 (d, 2H), 5.08 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H), 3.45-3.32 (m, 8H)

Example 148. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

33 mg of the title compound (yield: 35.6%) was prepared in the same fashion as Example 100, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 59 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 9.01 (s, 1H), 8.29 (d, 1H), 8.02 (s, 1H), 7.97 (s, 1H), 7.85 (d, 1H), 7.66 (s, 1H), 5.13 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H)

Example 149. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(dimethylamino)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 40.0%) was prepared in the same fashion as Example 100, except that in Step 1, X mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 53 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.20-8.17 (m, 2H), 8.00 (s, 1H), 7.68 (s, 1H), 7.51 (s, 1H), 7.16 (d, 1H), 5.10 (s, 2H), 4.59 (s, 2H), 3.72 (s, 2H), 3.27 (s, 6H)

Example 150. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1,3-benzodioxol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

40 mg of the title compound (yield: 45.8%) was prepared in the same fashion as Example 100, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 44 mg of 3,4-(methylenedioxy)phenyl boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.45 (d, 2H), 7.11 (d, 2H), 6.93 (s, 1H), 6.84 (d, 1H), 5.96 (s, 2H), 5.07 (s, 2H), 4.58 (s, 2H), 3.66 (s, 2H)

Example 151. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

36 mg of the title compound (yield: 37.6%) was prepared in the same fashion as Example 100, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 62 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. MS (ESI) m/z=444.1 (M+H)+

Example 152. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

40 mg of the title compound (yield: 41.8%) was prepared in the same fashion as Example 100, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 62 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.00 (s, 1H), 7.57-7.50 (m, 4H), 7.14 (d, 1H), 5.09 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.35 (s, 3H), 2.95 (t, 2H), 2.63 (t, 2H)

Example 153. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-ethylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

37 mg of the title compound (yield: 45.2%) was prepared in the same fashion as Example 100, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 48 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.91 (s, 1H), 7.73 (s, 1H), 7.36 (d, 2H), 5.05 (s, 2H), 4.58 (s, 2H), 4.18 (q, 2H), 3.67 (s, 2H), 1.47 (t, 3H)

Example 154. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-(4-methylsulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 43.3%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 43 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 21 mg of 4-(methanesulfonyl)phenylboronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.99-7.92 (m, 3H), 7.81 (d, 2H), 7.38 (s, 1H), 5.03 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.12 (s, 3H), 2.34 (s, 3H)

Example 155. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

6 mg of the title compound (yield: 13.5%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 43 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 40 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.90 (s, 1H), 7.51 (d, 2H), 7.06-7.02 (m, 3H), 4.98 (s, 2H), 4.58 (s, 2H), 3.67 (s, 2H), 3.45 (t, 4H), 3.38 (t, 4H), 2.30 (s, 3H)

Example 156. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

14 mg of the title compound (yield: 30.8%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 43 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 28 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.92 (s, 1H), 8.19 (d, 1H), 7.97 (s, 1H), 7.81 (d, 1H), 7.45 (s, 1H), 5.06 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 2.35 (s, 3H)

Example 157. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

17 mg of the title compound (yield: 38.5%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 43 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 26 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.11-8.07 (m, 2H), 7.92 (s, 1H), 7.18-7.14 (m, 2H), 5.10 (s, 2H), 4.58 (s, 2H), 3.68 (s, 2H), 3.27 (s, 6H), 2.32 (s, 3H)

Example 158. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

28 mg of the title compound (yield: 62.5%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 43 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 26 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.89 (s, 1H), 7.05-7.00 (m, 2H), 6.80 (d, 1H), 5.95 (s, 2H), 4.96 (s, 2H), 4.58 (s, 2H), 3.67 (s, 2H), 2.29 (s, 3H)

Example 159. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

10 mg of the title compound (yield: 24.0%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 43 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 23 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.88 (s, 1H), 7.86 (s, 1H), 7.64 (s, 1H), 6.91 (s, 1H), 4.96 (s, 2H), 4.58 (s, 2H), 4.18 (q, 2H), 3.67 (s, 2H), 2.28 (s, 3H), 1.46 (t, 3H)

Example 160. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one trifluoroacetate Step 1: tert-butyl N-[3,3-difluoro-2-[[4-[6-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate

60 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31, 10 mg of 4-ethynyl-1-methyl-1H-pyrazole, 8 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh₃)₄), and 3 mg of copper(I) iodide (CuI) were dissolved in 1 mL of N,N-dimethylformamide, followed by the addition of 56.0 uL of triethylamine, and the resulting solution was stirred overnight at 90° C. The resulting reaction mixture was filtered through a celite pad and concentrated under reduced pressure to give a residue. The residue thus obtained was dissolved in ethylacetate, washed with distilled water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=2/1) to give 51.7 mg of the title compound as a yellow liquid (yield: 82.1%). MS (ESI) m/z=372.0 (M+H)+

Step 2: 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one

51.7 mg of tert-butyl N-[3,3-difluoro-2-[[4-[6-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate prepared in Step 1 was dissolved in 1.0 mL of dichloromethane, followed by the addition of 0.1 mL of trifluoroacetic acid, and the resulting solution was stirred at room temperature for 2 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. The solution was concentrated under reduced pressure and then dried in vacuo to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 10 mg of the title compound as a white solid (yield: 24.5%). ¹H-NMR (MeOD, 400 MHz) δ 8.62 (s, 1H), 8.19 (d, 1H), 7.94 (s, 2H), 7.70 (s, 1H), 7.48 (d, 1H), 4.61 (s, 2H), 3.92 (s, 3H), 3.40 (s, 2H)

Example 161. 7-[(E)-2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]vinyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one Trifluoroacetate

17 mg of the title compound (yield: 36.4%) was prepared in the same fashion as Example 100, except that in Step 1, 42 mg of 7-[(E)-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]-1H,2H,3H-pyrido[2,3,b][1,4]oxazin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.87 (s, 1H), 7.44 (s, 1H), 7.23 (d, 1H), 7.04 (d, 2H), 6.85 (d, 1H), 5.04 (s, 2H), 4.84 (s, 2H), 4.58 (s, 2H), 3.60 (s, 2H)

Example 162. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-[6-(dimethylamino)-3-pyridyl]ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 54.5%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 39 mg of 5-ethynyl-N,N-dimethylpyridine-2-amine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.15 (s, 1H), 7.98 (s, 1H), 7.73 (d, 1H), 7.17 (s, 1H), 7.08 (s, 1H), 6.90 (d, 1H), 5.05 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.20 (s, 6H)

Example 163. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(6-morpholino-3-pyridyl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

42 mg of the title compound (yield: 81.8%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 51 mg of 4-(5-ethynylpyridin-2-yl)morpholine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.23 (s, 1H), 7.98 (s, 1H), 7.61 (d, 1H), 7.13 (s, 1H), 7.07 (s, 1H), 6.79 (d, 1H), 5.04 (s, 2H), 4.59 (s, 2H), 3.78 (s, 4H), 3.67 (s, 2H), 3.56 (s, 4H)

Example 164. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

26 mg of the title compound (yield: 81.8%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 70 mg of tert-butyl-6-ethynyl-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.07 (d, 2H), 6.72 (s, 1H), 6.67 (t, 2H), 5.03 (s, 2H), 4.58 (s, 2H), 4.21 (s, 2H), 3.67 (s, 2H), 3.34-3.31 (s, 2H)

Example 165. 6-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

38 mg of the title compound (yield: 72.7%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 46 mg of 6-ethynyl-1,2,3,4-tetrahydroquinolin-2-one was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.30 (d, 2H), 7.14 (s, 1H), 7.07 (s, 1H), 6.86 (d, 1H), 5.04 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H), 2.96 (t, 2H), 2.58 (t, 2H)

Example 166. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

38 mg of the title compound (yield: 81.8%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 43 mg of 7-ethynyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.52 (s, 1H), 7.16 (s, 1H), 7.07 (s, 1H), 7.01 (s, 1H), 5.05 (s, 2H), 4.59 (s, 2H), 4.39 (s, 2H), 3.67 (s, 2H), 3.38 (s, 2H)

Example 167. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

39 mg of the title compound (yield: 72.7%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 43 mg of 7-ethynyl-2H,3H,4H-pyrido[3,2-b][1,4]oxazine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.69 (s, 1H), 7.12 (s, 1H), 7.05 (d, 2H), 5.04 (s, 2H), 4.58 (s, 2H), 4.18 (s, 2H), 3.67 (s, 2H), 3.55 (s, 2H)

Example 168. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

26 mg of the title compound (yield: 54.5%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 43 mg of 6-ethynyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.16 (s, 1H), 7.07 (s, 1H), 7.01 (d, 1H), 6.91 (d, 1H), 5.04 (s, 2H), 4.58 (s, 2H), 4.36 (s, 2H), 3.66 (s, 2H), 3.41 (s, 2H)

Example 169. 7-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one Trifluoroacetate

32 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 47 mg of 7-ethynyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.93 (s, 1H), 7.32 (s, 1H), 7.21 (s, 1H), 7.10 (s, 1H), 5.06 (s, 2H), 4.87 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H)

Example 170. 7-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Trifluoroacetate

34 mg of the title compound (yield: 63.6%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 and 47 mg of 7-ethynyl-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (s, 1H), 7.98 (s, 1H), 7.37 (s, 1H), 7.20 (s, 1H), 7.09 (s, 1H), 5.06 (s, 2H), 4.68 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H)

Example 171. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 72.7%) was prepared in the same fashion as Example 160, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 was used instead of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.84 (s, 1H), 7.61 (s, 1H), 7.08 (d, 2H), 5.04 (s, 2H), 4.58 (s, 2H), 3.90 (s, 3H), 3.67 (s, 2H)

Example 172. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(2-thienyl)ethyl]-1,2,4-triazol-3-one Trifluoroacetate

43 mg of tert-butyl N-[3,3-difluoro-2-[[5-oxo-4-[2-(2-thienyl)ethyl]-1,2,4-triazol-1-yl]methyl]allyl]carbamate prepared in Reference Example 44 was dissolved in 5.0 mL of dichloromethane, followed by the addition of 0.5 mL of trifluoroacetate, and the resulting solution was stirred at room temperature for 3 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. The concentrated reaction mixture was washed with an aqueous solution of sodium hydrogen carbonate, then dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 34 mg of the title compound as a white solid (yield: 100%). ¹H-NMR (MeOD, 400 MHz) δ 7.67 (s, 1H), 7.25 (s, 1H), 6.94 (s, 1H), 6.86 (s, 1H), 4.55 (s, 2H), 3.96 (t, 2H), 3.63 (s, 2H), 3.27 (t, 2H)

Example 173. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(4-methyl sulfonylphenyl)-2-thienyl]ethyl]-1,2,4-triazol-3-one trifluoroacetate Step 1: tert-butyl N-[3,3-difluoro-2-[[4-[2-[5-(4-methylsulfonylphenyl)-2-thienyl]ethyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate

60 mg of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)ethyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 45 and 32 mg of 4-(methanesulfonyl)phenylboronic acid were dissolved in 1.6 mL of 1,4-dioxane, followed by the addition of 0.4 mL of 1 M potassium carbonate and 3 mg of palladiumdi[1,1′-bis(diphenylphospino)ferrocene]dichloride (PdCl₂(dppf)), and the resulting solution was stirred overnight at 90° C. The resulting reaction mixture was filtered through a celite pad and concentrated under reduced pressure to give a residue. The residue thus obtained was dissolved in ethylacetate, washed with distilled water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=1/2) to give 48 mg of the title compound (yield: 69.2%). MS (ESI) m/z=455.2 (M+H)+

Step 2: 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(4-methylsulfonylphenyl)-2-thienyl]ethyl]-1,2,4-triazol-3-one

48 mg of tert-butyl N-[3,3-difluoro-2-[[4-[2-[5-(4-methylsulfonylphenyl)-2-thienyl]ethyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate prepared in Step 1 was dissolved in 1.0 mL of dichloromethane, followed by the addition of 0.1 mL of trifluoroacetic acid, and the resulting solution was stirred at room temperature for 2 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. The solution was concentrated under reduced pressure and then dried in vacuo to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 34 mg of the title compound (yield: 59.2%). ¹H-NMR (MeOD, 400 MHz) δ 7.94-7.92 (m, 2H), 7.82-7.77 (m, 3H), 7.44 (s, 1H), 6.92 (s, 1H), 4.56 (s, 2H), 3.99 (t, 2H), 3.65 (s, 2H), 3.36 (s, 3H), 3.31 (t, 2H)

Example 174. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(4-piperazin-1-ylphenyl)-2-thienyl]ethyl]-1,2,4-triazol-3-one Ditrifluoroacetate

9 mg of the title compound (yield: 16.0%) was prepared in the same fashion as Example 173, except that in Step 1, 49 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.74 (s, 1H), 7.50 (d, 1H), 7.10 (s, 1H), 7.03 (d, 1H), 6.80 (s, 1H), 4.56 (s, 2H), 3.98 (t, 2H), 3.59 (s, 2H), 3.44 (t, 4H), 3.37 (t, 4H), 3.24 (t, 2H)

Example 175. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]ethyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 37.6%) was prepared in the same fashion as Example 173, except that in Step 1, 34 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.92 (s, 1H), 8.19 (d, 1H), 7.82 (d, 1H), 7.79 (s, 1H), 7.51 (s, 1H), 6.97 (s, 1H), 4.56 (s, 2H), 4.01 (t, 2H), 3.65 (s, 2H), 3.36 (s, 3H), 3.32 (t, 2H)

Example 176. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-[6-(dimethylamino)-3-pyridyl]-2-thienyl]ethyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 35.2%) was prepared in the same fashion as Example 173, except that in Step 1, 31 mg of 6-(dimethylamino)pyridine-3-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.10 (s, 1H), 8.06 (d, 1H), 7.76 (s, 1H), 7.22 (s, 1H), 7.13 (d, 1H), 6.87 (s, 1H), 4.56 (s, 2H), 3.99 (t, 2H), 3.65 (s, 2H), 3.36 (t, 2H), 3.27 (s, 6H)

Example 177. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(1,3-benzodioxol-5-yl)-2-thienyl]ethyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 55.2%) was prepared in the same fashion as Example 173, except that in Step 1, 34 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.73 (s, 1H), 7.06-7.02 (m, 3H), 6.82-6.77 (m, 2H), 5.97 (s, 2H), 4.59 (s, 2H), 3.97 (t, 2H), 3.63 (s, 2H), 3.23 (t, 2H)

Example 178. 6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

21 mg of the title compound (yield: 36.0%) was prepared in the same fashion as Example 173, except that in Step 1, 36 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.75 (s, 1H), 7.24 (d, 1H), 7.13 (d, 1H), 6.80 (d, 1H), 4.56 (s, 2H), 3.97 (t, 2H), 3.63 (s, 2H), 3.24 (t, 2H), 2.94 (t, 2H), 2.57 (t, 2H), 2.27 (s, 3H).

Example 179. 6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

17 mg of the title compound (yield: 30.4%) was prepared in the same fashion as Example 173, except that in Step 1, 36 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.75 (s, 1H), 7.47 (d, 1H), 7.43 (s, 1H), 7.18 (s, 1H), 7.12 (d, 1H), 6.83 (s, 1H), 4.56 (s, 2H), 3.99 (t, 2H), 3.64 (s, 2H), 3.32 (s, 3H), 3.26 (t, 2H), 2.94 (t, 2H), 2.64 (t, 2H)

Example 180. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(1-ethylpyrazol-4-yl)-2-thienyl]ethyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 42.4%) was prepared in the same fashion as Example 173, except that in Step 1, 28 mg of 1-ethylpyrazole-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.84 (s, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 6.95 (s, 1H), 6.75 (s, 1H), 4.56 (s, 2H), 4.19 (q, 2H), 3.96 (t, 2H), 3.63 (s, 2H), 3.22 (t, 2H), 1.47 (t, 3H)

Example 181. 3-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N,N-dimethyl-benzamide trifluoroacetate

925 mg of the title compound (yield: 99.3%) was prepared in the same fashion as Example 100, except that in Step 1, 539 mg of 3-(dimethylcarbamoyl)phenylboronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.00 (s, 1H), 7.70 (d, 1H), 7.65 (s, 1H), 7.49 (t, 1H), 7.36 (d, 2H), 7.16 (d, 1H), 5.08 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H), 3.13 (s, 3H), 3.03 (s, 3H)

Example 182. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3-methyl-1,4-dihydroquinazolin-2-one Trifluoroacetate

26 mg of the title compound (yield: 46.4%) was prepared in the same fashion as Example 100, except that in Step 1, 40 mg of 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dihydroquinazolin-2-one was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.37 (d, 1H), 7.32 (s, 1H), 7.15 (d, 1H), 7.09 (d, 1H), 6.78 (d, 1H), 5.04 (s, 2H), 4.59 (s, 2H), 4.48 (s, 2H), 3.67 (s, 2H), 2.98 (s, 3H).

Example 183. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[1-(difluoromethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

26 mg of the title compound (yield: 60.7%) was prepared in the same fashion as Example 100, except that in Step 1, 26 mg of 1-difluoromethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.31 (s, 1H), 7.95 (d, 2H), 7.49 (t, 1H), 7.13 (d, 2H), 5.05 (s, 2H), 4.58 (s, 2H), 3.67 (s, 2H)

Example 184. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-isopropylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

36 mg of the title compound (yield: 81.8%) was prepared in the same fashion as Example 100, except that in Step 1, 17 mg of (1-isopropylpyrazole-4-yl)boronic acid was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 7.94 (d, 2H), 7.67 (s, 1H), 7.04 (m, 2H), 5.03 (s, 2H), 4.55 (m, 3H), 3.68 (s, 2H), 1.51 (d, 6H)

Example 185. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

19 mg of the title compound (yield: 37.5%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of trimethyl-[2-[[3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2,4-triazole-1-yl]methoxy]ethyl]silane was used instead of 4-acetylphenylboronicacid. ¹H-NMR (MeOD, 400 MHz) δ 8.41 (bs, 1H), 8.21 (s, 1H), 8.02 (s, 1H), 7.96 (d, 1H), 7.70 (d, 1H), 7.52 (t, 1H), 7.39 (d, 1H), 7.18 (d, 1H), 5.10 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H)

Example 186. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-3-methyl-1,4-dihydroquinazolin-2-one Trifluoroacetate

19 mg of the title compound (yield: 30.4%) was prepared in the same fashion as Example 100, except that in Step 1, 58 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 40 mg of 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dihydroquinazolin-2-one was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (s, 1H), 7.47 (d, 2H), 7.42 (d, 1H), 7.37 (s, 1H), 6.80 (d, 1H), 5.07 (s, 2H), 4.59 (s, 2H), 4.50 (s, 2H), 3.67 (s, 2H), 2.83 (s, 3H)

Example 187. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-isopropyl-pyridin-2-one Trifluoroacetate

36 mg of the title compound (yield: 80.4%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 28 mg of 1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (s, 1H), 7.94 (d, 1H), 7.83 (dd, 1H), 7.56 (d, 1H), 7.48 (s, 1H), 6.61 (d, 1H), 5.24 (m, 1H), 5.09 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 1.46 (d, 6H)

Example 188. 4-[[4-[4-(4-acetylpiperazin-1-yl)phenyl]-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one Trifluoroacetate

28 mg of the title compound (yield: 53.3%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 27 mg of 4-(4-acetyl-1-piperazinyl)phenylboronic acid was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (s, 1H), 7.54 (d, 2H), 7.46 (d, 2H), 7.00 (d, 2H), 5.08 (s, 2H), 4.59 (s, 2H), 3.74 (t, 2H), 3.68 (d, 4H), 3.24 (d, 2H), 3.18 (d, 2H), 2.15 (s, 3H)

Example 189. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-8-fluoro-1H-quinolin-2-one Trifluoroacetate

35 mg of the title compound (yield: 73.8%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 31 mg of 8-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-quinolin-2-one was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.04 (s, 1H), 7.94 (d, 1H), 7.65 (m, 3H), 7.53 (s, 1H), 6.64 (d, 1H), 5.11 (s, 2H), 4.61 (s, 2H), 3.70 (s, 2H)

Example 190. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-methyl-pyridin-2-one Trifluoroacetate

39 mg of the title compound (yield: 93.4%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 25 mg of (1-methyl-6-oxo-1,6-dihydropyridin-3-yl)boronic acid pinacol ester was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (m, 2H), 7.87 (dd, 1H), 7.52 (d, 1H), 7.42 (s, 1H), 6.60 (d, 1H) 5.08 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H), 3.62 (s, 3H)

Example 191. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one Trifluoroacetate

43 mg of the title compound (yield: 92.5%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 30 mg of 1,4-dihydro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-3,1-benzoxazin-2-one was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (s, 1H), 7.59 (d, 1H), 7.48 (s, 1H), 7.31 (dd, 1H), 7.19 (d, 1H), 7.10 (s, 1H), 5.31 (s, 2H), 5.09 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H)

Example 192. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

25 mg of the title compound (yield: 54.2%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 29 mg of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.00 (s, 1H), 7.53 (d, 1H), 7.46 (m, 3H), 6.89 (d, 1H), 5.08 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H), 2.99 (t, 2H), 2.59 (t, 2H)

Example 193. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-ethyl-pyridin-2-one Trifluoroacetate

23 mg of the title compound (yield: 53.3%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 27 mg of 1-ethyl-6-oxo-1,6-dihydropyridin-3-boronic acid pinacol ester was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (m, 2H), 7.87 (dd, 1H), 7.54 (d, 1H), 7.44 (s, 1H), 6.61 (d, 1H), 5.09 (s, 2H), 4.60 (s, 2H), 4.11 (q, 2H), 3.68 (s, 2H), 1.38 (t, 3H)

Example 194. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[1-(difluoromethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

24 mg of the title compound (yield: 56.1%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 17 mg of 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.34 (s, 1H), 8.00 (d, 2H), 7.50 (m, 3H), 5.08 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H)

Example 195. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-isopropylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 87.3%) was prepared in the same fashion as Example 100, except that in Step 1, 51 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 17 mg of (1-isopropylpyrazol-4-yl)boronic acid was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (d, 2H), 7.74 (s, 1H), 7.37 (d, 2H), 5.06 (s, 2H), 4.56 (m, 3H), 3.68 (s, 2H), 1.52 (d, 6H)

Example 196. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

8 mg of the title compound (yield: 15.2%) was prepared in the same fashion as Example 100, except that in Step 1, 52 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 50 mg of trimethyl-[2-[[3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2,4-triazole-1-yl]methoxy]ethyl]silane was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.43 (bs, 1H), 8.24 (s, 1H), 8.04 (s, 1H), 7.95 (d, 1H), 7.76 (d, 1H), 7.73 (s, 1H), 7.65 (s, 1H), 7.57 (t, 1H), 5.13 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H)

Example 197. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one trifluoroacetate Step 1: tert-butyl N-[3,3-difluoro-2-[[4-[[6-(4-methyl sulfonylphenyl)benzothiophen-2-yl]methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate

40 mg of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 22 mg of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan were dissolved in 1.5 mL of 1,4-dioxane, followed by the addition of 0.2 mL of 1 M potassium carbonate and 2 mg of palladiumdi[1,1′-bis(diphenylphospino)ferrocene]dichloride (PdCl₂(dppf)), and the resulting solution was stirred overnight at 90° C. The resulting reaction mixture was filtered through a celite pad and concentrated under reduced pressure to give a residue. The residue thus obtained was dissolved in ethylacetate, washed with distilled water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=1/1) to give 38 mg of the title compound (yield: 83.8%). MS (ESI) m/z=491.2 (M+H)+

Step 2: 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one

47 mg of tert-butyl N-[3,3-difluoro-2-[[4-[[6-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate prepared in Step 1 was dissolved in 1.0 mL of dichloromethane, followed by the addition of 0.1 mL of trifluoroacetic acid, and the resulting solution was stirred at room temperature for 2 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. Dichloromethane was added to the concentrated reaction mixture, and it was concentrated under reduced pressure to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 4 mg of the title compound as a white solid (yield: 12.0%). ¹H-NMR (DMSO-d₆, 400 MHz) δ 8.40 (s, 1H), 8.22 (s, 1H), 8.02 (s, 4H), 7.97 (d, 1H), 7.79 (dd, 1H), 7.46 (s, 1H), 5.15 (s, 2H), 4.53 (s, 2H), 3.49 (s, 2H), 3.27 (s, 3H)

Example 198. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(4-piperazin-1-ylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

30 mg of the title compound (yield: 76.9%) was prepared in the same fashion as Example 197, except that in Step 1, 30 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (d, 2H), 7.82 (d, 1H), 7.62 (m, 3H), 7.39 (s, 1H), 7.12 (d, 2H), 5.17 (s, 2H), 4.61 (s, 2H), 3.68 (s, 2H), 3.49 (t, 4H), 3.40 (t, 4H)

Example 199. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-[6-(trifluoromethyl)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

37 mg of the title compound (yield: 98.5%) was prepared in the same fashion as Example 197, except that in Step 1, 21 mg of 2-(trifluoromethyl)pyridine-5-boronic acid pinacol ester was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 9.02 (s, 1H), 8.33 (dd, 1H), 8.24 (s, 1H), 8.05 (s, 1H), 7.91 (dd, 2H), 7.73 (dd, 1H), 7.46 (s, 1H), 5.21 (s, 2H), 4.62 (s, 2H), 3.70 (s, 2H)

Example 200. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-[6-(dimethylamino)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

24 mg of the title compound (yield: 65.8%) was prepared in the same fashion as Example 197, except that in Step 1, 13 mg of (6-(dimethylamino)pyridin-3-yl)boronic acid was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.24 (d, 2H), 8.11 (s, 1H), 8.04 (s, 1H), 7.89 (d, 1H), 7.62 (dd, 1H), 7.43 (s, 1H), 7.18 (d, 1H), 5.20 (s, 2H), 4.61 (s, 2H), 3.69 (s, 2H), 3.29 (s, 6H)

Example 201. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(1,3-benzodioxol-5-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

30 mg of the title compound (yield: 83.5%) was prepared in the same fashion as Example 197, except that in Step 1, 20 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (DMSO-d₆, 400 MHz) δ 8.19 (d, 2H), 8.01 (bs, 2H), 7.85 (d, 1H), 7.64 (dd, 1H), 7.40 (s, 1H), 7.32 (d, 1H), 7.21 (dd, 1H), 7.02 (d, 1H), 6.07 (s, 2H), 5.12 (s, 2H), 4.52 (s, 2H), 3.48 (s, 2H)

Example 202. 6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-6-yl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

36 mg of the title compound (yield: 92.4%) was prepared in the same fashion as Example 197, except that in Step 1, 23 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (s, 1H), 7.98 (s, 1H), 7.79 (d, 1H), 7.57 (dd, 1H), 7.38 (s, 1H), 7.32 (d, 2H), 5.17 (s, 2H), 4.62 (s, 2H), 3.69 (s, 2H), 2.96 (t, 2H), 2.56 (t, 2H), 2.31 (s, 3H)

Example 203. 6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-6-yl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

30 mg of the title compound (yield: 75.9%) was prepared in the same fashion as Example 197, except that in Step 1, 23 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-yl)boronic acid pinacol ester was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (d, 1H), 7.81 (d, 1H), 7.61 (dd, 1H), 7.56 (dd, 1H), 7.51 (s, 1H), 7.40 (s, 1H), 7.15 (d, 1H), 5.17 (s, 2H), 4.62 (s, 2H), 3.69 (s, 2H), 3.33 (m, 3H), 2.95 (t, 2H), 2.62 (t, 2H).

Example 204. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(1-ethylpyrazol-4-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

27 mg of the title compound (yield: 78.5%) was prepared in the same fashion as Example 197, except that in Step 1, 18 mg of 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.07 (s, 1H), 8.02 (d, 2H), 7.89 (s, 1H), 7.76 (d, 1H), 7.58 (dd, 1H), 7.36 (s, 1H), 5.15 (s, 2H), 4.61 (s, 2H), 4.23 (q, 2H), 3.68 (s, 2H), 1.50 (t, 3H)

Example 205. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

36 mg of the title compound (yield: 91.4%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57. ¹H-NMR (MeOD, 400 MHz) δ 8.10 (s, 1H), 8.03 (d, 3H), 7.93 (m, 3H), 7.68 (d, 1H), 7.48 (s, 1H), 5.20 (s, 2H), 4.62 (s, 2H), 3.69 (s, 2H), 3.17 (s, 3H)

Example 206. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-piperazin-1-ylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

18 mg of the title compound (yield: 44.4%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 31 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4,4,5,5-tetramethyl-2-(4-methyl sulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (d, 2H), 7.87 (d, 1H), 7.62 (m, 3H), 7.44 (s, 1H), 7.14 (s, 1H), 5.19 (s, 2H), 4.61 (s, 2H), 3.68 (s, 2H), 3.48 (d, 4H), 3.42 (d, 4H), 3.32 (s, 3H)

Example 207. 5-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-1-ethyl-pyridin-2-one Trifluoroacetate

32 mg of the title compound (yield: 86.4%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 20 mg of 1-ethyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4,4,5,5-tetramethyl-2-(4-methyl sulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (d, 2H), 7.91 (m, 3H), 7.54 (d, 1H), 7.44 (s, 1H), 6.66 (d, 1H), 5.19 (s, 2H), 4.61 (s, 2H), 4.13 (q, 2H), 3.69 (s, 2H), 1.40 (t, 3H)

Example 208. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 94.6%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 20 mg of 6-(dimethylamino)pyridine-3-boronic acid pinacol ester was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.30 (d, 1H), 8.21 (s, 1H), 8.04 (s, 2H), 7.96 (d, 1H), 7.60 (d, 1H), 7.48 (s, 1H), 7.27 (d, 1H), 5.20 (s, 2H), 4.61 (s, 2H), 3.70 (s, 2H), 3.32 (s, 6H)

Example 209. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

31 mg of the title compound (yield: 82.7%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 20 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4,4,5,5-tetramethyl-2-(4-methyl sulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (s, 1H), 7.92 (s, 1H), 7.84 (d, 1H), 7.54 (d, 1H), 7.42 (s, 1H), 7.14 (d, 2H), 7.91 (d, 1H), 6.00 (s, 2H), 5.17 (s, 2H), 4.61 (s, 2H), 3.68 (s, 2H)

Example 210. 6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

29 mg of the title compound (yield: 71.6%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 23 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4,4,5,5-tetramethyl-2-(4-methyl sulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (s, 1H), 7.94 (s, 1H), 7.85 (d, 1H), 7.57 (d, 1H), 7.42 (s, 1H), 7.34 (d, 2H), 5.18 (s, 2H), 4.61 (s, 2H), 3.69 (s, 2H), 2.98 (t, 2H), 2.58 (t, 2H), 2.33 (s, 3H)

Example 211. 6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

27 mg of the title compound (yield: 66.7%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 23 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-yl)boronic acid pinacol ester was used instead of 4,4,5,5-tetramethyl-2-(4-methylsulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (d, 2H), 7.87 (d, 1H), 7.58 (m, 3H), 7.44 (s, 1H), 7.19 (d, 1H), 5.18 (s, 2H), 4.62 (s, 2H), 3.69 (s, 2H), 3.38 (s, 3H), 2.98 (t, 2H), 2.65 (t, 2H)

Example 212. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 72.8%) was prepared in the same fashion as Example 197, except that in Step 1, 42 mg of tert-butyl N-[2-[[4-[(5-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 58 was used instead of tert-butyl N-[2-[[4-[(6-bromobenzothiophen-2-yl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 57 and 18 mg of 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole was used instead of 4,4,5,5-tetramethyl-2-(4-methyl sulfonylphenyl)-1,3,2-dioxaborolan. ¹H-NMR (MeOD, 400 MHz) δ 8.04 (d, 2H), 7.97 (s, 1H), 7.88 (s, 1H), 7.81 (d, 1H), 7.57 (d, 1H), 7.39 (s, 1H), 5.17 (s, 2H), 4.61 (s, 2H), 4.24 (q, 2H), 3.68 (s, 2H), 1.51 (t, 3H)

Example 213. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(6-piperazin-1-yl-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

28 mg of the title compound (yield: 56.2%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 57 mg of tert-butyl 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.93 (s, 1H), 8.80 (s, 1H), 8.35 (d, 1H), 8.12 (d, 1H), 7.98 (t, 1H), 7.81 (d, 1H), 7.03 (d, 1H), 4.68 (s, 2H), 3.93 (s, 4H), 3.75 (s, 2H), 3.36 (s, 4H)

Example 214. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[4-(morpholine-4-carbonyl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

28 mg of the title compound (yield: 53.6%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 46 mg of 4-(morpholine-4-carbonyl)phenylboronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.84 (s, 1H), 8.23 (t, 3H), 8.06 (t, 1H), 7.94 (d, 1H), 7.57 (d, 2H), 4.68 (s, 2H), 3.76-3.66 (m, 8H), 3.51 (bs, 2H)

Example 215. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(6-morpholino-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 70.5%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 42 mg of 6-(morpholin-4-yl)pyridine-3-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.81 (d, 2H), 8.40 (d, 1H), 8.13 (d, 1H), 7.99 (t, 1H), 7.79 (d, 1H), 7.05 (d, 1H), 4.68 (s, 2H), 3.84 (s, 4H), 3.76 (s, 2H), 3.64 (s, 4H)

Example 216. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(3-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

36 mg of the title compound (yield: 74.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 56 mg of 3-[4-N-Boc-piperazin-1-yl]phenylboronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.81 (s, 1H), 8.17 (d, 1H), 8.02 (t, 1H), 7.88 (d, 1H), 7.75 (s, 1H), 7.66 (d, 1H), 7.43 (t, 1H), 7.14 (d, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 3.52 (d, 4H), 3.43 (d, 4H)

Example 217. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[3-(dimethylamino)-4-fluoro-phenyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

30 mg of the title compound (yield: 62.5%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 27 mg of (3-(dimethylamino)-4-fluorophenyl)boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.75 (s, 1H), 8.13 (d, 1H), 7.99 (t, 1H), 7.83 (d, 1H), 7.70 (d, 1H), 7.66-7.64 (m, 1H), 7.15 (dd, 1H), 4.68 (s, 2H), 3.76 (s, 2H), 2.92 (s, 6H)

Example 218. 5-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-ethyl-pyridin-2-one Trifluoroacetate

33 mg of the title compound (yield: 74.1%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 36 mg of 1-ethyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.88 (s, 1H), 8.55 (d, 1H), 8.26 (dd, 1H), 8.13 (d, 1H), 7.97 (t, 1H), 7.72 (d, 1H), 6.62 (d, 1H), 4.68 (s, 2H), 4.15 (q, 2H), 3.77 (s, 2H), 1.41 (t, 3H)

Example 219. 7-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1,4-dihydro-3,1-benzoxazin-2-one Trifluoroacetate

20 mg of the title compound (yield: 36.6%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(6-bromo-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 31 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 40 mg of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4,4a,8a-tetrahydro-2H-benzo[d][1,3]oxazin-2-one was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (DMSO-d₆, 400 MHz) δ 10.22 (s, 1H), 8.81 (s, 1H), 8.13 (s, 2H), 7.89 (t, 1H), 7.84 (d, 1H), 7.71 (s, 1H), 7.34 (d, 1H), 5.36 (s, 2H), 4.62 (s, 2H), 3.56 (s, 2H)

Example 220. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(6-piperazin-1-yl-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

38 mg of the title compound (yield: 70.6%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 55 mg of tert-butyl 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.64 (s, 1H), 8.55 (S, 1H), 8.14 (d, 2H), 8.01 (s, 1H), 7.06 (s, 1H), 4.68 (s, 2H), 3.91 (s, 4H), 3.76 (s, 2H), 3.35 (s, 4H), 2.40 (s, 3H)

Example 221. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-4H-1,4-benzoxazin-3-one Trifluoroacetate

33 mg of the title compound (yield: 35.5%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 60 mg of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-Benzo[b][1,4]oxazin-3 (4H)-one was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.57 (s, 1H), 8.17 (s, 1H), 8.06 (s, 1H), 7.30 (d, 1H), 7.19 (s, 1H), 7.08 (d, 1H), 4.69 (s, 2H), 4.64 (s, 2H), 3.77 (s, 2H), 2.41 (s, 3H)

Example 222. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2-methoxyethylamino)pyrimidin-5-yl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

377 mg of the title compound (yield: 40.0%) was prepared in the same fashion as Example 17, except that in Step 1, 1000 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 788 mg of N-(2-methoxyethyl)-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.66 (d, 3H), 8.16 (d, 2H), 4.68 (s, 2H), 3.75 (s, 2H), 3.62 (dd, 4H), 3.40 (s, 3H), 2.41 (s, 3H)

Example 223. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 41.0%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 60 mg of 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-1,4-benzoxazine was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.56 (s, 1H), 8.14 (s, 1H), 8.03 (s, 1H), 7.19 (d, 1H), 7.07 (s, 1H), 6.81 (d, 1H), 4.68 (s, 2H), 4.30 (t, 2H), 3.76 (s, 2H), 3.32 (t, 2H) 2.95 (s, 3H), 2.37 (s, 3H)

Example 224. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3,4,5-trimethoxyphenyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

487 mg of the title compound (yield: 50.0%) was prepared in the same fashion as Example 17, except that in Step 1, 1000 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 599 mg of 3,4,5-trimethoxyphenylboronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.68 (s, 1H), 8.18 (d, 2H), 6.99 (s, 2H), 4.69 (s, 2H), 3.94 (s, 6H), 3.83 (s, 3H), 3.76 (s, 2H), 2.43 (s, 3H)

Example 225. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(6-methoxy-3-pyridyl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

46 mg of the title compound (yield: 54.4%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 33 mg of 6-methoxy-3-pyridinylboronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.64 (s, 1H), 8.48 (s, 1H), 8.17 (d, 1H), 8.14 (d, 1H), 8.03 (s, 1H), 6.95 (s, 1H), 4.68 (s, 2H), 3.97 (s, 3H), 3.76 (s, 2H), 2.41 (s, 3H)

Example 226. 4-[5-(2-amino-1,3-benzothiazol-5-yl)-3-methyl-2-pyridyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one Trifluoroacetate

23 mg of the title compound (yield: 24.9%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 75 mg of N-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl]acetamide was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.68 (s, 1H), 8.18 (s, 2H), 7.75-7.68 (m, 2H), 7.42 (s, 1H), 4.68 (s, 2H), 3.74 (s, 2H), 2.43 (s, 3H)

Example 227. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(2,1,3-benzoxadiazol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

40 mg of the title compound (yield: 46.1%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 53 mg of benzo[c][1,2,5]oxadiazol-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.81 (s, 1H), 8.29 (d, 2H), 8.21 (s, 1H), 8.07 (s, 1H), 7.92 (s, 1H), 4.69 (s, 2H), 3.78 (s, 2H), 2.47 (s, 3H)

Example 228. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

33 mg of the title compound (yield: 38.2%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 53 mg of 7-azaindol-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.70 (s, 1H), 8.51 (s, 1H), 8.32 (s, 1H), 8.19 (s, 2H), 7.48 (s, 1H), 6.60 (d, 1H), 4.69 (s, 2H), 3.77 (s, 2H), 2.43 (s, 3H)

Example 229. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzoxazol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 48.0%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of benzo[d]oxazol-5-yl boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.61 (s, 1H), 8.50 (s, 1H), 8.38 (s, 1H), 8.18 (s, 1H), 8.10 (s, 1H), 7.36 (s, 1H), 7.01 (s, 1H), 4.68 (s, 2H), 3.75 (s, 2H), 2.40 (s, 3H)

Example 230. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[4-(2-oxopyrrolidin-1-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

395 mg of the title compound (yield: 40.6%) was prepared in the same fashion as Example 17, except that in Step 1, 1000 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 811 mg of 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidin-2-one was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.69 (s, 1H), 8.19 (s, 2H), 7.82 (d, 2H), 7.77 (d, 2H), 4.69 (s, 2H), 4.00 (t, 2H), 3.76 (s, 2H), 2.65 (t, 2H), 2.43 (s, 3H), 2.23 (p, 2H)

Example 231. 4-[5-(5-acetyl-2-thienyl)-3-methyl-2-pyridyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 56.6%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 40 mg of 5-acetyl-2-thiopheneboronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.75 (s, 1H), 8.23-8.17 (m, 2H), 7.90 (s, 1H), 7.67 (s, 1H), 4.67 (s, 2H), 3.75 (s, 2H), 2.60 (s, 3H), 2.42 (s, 3H)

Example 232. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[3-(1H-pyrazol-3-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

50 mg of the title compound (yield: 54.4%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 41 mg of [3-(1H-pyrazol-3-yl)phenyl]boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. MS (ESI) m/z=424.2 (M+H)+

Example 233. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1H-indazol-6-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 40.6%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 76 mg of 1H-indazole-6-boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. MS (ESI) m/z=398.2 (M+H)+

Example 234. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3-methyl sulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 51.3%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 30 mg of 3-(methanesulfonyl)phenylboronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.74 (s, 1H), 8.28-8.19 (m, 3H), 8.07 (s, 2H), 7.80 (s, 1H), 4.69 (s, 2H), 3.77 (s, 2H), 3.21 (s, 3H), 2.45 (s, 3H)

Example 235. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

40 mg of the title compound (yield: 59.9%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 59 mg of tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.66 (s, 1H), 8.17 (s, 2H), 7.45 (s, 1H), 7.33 (s, 1H), 7.27 (s, 1H), 7.13 (s, 1H), 4.68 (s, 2H), 3.74 (s, 2H), 3.51-3.31 (m, 8H), 2.42 (s, 3H)

Example 236. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[4-(morpholine-4-carbonyl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

33 mg of the title compound (yield: 46.0%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 36 mg of [4-(morpholine-4-carbonyl)phenyl]boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.72 (s, 1H), 8.20 (d, 2H), 7.84 (s, 2H), 7.60 (d, 2H), 4.68 (s, 2H), 3.76-3.31 (m, 10H), 2.44 (s, 3H)

Example 237. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-morpholinophenyl)-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

50 mg of the title compound (yield: 52.1%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 63 mg of 4-morpholinophenylboronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.62 (s, 1H), 8.16 (s, 1H), 8.10 (s, 1H), 7.64 (d, 2H), 7.10 (d, 2H), 4.68 (s, 2H), 3.86 (m, 4H), 3.76 (s, 2H), 3.23 (m, 4H), 2.40 (s, 3H)

Example 238. 4-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-N,N-dimethyl-benzenesulfonamide trifluoroacetate

55 mg of the title compound (yield: 54.4%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 68 mg of N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.74 (s, 1H), 8.25 (s, 1H), 8.20 (s, 1H), 7.95 (d, 4H), 4.68 (s, 2H), 3.75 (s, 2H), 2.73 (s, 6H), 2.45 (s, 3H)

Example 239. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one trifluoroacetate

8 mg of the title compound (yield: 12.8%) was prepared in the same fashion as Example 17, except that in Step 1, 52 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 50 mg of trimethyl-[2-[[3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2,4-triazol-1-yl]methoxy]ethyl]silane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 9.09 (d, 1H), 8.77 (s, 1H), 8.48-8.44 (m, 2H), 8.41 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 7.83 (d, 1H), 6.24 (s, 1H), 4.91 (s, 2H), 3.74 (s, 2H), 2.46 (s, 3H)

Example 240. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one trifluoroacetate Step 1: tert-butyl N-[3,3-difluoro-2-[[4-[3-methyl-5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate

50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34, 29 mg of 4-ethynyl-1-methyl-1H-pyrazole, 6 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh₃)₄), and 2 mg of copper(I) iodide (CuI) were dissolved in 1.0 mL of N,N-dimethylformamide. To the resulting solution, 45 uL of triethylamine was added and then the solution was stirred overnight at 90° C. The resulting reaction mixture was filtered through a celite pad and concentrated under reduced pressure to give a residue. The residue thus obtained was dissolved in ethylacetate, washed with distilled water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=1/1) to give 30 mg of the title compound as a yellow solid (yield: 27.6%). MS (ESI) m/z=386.1 (M+H)+

Step 2: 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one

30 mg of tert-butyl N-[3,3-difluoro-2-[[4-[3-methyl-5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-5-oxo-1,2,4-triazol-1-yl]methyl]allyl]carbamate prepared in Step 1 was dissolved in 1.0 mL of dichloromethane, and 150 uL of trifluoroacetic acid was added thereto. The solution was stirred at room temperature for 2 hours. The reaction mixture thus obtained was concentrated, followed by the addition of dichloromethane. Dichloromethane was added to the concentrated reaction mixture, and it was concentrated under reduced pressure to obtain a yellow liquid residue. The residue was purified with silica gel column chromatography (developing solvent: dichloromethane/methanol=10/1) to give 19 mg of the title compound as a pale yellow solid (yield: 80.2%). ¹H-NMR (MeOD, 400 MHz) δ 8.47 (s, 1H), 8.16 (s, 1H), 7.96 (s, 1H), 7.92 (s, 1H), 7.69 (s, 1H), 4.67 (S, 2H), 3.93 (s, 3H), 3.75 (s, 2H), 2.36 (s, 3H)

Example 241. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-[6-(dimethylamino)-3-pyridyl]ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

22 mg of the title compound (yield: 45.0%) was prepared in the same fashion as Example 240 except that in Step 1, 40 mg of 5-ethynyl-N,N-dimethylpyridin-2-amine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.51 (s, 1H), 8.26 (s, 1H), 8.17 (s, 1H), 8.01 (s, 1H), 7.78 (d, 1H), 6.88 (d, 1H), 4.67 (s, 2H), 3.75 (s, 2H), 3.32 (s, 3H), 3.20 (s, 6H), 2.37 (s, 3H)

Example 242. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[2-(6-morpholino-3-pyridyl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 48.6%) was prepared in the same fashion as Example 240 except that in Step 1, 51 mg of 4-(5-ethynylpyridin-2-yl)morpholine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.50 (s, 1H), 8.33 (s, 1H), 8.16 (s, 1H), 7.99 (s, 1H), 7.70 (d, 1H), 6.84 (d, 1H), 4.67 (s, 2H), 3.79 (t, 4H), 3.75 (s, 2H), 3.59 (t, 4H), 2.37 (s, 3H)

Example 243. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Ditrifluoroacetate

27 mg of the title compound (yield: 55.0%) was prepared in the same fashion as Example 240 except that in Step 1, 70 mg of tert-butyl 6-ethynyl-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.46 (s, 1H), 8.15 (s, 1H), 7.95 (s, 1H), 6.79 (d, 2H), 6.69 (d, 1H), 4.67 (s, 2H), 4.22 (t, 2H), 3.75 (s, 2H), 3.36 (t, 2H), 2.35 (s, 3H)

Example 244. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one ditrifluoroacetate

22 mg of the title compound (yield: 45.9%) was prepared in the same fashion as Example 240 except that in Step 1, 44 mg of 7-ethynyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.51 (s, 1H), 8.17 (s, 1H), 8.01 (s, 1H), 7.62 (s, 1H), 7.10 (s, 1H), 4.67 (s, 2H), 4.41 (t, 2H), 3.75 (s, 2H), 3.40 (t, 2H), 2.37 (s, 3H)

Example 245. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one ditrifluoroacetate

24 mg of the title compound (yield: 47.7%) was prepared in the same fashion as Example 240 except that in Step 1, 44 mg of 7-ethynyl-2H,3H,4H-pyrido[3,2-b][1,4]oxazine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.49 (s, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.80 (s, 1H), 7.14 (s, 1H), 4.67 (s, 2H), 4.20 (t, 2H), 3.75 (s, 2H), 3.57 (t, 2H), 2.36 (s, 3H)

Example 246. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one ditrifluoroacetate

24 mg of the title compound (yield: 49.5%) was prepared in the same fashion as Example 240 except that in Step 1, 44 mg of 6-ethynyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.51 (s, 1H), 8.16 (s, 1H), 8.01 (s, 1H), 7.11 (d, 1H), 6.94 (d, 1H), 4.67 (s, 2H), 4.38 (t, 2H), 3.75 (s, 2H), 3.43 (t, 2H), 2.36 (s, 3H)

Example 247. 7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one Trifluoroacetate

22 mg of the title compound (yield: 44.0%) was prepared in the same fashion as Example 240 except that in Step 1, 47 mg of 7-ethynyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.54 (s, 1H), 8.18 (s, 1H), 8.03 (t, 2H), 7.40 (d, 1H), 4.89 (s, 2H), 4.68 (s, 2H), 3.76 (s, 2H), 2.38 (s, 3H)

Example 248. 7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one trifluoroacetate

16 mg of the title compound (yield: 32.1%) was prepared in the same fashion as Example 240 except that in Step 1, 47 mg of 7-ethynyl-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.55 (s, 1H), 8.17 (s, 1H), 8.14 (s, 1H), 8.05 (s, 1H), 7.49 (s, 1H), 4.71 (s, 2H), 4.66 (s, 2H), 3.65 (s, 2H), 2.38 (s, 3H)

Example 249. 6-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

25 mg of the title compound (yield: 47.7%) was prepared in the same fashion as Example 240 except that in Step 1, 46 mg of 6-ethynyl-1,2,3,4-tetrahydroquinolin-2-one was used instead of 4-ethynyl-1-methyl-1H-pyrazole. ¹H-NMR (MeOD, 400 MHz) δ 8.52 (s, 1H), 8.18 (s, 1H), 8.02 (s, 1H), 7.43 (s, 1H), 7.40 (d, 1H), 6.90 (d, 1H), 4.67 (s, 2H), 3.75 (s, 2H), 3.00 (t, 2H), 2.61 (t, 2H), 2.38 (s, 3H)

Example 250. 6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-3-methyl-1,4-dihydroquinazolin-2-one Trifluoroacetate

20 mg of the title compound (yield: 33.6%) was prepared in the same fashion as Example 17, except that in Step 1, 58 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 40 mg of 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,4-dihydroquinazolin-2-one was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.60 (s, 1H), 8.17 (s, 1H), 8.08 (s, 1H), 7.51 (d, 1H), 7.47 (s, 1H), 6.88 (d, 1H), 4.69 (s, 2H), 4.56 (s, 2H), 3.76 (s, 2H), 3.01 (s, 3H), 2.40 (s, 3H)

Example 251. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[1-(difluoromethyl)pyrazol-4-yl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

22 mg of the title compound (yield: 51.4%) was prepared in the same fashion as Example 17, except that in Step 1, 49 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 26 mg of 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.70 (d, 2H), 8.21 (m, 3H), 7.57 (t, 1H), 4.69 (s, 2H), 3.61 (s, 2H), 2.40 (s, 3H)

Example 252. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-isopropylpyrazol-4-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 75.4%) was prepared in the same fashion as Example 17, except that in Step 1, 51 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 17 mg of (1-isopropylpyrazole-4-yl)boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.64 (s, 1H), 8.10 (m, 4H), 4.64 (m, 3H), 3.76 (s, 2H), 2.37 (s, 3H), 1.56 (d, 6H)

Example 253. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one Trifluoroacetate

37 mg of the title compound (yield: 98.8%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.08 (m, 3H), 7.65 (d, 2H), 7.46 (m, 3H), 4.69 (s, 2H), 3.77 (s, 2H), 3.20 (s, 2H), 2.11 (s, 3H)

Example 254. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one Ditrifluoroacetate

28 mg of the title compound (yield: 73.6%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 34 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.06 (d, 2H), 7.39 (m, 2H), 7.32 (m, 3H), 7.13 (d, 2H), 4.69 (s, 2H), 3.76 (s, 2H), 3.49 (t, 4H), 3.41 (t, 4H), 2.11 (s, 3H)

Example 255. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one Trifluoroacetate

32 mg of the title compound (yield: 86.2%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 24 mg of 2-(trifluoromethyl)pyridin-5-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.75 (s, 1H), 8.09 (t, 2H), 7.96 (d, 1H), 7.51 (m, 3H), 4.69 (s, 2H), 3.77 (s, 2H), 2.13 (s, 3H)

Example 256. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(dimethylamino)-3-pyridyl]-2-methyl-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 100%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 6-(dimethylamino)pyridin-3-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.07 (s, 1H), 7.96 (m, 2H), 7.46 (m, 3H), 7.25 (d, 1H), 4.69 (s, 2H), 3.77 (s, 2H), 3.33 (s, 6H), 2.16 (s, 3H)

Example 257. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1,3-benzodioxol-5-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 82.8%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.06 (s, 1H), 7.39 (t, 2H), 7.32 (m, 1H), 6.91 (d, 1H), 6.80 (m, 2H), 6.01 (s, 2H), 4.68 (d, 2H), 3.76 (d, 2H), 2.06 (d, 3H)

Example 258. 6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

31 mg of the title compound (yield: 81.6%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.06 (s, 1H), 7.86 (m, 3H), 7.04 (s, 2H), 4.69 (s, 2H), 3.77 (s, 2H), 2.99 (t, 2H), 2.61 (t, 2H), 2.31 (s, 3H), 2.11 (s, 3H)

Example 259. 6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl-phenyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

29 mg of the title compound (yield: 77.0%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.07 (s, 1H), 7.41 (t, 2H), 7.35 (m, 1H), 7.27 (m, 1H), 7.23 (d, 2H), 4.69 (s, 2H), 3.77 (s, 2H), 3.41 (s, 3H), 2.99 (t, 2H), 2.68 (t, 2H), 2.12 (s, 3H)

Example 260. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-ethylpyrazol-4-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

24 mg of the title compound (yield: 73.6%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 19 mg of 1-ethylpyrazol-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.05 (s, 1H), 7.88 (s, 1H), 7.67 (s, 1H), 7.52 (d, 1H), 7.38 (t, 1H), 7.27 (d, 1H), 4.69 (s, 2H), 4.26 (q, 2H), 3.77 (s, 2H), 2.24 (s, 3H), 1.52 (t, 3H)

Example 261. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[1-(difluoromethyl)pyrazol-4-yl]-2-methyl-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

22 mg of the title compound (yield: 52.3%) was prepared in the same fashion as Example 17, except that in Step 1, 49 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 26 mg of 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.27 (s, 1H), 8.06 (s, 1H), 7.92 (s, 1H), 7.70 (d, 2H), 7.39 (m, 2H), 4.69 (s, 2H), 3.77 (s, 2H), 2.24 (s, 3H)

Example 262. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-isopropylpyrazol-4-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one Trifluoroacetate

40 mg of the title compound (yield: 92.7%) was prepared in the same fashion as Example 17, except that in Step 1, 51 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 17 mg of (1-isopropylpyrazole-4-yl)boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (d, 2H), 7.67 (s, 1H), 7.40 (m, 3H), 4.62 (m, 3H), 3.77 (s, 2H), 2.24 (s, 3H), 1.56 (d, 6H)

Example 263. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-[3-(1H-1,2,4-triazol-3-yl)phenyl]phenyl]-1,2,4-triazol-3-one Trifluoroacetate

8 mg of the title compound (yield: 13.6%) was prepared in the same fashion as Example 17, except that in Step 1, 57 mg of tert-butyl N-[2-[[4-(3-bromo-2-methyl-phenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 53 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 50 mg of trimethyl-[2-[[3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2,4-triazole-1-yl]methoxy]ethyl]silane was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.67 (s, 1H), 8.65-8.63 (m, 1H), 8.12-8.10 (m, 2H), 8.08-8.06 (m, 2H), 7.59 (t, 1H), 7.48 (d, 1H), 7.47-7.38 (m, 2H), 5.60 (bs, 1H), 4.69 (s, 2H), 3.73 (s, 2H), 2.15 (s, 3H)

Example 264. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

23 mg of the title compound (yield: 28.0%) was prepared in the same fashion as Example 17, except that in Step 1, 100 mg of tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 54 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 48 mg of 1-ethylpyrazol-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (s, 1H), 7.94 (s, 1H), 7.83 (s, 1H), 7.57 (d, 2H), 7.35 (d, 2H), 4.86 (s, 2H), 4.60 (s, 2H), 4.21 (q, 2H), 3.68 (s, 2H), 1.49 (t, 3H)

Example 265. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

7 mg of the title compound (yield: 10.5%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 54 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.04 (d, 2H), 7.99 (s, 1H), 7.89 (d, 2H), 7.74 (d, 2H), 7.50 (d, 2H), 4.96 (s, 2H), 4.61 (s, 2H), 3.69 (s, 2H), 3.17 (s, 3H)

Example 266. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-piperazin-1-ylphenyl)phenyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

9 mg of the title compound (yield: 11.8%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 54 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 59 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.95 (s, 1H), 7.61 (d, 2H), 7.58 (d, 2H), 7.41 (d, 2H), 7.11 (d, 2H), 4.90 (s, 2H), 4.60 (s, 2H), 3.66 (s, 2H), 3.47 (d, 4H), 3.39 (d, 4H)

Example 267. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

12 mg of the title compound (yield: 18.4%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 54 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of (6-(dimethylamino)pyridine-3-yl)boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.19 (s, 1H), 8.18 (d, 1H), 7.97 (s, 1H), 7.64 (d, 2H), 7.47 (d, 2H), 7.19 (d, 1H), 4.93 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 3.29 (s, 6H)

Example 268. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

12 mg of the title compound (yield: 19.7%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 54 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of 3,4-(methylenedioxy)phenylboronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.95 (s, 1H), 7.56 (d, 2H), 7.39 (d, 2H), 7.09 (d, 2H), 6.89 (d, 1H), 5.99 (s, 2H), 4.90 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H)

Example 269. 6-[4-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

7 mg of the title compound (yield: 9.9%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 54 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 44 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.96 (s, 1H), 7.61 (d, 2H), 7.40 (d, 2H), 7.32 (s, 2H), 4.90 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 3.01 (t, 2H), 2.60 (t, 2H), 2.33 (s, 3H)

Example 270. 5-[4-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one Trifluoroacetate

8 mg of the title compound (yield: 12.5%) was prepared in the same fashion as Example 17, except that in Step 1, 70 mg of tert-butyl N-[2-[[4-[(4-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 54 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 38 mg of 1-ethyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (d, 1H), 7.96 (s, 1H), 7.87 (dd, 1H), 7.58 (d, 2H), 7.43 (d, 2H), 6.65 (d, 1H), 4.90 (s, 2H), 4.60 (s, 2H), 4.13 (q, 2H), 3.69 (s, 2H), 1.39 (t, 3H)

Example 271. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

25 mg of the title compound (yield: 75.9%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 55 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 19 mg of 1-ethylpyrazol-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.04 (s, 1H), 7.97 (s, 1H), 7.84 (s, 1H), 7.55 (t, 2H), 7.38 (t, 1H), 7.20 (d, 1H), 4.89 (s, 2H), 4.60 (s, 2H), 4.23 (dd, 2H), 3.68 (s, 2H), 1.50 (t, 3H)

Example 272. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

33 mg of the title compound (yield: 87.4%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 55 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (t, 3H), 7.90 (d, 2H), 7.71 (m, 2H), 7.54 (t, 1H), 7.44 (d, 1H), 4.98 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 3.17 (s, 3H)

Example 273. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

34 mg of the title compound (yield: 98.8%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 55 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of (6-(dimethylamino)pyridine-3-yl)boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.25 (dd, 1H), 8.19 (d, 1H), 8.00 (s, 1H), 7.66 (s, 1H), 7.62 (d, 1H), 7.52 (t, 1H), 7.40 (d, 1H), 7.27 (d, 1H), 4.96 (s, 2H), 4.60 (s, 2H), 3.69 (s, 2H), 3.33 (s, 6H)

Example 274. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

33 mg of the title compound (yield: 94.2%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 55 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 3,4-(methylenedioxy)phenylboronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 2H), 7.53 (d, 2H), 7.42 (t, 1H), 7.29 (d, 1H), 7.09 (t, 2H), 6.90 (d, 1H), 5.99 (s, 2H), 4.92 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H)

Example 275. 6-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

26 mg of the title compound (yield: 66.7%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 55 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (s, 1H), 7.58 (m, 2H), 7.43 (t, 1H), 7.30 (m, 3H), 4.93 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H), 3.01 (t, 2H), 2.59 (t, 2H), 2.33 (s, 3H)

Example 276. 6-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-methyl-3,4-dihydroquinolin-2-one Trifluoroacetate

28 mg of the title compound (yield: 73.6%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 55 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.99 (s, 1H), 7.62 (m, 2H), 7.56 (t, 1H), 7.51 (s, 1H), 7.46 (t, 1H), 7.32 (d, 1H), 7.21 (d, 1H), 4.94 (s, 2H), 4.60 (s, 2H), 3.68 (s, 2H), 3.40 (s, 3H), 3.00 (t, 2H), 2.67 (t, 2H)

Example 277. 5-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one Trifluoroacetate

30 mg of the title compound (yield: 86.2%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(3-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 55 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 1-ethyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.02 (d, 2H), 7.88 (m, 1H), 7.56 (m, 2H), 7.46 (t, 1H), 7.33 (d, 1H), 6.65 (d, 1H), 4.93 (s, 2H), 4.60 (s, 2H), 4.14 (q, 2H), 3.69 (s, 2H), 1.40 (t, 3H)

Example 278. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one trifluoroacetate

26 mg of the title compound (yield: 78.2%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 19 mg of 1-ethylpyrazol-4-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.81 (s, 1H), 7.55 (d, 2H), 7.35 (m, 3H), 7.27 (d, 1H), 4.98 (s, 2H), 4.55 (s, 2H), 4.26 (q, 2H), 3.66 (s, 2H), 1.52 (t, 3H)

Example 279. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

30 mg of the title compound (yield: 78.2%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25. ¹H-NMR (MeOD, 400 MHz) δ 8.03 (d, 2H), 7.60 (d, 2H), 7.49 (m, 3H), 7.41 (m, 1H), 7.32 (m, 1H), 4.87 (s, 2H), 4.46 (s, 2H), 3.61 (s, 2H), 3.20 (s, 3H)

Example 280. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(4-piperazin-1-ylphenyl)phenyl]methyl]-1,2,4-triazol-3-one Ditrifluoroacetate

27 mg of the title compound (yield: 69.0%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 34 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.47 (m, 3H), 7.28 (m, 4H), 7.12 (d, 2H), 4.88 (s, 2H), 4.51 (s, 2H), 3.64 (s, 2H), 3.50 (t, 4H), 3.41 (t, 4H), 3.33 (m, 2H)

Example 281. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 100%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of (6-(dimethylamino)pyridine-3-yl)boronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.94 (m, 2H), 7.75 (s, 1H), 7.48 (m, 2H), 7.39 (m, 1H), 7.33 (m, 1H), 7.24 (d, 1H), 4.88 (s, 2H), 4.52 (s, 2H), 3.67 (d, 2H), 3.32 (s, 6H)

Example 282. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

35 mg of the title compound (yield: 100%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 3,4-(methylenedioxy)phenylboronic acid was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.39 (m, 3H), 7.32 (t, 1H), 7.23 (m, 1H), 6.89 (d, 1H), 6.75 (m, 2H), 6.01 (s, 2H), 4.86 (s, 2H), 4.50 (s, 2H), 3.64 (s, 2H)

Example 283. 6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one Trifluoroacetate

25 mg of the title compound (yield: 65.5%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.39 (m, 3H), 7.31 (t, 1H), 7.27 (m, 1H), 6.99 (d, 2H), 4.87 (s, 2H), 4.94 (s, 2H), 3.64 (s, 2H), 2.99 (t, 2H), 2.61 (t, 2H), 2.31 (s, 3H)

Example 284. 6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-methyl-3,4-dihydroquinolin-2-one trifluoroacetate

28 mg of the title compound (yield: 72.4%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 25 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-yl)boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.40 (d, 3H), 7.34 (d, 1H), 7.30 (t, 1H), 7.21 (t, 3H), 4.88 (s, 2H), 4.49 (s, 2H), 3.64 (s, 2H), 3.41 (s, 3H), 2.97 (t, 2H), 2.68 (t, 2H)

Example 285. 5-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one Trifluoroacetate

17 mg of the title compound (yield: 49.4%) was prepared in the same fashion as Example 17, except that in Step 1, 40 mg of tert-butyl N-[2-[[4-[(2-bromophenyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 56 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 22 mg of 1-ethyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.76 (d, 1H), 7.62 (s, 1H), 7.46 (m, 3H), 7.38 (t, 1H), 7.32 (m, 1H), 6.58 (d, 1H), 4.90 (s, 2H), 4.49 (s, 2H), 4.10 (q, 2H), 3.64 (s, 2H), 1.40 (t, 3H)

Example 286. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[4-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

37 mg of the title compound (yield: 75.7%) was prepared in the same fashion as Example 100, except that in Step 1, 48 mg of 1-ethyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (d, 2H), 7.85 (s, 1H), 7.58 (s, 4H), 7.27 (d, 1H), 7.13 (d, 1H), 5.06 (s, 2H), 4.60 (s, 2H), 4.22 (dd, 2H), 3.68 (s, 2H), 1.50 (t, 3H)

Example 287. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 58.9%) was prepared in the same fashion as Example 100, except that in Step 1, 48 mg of 1-ethyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.07 (s, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 7.77 (s, 1H), 7.50 (d, 1H), 7.43 (d, 1H), 7.37 (m, 2H), 7.15 (d, 1H), 5.08 (s, 2H), 4.60 (s, 2H), 4.24 (q, 2H), 3.68 (s, 2H), 1.51 (t, 3H)

Example 288. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[4-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

27 mg of the title compound (yield: 51.8%) was prepared in the same fashion as Example 100, except that in Step 1, 52 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 50 mg of 1-ethyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.01 (d, 2H), 7.85 (s, 1H), 7.59 (m, 6H), 5.10 (s, 2H), 4.60 (s, 2H), 4.22 (q, 2H), 3.68 (s, 2H), 1.50 (t, 3H)

Example 289. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[3-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

29 mg of the title compound (yield: 57.1%) was prepared in the same fashion as Example 100, except that in Step 1, 52 mg of tert-butyl N-[2-[[4-(4-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 42 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 50 mg of 1-ethyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.04 (d, 2H), 7.86 (d, 2H), 7.68 (d, 1H), 7.59 (s, 1H), 7.49 (d, 2H), 7.38 (t, 1H), 5.11 (s, 2H), 4.60 (s, 2H), 4.24 (dd, 2H), 3.68 (s, 2H), 1.51 (t, 3H)

Example 290. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[4-(1-ethylpyrazol-4-yl)phenyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

15 mg of the title compound (yield: 30.3%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 48 mg of 1-ethyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.70 (s, 1H), 8.19 (s, 2H), 8.11 (s, 1H), 7.91 (s, 1H), 7.73 (s, 4H), 4.70 (s, 2H), 4.25 (q, 2H), 3.77 (s, 2H), 2.43 (s, 3H), 1.50 (t, 3H)

Example 291. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[3-(1-ethylpyrazol-4-yl)phenyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one Trifluoroacetate

27 mg of the title compound (yield: 56.0%) was prepared in the same fashion as Example 17, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-(5-bromo-3-methyl-2-pyridyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 34 was used instead of tert-butyl N-[2-[[4-(3-bromophenyl)-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 25 and 48 mg of 1-ethyl-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole was used instead of 4-(methanesulfonyl)phenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.71 (s, 1H), 8.20 (s, 1H), 8.14 (s, 1H), 7.95 (s, 1H), 7.90 (s, 1H), 7.66 (d, 1H), 7.54 (m, 2H), 4.70 (s, 2H), 4.25 (q, 2H), 3.78 (s, 2H), 2.44 (s, 3H), 1.52 (t, 3H)

Example 292. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1H-pyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

22 mg of the title compound (yield: 57.0%) was prepared in the same fashion as Example 100, except that in Step 1, 25 mg of 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]ethanone was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.83 (s, 2H), 7.55 (m, 2H), 5.03 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H)

Example 293. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methylsulfonylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

13 mg of the title compound (yield: 28.0%) was prepared in the same fashion as Example 100, except that in Step 1, 20 mg of (1-methylsulfonylpyrazol-4-yl)boronic acid was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.42 (s, 1H), 8.12 (s, 1H), 7.98 (s, 1H), 7.22 (d, 1H), 7.13 (d, 1H), 5.06 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.45 (s, 3H)

Example 294. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-cyclopropylsulfonylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

38 mg of the title compound (yield: 77.6%) was prepared in the same fashion as Example 100, except that in Step 1, 32 mg of 1-cyclopropylsulfonyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.40 (s, 1H), 8.10 (s, 1H), 7.98 (s, 1H), 7.21 (d, 1H), 7.12 (d, 1H), 5.06 (s, 2H), 4.59 (s, 2H), 3.69 (s, 2H), 2.97 (m, 1H), 1.41 (m, 2H), 1.23 (m, 2H)

Example 295. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[1-(cyclopropylmethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

31 mg of the title compound (yield: 72.0%) was prepared in the same fashion as Example 100, except that in Step 1, 27 mg of 1-(cyclopropylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.95 (d, 2H), 7.67 (s, 1H), 7.05 (dd, 2H), 5.03 (s, 2H), 4.59 (s, 2H), 4.00 (d, 2H), 3.68 (s, 2H), 1.30 (m, 1H), 0.63 (m, 2H), 0.42 (m, 2H)

Example 296. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

12 mg of the title compound (yield: 29.0%) was prepared in the same fashion as Example 100, except that in Step 1, 22 mg of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.96 (s, 2H), 7.85 (s, 1H), 7.66 (s, 1H), 7.06 (d, 1H), 7.01 (d, 1H), 5.03 (s, 2H), 4.59 (s, 2H), 3.90 (s, 3H), 3.67 (s, 2H)

Example 297. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-benzylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

23 mg of the title compound (yield: 48.6%) was prepared in the same fashion as Example 100, except that in Step 1, 30 mg of 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.94 (d, 2H), 7.71 (s, 1H), 7.34 (m, 3H), 7.27 (m, 2H), 7.04 (dd, 2H), 5.34 (s, 2H), 5.02 (s, 2H), 4.58 (s, 2H), 3.67 (s, 2H)

Example 298. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-fluoro-5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one ditrifluoroacetate

17 mg of the title compound (yield: 35.9%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 59 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 40 mg of tert-butyl 4-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.54 (d, 2H), 7.07 (t, 3H), 5.01 (s, 2H), 4.59 (s, 2H), 3.67 (s, 2H), 3.49 (t, 4H), 3.39 (m, 4H)

Example 299. 5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4-fluoro-2-thienyl]-1-ethyl-pyridin-2-one Trifluoroacetate

28 mg of the title compound (yield: 65.0%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 59 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 26 mg of 1-ethyl-6-oxo-1,6-dihydropyridine-3-boronic acid pinacol ester was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.05 (d, 2H), 7.75 (q, 1H), 7.11 (s, 1H), 5.02 (s, 2H), 4.59 (s, 2H), 4.08 (q, 2H), 3.69 (s, 2H), 1.37 (t, 3H)

Example 300. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-3-fluoro-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

26 mg of the title compound (yield: 59.2%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 59 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 26 mg of 2-(1,3-benzodioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.97 (s, 1H), 7.08 (m, 3H), 6.85 (d, 1H), 6.01 (s, 2H), 5.00 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H)

Example 301. 6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4-fluoro-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one trifluoroacetate

25 mg of the title compound (yield: 52.4%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 59 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 30 mg of (1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)boronic acid pinacol ester was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.98 (s, 1H), 7.49 (m, 2H), 7.16 (t, 2H), 5.02 (s, 2H), 4.59 (s, 2H), 3.68 (s, 2H), 3.36 (s, 3H), 2.96 (t, 2H), 2.64 (t, 2H)

Example 302. 2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-3-fluoro-2-thienyl]methyl]-1,2,4-triazol-3-one Trifluoroacetate

21 mg of the title compound (yield: 51.4%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 59 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 23 mg of 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.96 (s, 2H), 7.70 (s, 1H), 6.95 (s, 1H), 4.98 (s, 2H), 4.58 (s, 2H), 4.20 (q, 2H), 3.67 (s, 2H), 1.47 (t, 3H),

Example 303. 2-(2-(aminomethyl)-3,3-difluoroallyl)-4-((5-(6-(dimethylamino)pyridin-3-yl)-3-fluorothiophen-2-yl)methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one trifluoroacetate

2 mg of the title compound (yield: 3.9%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 59 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 26 mg of 6-(dimethylamino)pyridine-3-boronic acid pinacol ester was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 8.29 (d, 1H), 7.95 (s, 1H), 7.74 (m, 1H), 7.05 (s, 1H), 6.71 (d, 1H), 5.00 (s, 2H), 4.57 (s, 2H), 3.47 (s, 2H), 3.13 (s, 6H)

Example 304. 6-(5-((1-(2-(aminomethyl)-3,3-difluoroallyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)methyl)-4-fluorothiophen-2-yl)-8-methyl-3,4-dihydroquinolin-2(1H)-one Trifluoroacetate

2 mg of the title compound (yield: 4.8%) was prepared in the same fashion as Example 100, except that in Step 1, 50 mg of tert-butyl N-[2-[[4-[(5-bromo-3-fluoro-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 59 was used instead of tert-butyl N-[2-[[4-(5-bromo-2-thienyl)methyl]-5-oxo-1,2,4-triazol-1-yl]methyl]-3,3-difluoro-allyl]carbamate prepared in Reference Example 41 and 30 mg of 8-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-boronic acid pinacol ester was used instead of 4-acetylphenylboronic acid. ¹H-NMR (MeOD, 400 MHz) δ 7.96 (s, 1H), 7.31 (s, 2H), 7.15 (s, 1H), 5.01 (s, 2H), 4.58 (s, 2H), 3.65 (s, 2H), 2.99 (t, 2H), 2.59 (t, 2H), 2.30 (s, 3H)

Compounds from the Examples are shown in Table 1.

TABLE 1* Ex No Structure Chemical Name    1

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (4-fluorophenyl)-1,2,4-triazol-3-one  2

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (3-bromophenyl)-1,2,4-triazol-3-one  3

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (3,4-difluorophenyl)-1,2,4-triazol-3-one  4

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (4-bromo-3-fluoro-phenyl)-1,2,4-triazol- 3-one  5

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (4-bromo-2-fluoro-phenyl)-1,2,4-triazol- 3-one  6

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (4-bromo-2-methyl-phenyl)-1,2,4-triazol 3-one  7

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (6-bromo-3-pyridyl)-1,2,4-triazol-3-one  8

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (6-bromo-2-pyridyl)-1,2,4-triazol-3-one  9

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (4-bromo-2-pyridyl)-1,2,4-triazol-3-one  10

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (2-bromo-4-pyridyl)-1,2,4-triazol-3-one  11

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (5-bromo-3-methyl-2-pyridyl)-1,2,4- triazol-3-one  12

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (6-bromo-4-methyl-3-pyridyl)-1,2,4- triazol-3-one  13

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (6-bromo-5-methyl-3-pyridyl)-1,2,4- triazol-3-one  14

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (5-bromo-3-fluoro-2-pyridyl)-1,2,4- triazol-3-one  15

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (6-bromo-3-methyl-2-pyridyl)-1,2,4- triazol-3-one  16

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- (5-bromopyrazin-2-yl)-1,2,4-triazol-3-one  17

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-(4-methylsulfonylphenyl)phenyl]- 1,2,4-triazol-3-one  18

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-(4-piperazin-1-ylphenyl)phenyl]-1,2,4- triazol-3-one  19

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-[6-(trifluoromethyl)-3-pyridyl]phenyl]- 1,2,4-triazol-3-one  20

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-[6-(dimethylamino)-3-pyridyl]phenyl]- 1,2,4-triazol-3-one  21

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-(1,3-benzodioxol-5-yl)phenyl]-1,2,4- triazol-3-one  22

6-[3-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]phenyl]-8- methyl-3,4-dihydro-1H-quinolin-2-one  23

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-(1-ethylpyrazol-4-yl)phenyl]-1,2,4- triazol-3-one  24

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-fluoro-4-(4- methylsulfonylphenyl)phenyl]-1,2,4- triazol-3-one  25

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-fluoro-4-(4-piperazin-1- ylphenyl)phenyl]-1,2,4-triazol-3-one  26

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-fluoro-4-[6-(trifluoromethyl)-3- pyridyl]phenyl]-1,2,4-triazol-3-one  27

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-[6-(dimethylamino)-3-pyridyl]-3- fluoro-phenyl]-1,2,4-triazol-3-one  28

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(1,3-benzodioxol-5-yl)-3-fluoro- phenyl]-1,2,4-triazol-3-one  29

6-[4-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-fluoro- phenyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one  30

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(1-ethylpyrazol-4-yl)-3-fluoro-phenyl]- 1,2,4-triazol-3-one  31

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-fluoro-4-(4- methylsulfonylphenyl)phenyl]-1,2,4- triazol-3-one  32

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-fluoro-4-(4-piperazin-1- ylphenyl)phenyl]-1,2,4-triazol-3-one  33

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-fluoro-4-[6-(trifluoromethyl)-3- pyridyl]phenyl]-1,2,4-triazol-3-one  34

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-[6-(dimethylamino)-3-pyridyl]-2- fluoro-phenyl]-1,2,4-triazol-3-one  35

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(1,3-benzodioxol-5-yl)-2-fluoro- phenyl]-1,2,4-triazol-3-one  36

6-[4-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-3-fluoro- phenyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one  37

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(1-ethylpyrazol-4-yl)-2-fluoro-phenyl]- 1,2,4-triazol-3-one  38

2-(2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(4-methylsulfonylphenyl)-3-pyridyl]- 1,2,4-triazol-3-one  39

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(4-piperazin-1-ylphenyl)-3-pyridyl]- 1,2,4-triazol-3-one  40

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[6-(trifluoromethyl)-3-pyridyl]-3- pyridyl]-1,2,4-triazol-3-one  41

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[6-(dimethylamino)-3-pyridyl]-3- pyridyl]-1,2,4-triazol-3-one  42

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(1,3-benzodioxol-5-yl)-3-pyridyl]- 1,2,4-triazol-3-one  43

6-[5-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 8-methyl-3,4-dihydro-1H-quinolin-2-one  44

6-[5-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 1-methyl-3,4-dihydroquinolin-2-one  45

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(1-ethylpyrazol-4-yl)-3-pyridyl]-1,2,4 triazol-3-one  46

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(4-methylsulfonylphenyl)-2-pyridyl]- 1,2,4-triazol-3-one  47

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(4-piperazin-1-ylphenyl)-2-pyridyl]- 1,2,4-triazol-3-one  48

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[6-(trifluoromethyl)-3-pyridyl]-2- pyridyl]-1,2,4-triazol-3-one  49

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[6-(dimethylamino)-3-pyridyl]-2- pyridyl]-1,2,4-triazol-3-one  50

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(1,3-benzodioxol-5-yl)-2-pyridyl]- 1,2,4-triazol-3-one  51

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 8-methyl-3,4-dihydro-1H-quinolin-2-one  52

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 1-methyl-3,4-dihydroquinolin-2-one  53

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4- triazol-3-one  54

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(4-methylsulfonylphenyl)-2-pyridyl]- 1,2,4-triazol-3-one  55

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(4-piperazin-1-ylphenyl)-2-pyridyl]- 1,2,4-triazol-3-one  56

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-[6-(trifluoromethyl)-3-pyridyl]-2- pyridyl]-1,2,4-triazol-3-one  57

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-[6-(dimethylamino)-3-pyridyl]-2- pyridyl]-1,2,4-triazol-3-one  58

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(1,3-benzodioxol-5-yl)-2-pyridyl]- 1,2,4-triazol-3-one  59

6-[2-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-4-pyridyl]- 8-methyl-3,4-dihydro-1H-quinolin-2-one  60

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [4-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4- triazol-3-one  61

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-(4-methylsulfonylphenyl)-4-pyridyl]- 1,2,4-triazol-3-one  62

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-(4-piperazin-1-ylphenyl)-4-pyridyl]- 1,2,4-triazol-3-one  63

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-[6-(dimethylamino)-3-pyridyl]-4- pyridyl]-1,2,4-triazol-3-one  64

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-(1,3-benzodioxol-5-yl)-4-pyridyl]- 1,2,4-triazol-3-one  65

6-[4-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 8-methyl-3,4-dihydro-1H-quinolin-2-one  66

6-[4-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 1-methyl-3,4-dihydroquinolin-2-one  67

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-(1-ethylpyrazol-4-yl)-4-pyridyl]-1,2,4- triazol-3-one  68

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(4-methylsulfonylphenyl)-2- pyridyl]-1,2,4-triazol-3-one  69

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(4-piperazin-1-ylphenyl)-2- pyridyl]-1,2,4-triazol-3-one  70

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-[6-(trifluoromethyl)-3- pyridyl]-2-pyridyl]-1,2,4-triazol-3-one  71

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[6-(dimethylamino)-3-pyridyl]-3 methyl-2-pyridyl]-1,2,4-triazol-3-one  72

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1,3-benzodioxol-5-yl)-3-methyl-2- pyridyl]-1,2,4-triazol-3-one  73

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one  74

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]-1-methyl-3,4-dihydroquinolin- 2-one  75

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1-ethylpyrazol-4-yl)-3-methyl-2- pyridyl]-1,2,4-triazol-3-one  76

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-methyl-6-(4-methylsulfonylphenyl)-3- pyridyl]-1,2,4-triazol-3-one  77

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-methyl-6-[6-(trifluoromethyl)-3- pyridyl]-3-pyridyl]-1,2,4-triazol-3-one  78

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[6-(dimethylamino)-3-pyridyl]-5- methyl-3-pyridyl]-1,2,4-triazol-3-one  79

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(1,3-benzodioxol-5-yl)-5-methyl-3- pyridyl]-1,2,4-triazol-3-one  80

6-[5-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl- 2-pyridyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one  81

6-[5-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl- 2-pyridyl]-1-methyl-3,4-dihydroquinolin- 2-one  82

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-fluoro-5-(4-methylsulfonylphenyl)-2- pyridyl]-1,2,4-triazol-3-one  83

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-fluoro-5-(4-piperazin-1-ylphenyl)-2- pyridyl]-1,2,4-triazol-3-one  84

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-fluoro-5-[6-(trifluoromethyl)-3- pyridyl]-2-pyridyl]-1,2,4-triazol-3-one  85

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1,3-benzodioxol-5-yl)-3-fluoro-2- pyridyl]-1,2,4-triazol-3-one  86

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-l,2,4-triazol-4-yl]-5-fluoro- 3-pyridyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one  87

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-fluoro- 3-pyridyl]-1-methyl-3,4-dihydroquinolin- 2-one  88

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1-ethylpyrazol-4-yl)-3-fluoro-2- pyridyl]-1,2,4-triazol-3-one  89

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(4-methylsulfonylphenyl)pyrazin-2- yl]-1,2,4-triazol-3-one  90

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(4-piperazin-1-ylphenyl)pyrazin-2-yl]- 1,2,4-triazol-3-one  91

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[6-(trifluoromethyl)-3-pyridyl]pyrazin- 2-yl]-1,2,4-triazol-3-one  92

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[6-(dimethylamino)-3-pyridyl]pyrazin- 2-yl]-1,2,4-triazol-3-one  93

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1,3-benzodioxol-5-yl)pyrazin-2-yl]- 1,2,4-triazol-3-one  94

6-[5-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]pyrazin-2- yl]-1-methyl-3,4-dihydro-1H-quinolin-2- one  95

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1-ethylpyrazol-4-yl)pyrazin-2-yl]- 1,2,4-triazol-3-one  96

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [(4-benzyloxyphenyl)methyl]-1,2,4- triazol-3-one  97

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [(5-bromo-2-thienyl)methyl]-1,2,4- triazol-3-one  98

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [(4-bromo-2-thienyl)methyl]-1,2,4- triazol-3-one  99

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [(5-bromo-3-methyl-2-thienyl)methyl]- 1,2,4-triazol-3-one 100

4-[[5-(4-acetylphenyl)-2-thienyl]methyl]- 2-[2-(aminomethyl)-3,3-difluoro-allyl]- 1,2,4-triazol-3-one 101

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(4-methylsulfonylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 102

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(3-methylsulfonylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 103

3-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-N,N-dimethyl- benzenesulfonamide 104

4-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-N-methyl-benzamide 105

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(3,4,5-trimethoxyphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 106

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(4-piperazin-1-ylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 107

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(3-piperazin-1-ylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 108

4-[[5-[4-(4-acetylpiperazin-1-yl)phenyl]- 2-thienyl]methyl]-2-[2-(aminomethyl)- 3,3-difluoro-allyl]-1,2,4-triazol-3-one 109

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[4-(morpholine-4-carbonyl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 110

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[3-(1H-pyrazol-3-yl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 111

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[6-(trifluoromethyl)-3-pyridyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 112

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[6-(dimethylamino)-3-pyridyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 113

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(6-methoxy-3-pyridyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 114

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(6-piperazin-1-yl-3-pyridyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 115

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[6-(dimethylamino)-5-fluoro-3- pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3- one 116

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(2-aminopyrimidin-5-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 117

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(2-ethoxypyrimidin-5-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 118

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-(2-methoxyethylamino)pyrimidin- 5-yl]-2-thienyl]methyl]-1,2,4-triazol-3- one 119

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-ethylpyrazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 120

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(2-chloro-3-methyl-imidazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 121

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-1-methyl-pyridin-2-one 122

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-1-ethyl-pyridin-2-one 123

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-1-isopropyl-pyridin-2-one 124

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-methyl-3,6-dihydro-2H-pyridin-4- yl)-2-thienyl]methyl]-1,2,4-triazol-3-one 125

4-[[5-(1-acetyl-3,6-dihydro-2H-pyridin-4- yl)-2-thienyl]methyl]-2-[2- (aminomethyl)-3,3-difluoro-allyl]-1,2,4- triazol-3-one 126

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1,3-benzodioxol-5-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 127

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1H-indazol-6-yl)-2-thienyl]methyl]- 1,2,4-triazol-3-one 128

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 129

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(2,1,3-benzoxadiazol-5-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 130

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-7-fluoro-indolin-2-one 131

N-[6-[5-[[1-[2-(aminomethyl)-3,3- difluoro-allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]-2-thienyl]-1,3-benzothiazol-2- yl]acetamide 132

7-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-3,4-dihydro-2H-isoquinolin-1- one 133

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-3,4-dihydro-1H-quinolin-2-one 134

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one 135

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-8-methyl-1H-quinolin-2-one 136

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-8-fluoro-3,4-dihydro-1H- quinolin-2-one 137

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-8-fluoro-1H-quinolin-2-one 138

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-1-methyl-3,4-dihydroquinolin-2- one 139

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(5-methyl-3,4-dihydro-2H-1,4- benzoxazin-6-yl)-2-thienyl]methyl]-1,2,4- triazol-3-one 140

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(4-methyl-2,3-dihydro-1,4- benzoxazin-7-yl)-2-thienyl]methyl]-1,2,4- triazol-3-one 141

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-4H-1,4-benzoxazin-3-one 142

7-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-1,4-dihydro-3,1-benzoxazin-2- one 143

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-1,4-dihydro-3,1-benzoxazin-2- one 144

7-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-4-methyl-1,4-benzoxazin-3-one 145

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(5,6,7,8-tetrahydro-1,8-naphthyridin- 3-yl)-2-thienyl]methyl]-1,2,4-triazol-3- one 146

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(4-methylsulfonylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 147

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(4-piperazin-1-ylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 148

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-[6-(trifluoromethyl)-3-pyridyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 149

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-[6-(dimethylamino)-3-pyridyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 150

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(1,3-benzodioxol-5-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 151

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one 152

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-1-methyl-3,4-dihydroquinolin-2- one 153

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(1-ethylpyrazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 154

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-methyl-5-(4-methylsulfonylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 155

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-methyl-5-(4-piperazin-1-ylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 156

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-methyl-5-[6-(trifluoromethyl)-3- pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3- one 157

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[6-(dimethylamino)-3-pyridyl]-3- methyl-2-thienyl]methyl]-1,2,4-triazol-3- one 158

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1,3-benzodioxol-5-yl)-3-methyl-2- thienyl]methyl]-1,2,4-triazol-3-one 159

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-ethylpyrazol-4-yl)-3-methyl-2- thienyl]methyl]-1,2,4-triazol-3-one 160

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[2-(1-methylpyrazol-4-yl)ethynyl]-2- pyridyl]-1,2,4-triazol-3-one 161

7-[(E)-2-[5-[[1-[2-(aminomethyl)-3,3- difluoro-allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]-2-thienyl]vinyl]-1H- pyrido[2,3-b][1,4]oxazin-2-one 162

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-[6-(dimethylamino)-3- pyridyl]ethynyl]-2-thienyl]methyl]-1,2,4- triazol-3-one 163

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-(6-morpholino-3-pyridyl)ethynyl]- 2-thienyl]methyl]-1,2,4-triazol-3-one 164

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6- yl)ethynyl]-2-thienyl]methyl]-1,2,4- triazol-3-one 165

6-[2-[5-[[1-[2-(aminomethyl)-3,3- difluoro-allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]-2-thienyl]ethynyl]-3,4- dihydro-1H-quinolin-2-one 166

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-(2,3-dihydro-1H-pyrido[2,3- b][1,4]oxazin-7-yl)ethynyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 167

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)ethynyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 168

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-(2,3-dihydro-1H-pyrido[2,3- b][1,4]oxazin-6-yl)ethynyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 169

7-[2-[5-[[1-[2-(aminomethyl)-3,3- difluoro-allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]-2-thienyl]ethynyl]-1H- pyrido[2,3-b][1,4]oxazin-2-one 170

7-[2-[5-[[1-[2-(aminomethyl)-3,3- difluoro-allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]-2-thienyl]ethynyl]-4H- pyrido[3,2-b][1,4]oxazin-3-one 171

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[2-(1-methylpyrazol-4-yl)ethynyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 172

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-(2-thienyl)ethyl]-1,2,4-triazol-3-one 173

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-[5-(4-methylsulfonylphenyl)-2- thienyl]ethyl]-1,2,4-triazol-3-one 174

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-[5-(4-piperazin-1-ylphenyl)-2- thienyl]ethyl]-1,2,4-triazol-3-one 175

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-[5-[6-(trifluoromethyl)-3-pyridyl]-2- thienyl]ethyl]-1,2,4-triazol-3-one 176

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-[5-[6-(dimethylamino)-3-pyridyl]-2- thienyl]ethyl]-1,2,4-triazol-3-one 177

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-[5-(1,3-benzodioxol-5-yl)-2- thienyl]ethyl]-1,2,4-triazol-3-one 178

6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2- thienyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one 179

6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2- thienyl]-1-methyl-3,4-dihydroquinolin-2- one 180

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-[5-(1-ethylpyrazol-4-yl)-2- thienyl]ethyl]-1,2,4-triazol-3-one 181

3-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yllmethyl]-2- thienyl]-N,N-dimethyl-benzamide 182

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2- thienyl]-3-methyl-1,4-dihydroquinazolin- 2-one 183

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[1-(difluoromethyl)pyrazol-4-yl]-2- thienyl]methyl]-1,2,4-triazol-3-one 184

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-isopropylpyrazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 185

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 186

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-3-methyl-1,4-dihydroquinazolin- 2-one 187

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-1-isopropyl-pyridin-2-one 188

4-[[4-[4-(4-acetylpiperazin-1-yl)phenyl]- 2-thienyl]methyl]-2-[2-(aminomethyl)- 3,3-difluoro-allyl]-1,2,4-triazol-3-one 189

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-8-fluoro-1H-quinolin-2-one 190

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-1-methyl-pyridin-2-one 191

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-1,4-dihydro-3,1-benzoxazin-2- one 192

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-3,4-dihydro-1H-quinolin-2-one 193

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3- thienyl]-1-ethyl-pyridin-2-one 194

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-[1-(difluoromethyl)pyrazol-4-yl]-2- thienyl]methyl]-1,2,4-triazol-3-one 195

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(1-isopropylpyrazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 196

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 197

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[6-(4- methylsulfonylphenyl)benzothiophen-2- yl]methyl]-1,2,4-triazol-3-one 198

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[6-(4-piperazin-1- ylphenyl)benzothiophen-2-yl]methyl]- 1,2,4-triazol-3-one 199

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[6-[6-(trifluoromethyl)-3- pyridyl]benzothiophen-2-yl]methyl]- 1,2,4-triazol-3-one 200

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[6-[6-(dimethylamino)-3- pyridyl]benzothiophen-2-yl]methyl]- 1,2,4-triazol-3-one 201

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[6-(1,3-benzodioxol-5-yl)benzothiophen- 2-yl]methyl]-1,2,4-triazol-3-one 202

6-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]benzothiophen-6-yl]-8-methyl- 3,4-dihydro-1H-quinolin-2-one 203

6-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]benzothiophen-6-yl]-1-methyl- 3,4-dihydroquinolin-2-one 204

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[6-(1-ethylpyrazol-4-yl)benzothiophen-2- yl]methyl]-1,2,4-triazol-3-one 205

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(4- methylsulfonylphenyl)benzothiophen-2- yl]methyl]-1,2,4-triazol-3-one 206

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(4-piperazin-1- ylphenyl)benzothiophen-2-yl]methyl]- 1,2,4-triazol-3-one 207

5-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]benzothiophen-5-yl]-1-ethyl- pyridin-2-one 208

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[6-(dimethylamino)-3- pyridyl]benzothiophen-2-yl]methyl]- 1,2,4-triazol-3-one 209

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1,3-benzodioxol-5-yl)benzothiophen- 2-yl]methyl]-1,2,4-triazol-3-one 210

6-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]benzothiophen-5-yl]-8-methyl- 3,4-dihydro-1H-quinolin-2-one 211

6-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]benzothiophen-5-yl]-1-methyl- 3,4-dihydroquinolin-2-one 212

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-ethylpyrazol-4-yl)benzothiophen-2- yl]methyl]-1,2,4-triazol-3-one 213

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(6-piperazin-1-yl-3-pyridyl)-2- pyridyl]-1,2,4-triazol-3-one 214

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[4-(morpholine-4-carbonyl)phenyl]-2- pyridyl]-1,2,4-triazol-3-one 215

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(6-morpholino-3-pyridyl)-2-pyridyl]- 1,2,4-triazol-3-one 216

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-(3-piperazin-1-ylphenyl)-2-pyridyl]- 1,2,4-triazol-3-one 217

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [6-[3-(dimethylamino)-4-fluoro-phenyl]- 2-pyridyl]-1,2,4-triazol-3-one 218

5-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 1-ethyl-pyridin-2-one 219

7-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]- 1,4-dihydro-3,1-benzoxazin-2-one 220

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(6-piperazin-1-yl-3-pyridyl)- 2-pyridyl]-1,2,4-triazol-3-one 221

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]-4H-1,4-benzoxazin-3-one 222

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[2-(2-methoxyethylamino)pyrimidin-5- yl]-3-methyl-2-pyridyl]-1,2,4-triazol-3- one 223

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(4-methyl-2,3-dihydro-1,4- benzoxazin-7-yl)-2-pyridyl]-1,2,4-triazol- 3-one 224

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(3,4,5-trimethoxyphenyl)-2- pyridyl]-1,2,4-triazol-3-one 225

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(6-methoxy-3-pyridyl)-3-methyl-2- pyridyl]-1,2,4-triazol-3-one 226

4-[5-(2-amino-1,3-benzothiazol-5-yl)-3- methyl-2-pyridyl]-2-[2-(aminomethyl)- 3,3-difluoro-allyl]-1,2,4-triazol-3-one 227

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(2,1,3-benzoxadiazol-5-yl)-3-methyl-2- pyridyl]-1,2,4-triazol-3-one 228

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-5- yl)-2-pyridyl]-1,2,4-triazol-3-one 229

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1,3-benzoxazol-5-yl)-3-methyl-2- pyridyl]-1,2,4-triazol-3-one 230

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-[4-(2-oxopyrrolidin-1- yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one 231

4-[5-(5-acetyl-2-thienyl)-3-methyl-2- pyridyl]-2-[2-(aminomethyl)-3,3-difluoro- allyl]-1,2,4-triazol-3-one 232

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-[3-(1H-pyrazol-3-yl)phenyl]- 2-pyridyl]-1,2,4-triazol-3-one 233

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1H-indazol-6-yl)-3-methyl-2-pyridyl]- 1,2,4-triazol-3-one 234

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(3-methylsulfonylphenyl)-2- pyridyl]-1,2,4-triazol-3-one 235

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(3-piperazin-1-ylphenyl)-2- pyridyl]-1,2,4-triazol-3-one 236

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-[4-(morpholine-4- carbonyl)phenyl]-2-pyridyl]-1,2,4-triazol- 3-one 237

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-(4-morpholinophenyl)-2- pyridyl]-1,2,4-triazol-3-one 238

4-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]-N,N-dimethyl- benzenesulfonamide 239

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-[3-(1H-1,2,4-triazol-3- yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one 240

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-[2-(1-methylpyrazol-4- yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one 241

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[2-[6-(dimethylamino)-3- pyridyl]ethynyl]-3-methyl-2-pyridyl]- 1,2,4-triazol-3-one 242

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-methyl-5-[2-(6-morpholino-3- pyridyl)ethynyl]-2-pyridyl]-1,2,4-triazol- 3-one 243

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6- yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4- triazol-3-one 244

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[2-(2,3-dihydro-1H-pyrido[2,3- b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2- pyridyl]-1,2,4-triazol-3-one 245

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[2-(3,4-dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2- pyridyl]-1,2,4-triazol-3-one 246

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[2-(2,3-dihydro-1H-pyrido[2,3- b][1,4]oxazin-6-yl)ethynyl]-3-methyl-2- pyridyl]-1,2,4-triazol-3-one 247

7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]ethynyl]-1H-pyrido[2,3- b][1,4]oxazin-2-one 248

7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]ethynyl]-4H-pyrido[3,2- b][1,4]oxazin-3-one 249

6-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]ethynyl]-3,4-dihydro-1H- quinolin-2-one 250

6-[6-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl- 3-pyridyl]-3-methyl-1,4- dihydroquinazolin-2-one 251

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[1-(difluoromethyl)pyrazol-4-yl]-3- methyl-2-pyridyl]-1,2,4-triazol-3-one 252

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-(1-isopropylpyrazol-4-yl)-3-methyl-2- pyridyl]-1,2,4-triazol-3-one 253

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-methyl-3-(4- methylsulfonylphenyl)phenyl]-1,2,4- triazol-3-one 254

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-methyl-3-(4-piperazin-1- ylphenyl)phenyl]-1,2,4-triazol-3-one 255

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-methyl-3-[6-(trifluoromethyl)-3- pyridyl]phenyl]-1,2,4-triazol-3-one 256

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-[6-(dimethylamino)-3-pyridyl]-2- methyl-phenyl]-1,2,4-triazol-3-one 257

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-(1,3-benzodioxol-5-yl)-2-methyl- phenyl]-1,2,4-triazol-3-one 258

6-[3-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl- phenyl]-8-methyl-3,4-dihydro-1H- quinolin-2-one 259

6-[3-[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl- phenyl]-1-methyl-3,4-dihydroquinolin-2- one 260

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-(1-ethylpyrazol-4-yl)-2-methyl- phenyl]-1,2,4-triazol-3-one 261

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-[1-(difluoromethyl)pyrazol-4-yl]-2- methyl-phenyl]-1,2,4-triazol-3-one 262

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [3-(1-isopropylpyrazol-4-yl)-2-methyl- phenyl]-1,2,4-triazol-3-one 263

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [2-methyl-3-[3-(1H-1,2,4-triazol-3- yl)phenyl]phenyl]-1,2,4-triazol-3-one 264

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(1-ethylpyrazol-4-yl)phenyl]methyl]- 1,2,4-triazol-3-one 265

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(4- methylsulfonylphenyl)phenyl]methyl]- 1,2,4-triazol-3-one 266

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(4-piperazin-1- ylphenyl)phenyl]methyl]-1,2,4-triazol-3- one 267

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-[6-(dimethylamino)-3- pyridyl]phenyl]methyl]-1,2,4-triazol-3- one 268

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-(1,3-benzodioxol-5- yl)phenyl]methyl]-1,2,4-triazol-3-one 269

6-[4-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-8-methyl-3,4-dihydro- 1H-quinolin-2-one 270

5-[4-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-1-ethyl-pyridin-2-one 271

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-(1-ethylpyrazol-4-yl)phenyl]methyl]- 1,2,4-triazol-3-one 272

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-(4- methylsulfonylphenyl)phenyl]methyl]- 1,2,4-triazol-3-one 273

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-[6-(dimethylamino)-3- pyridyl]phenyl]methyl]-1,2,4-triazol-3- one 274

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-(1,3-benzodioxol-5- yl)phenyl]methyl]-1,2,4-triazol-3-one 275

6-[3-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-8-methyl-3,4-dihydro- 1H-quinolin-2-one 276

6-[3-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-1-methyl-3,4- dihydroquinolin-2-one 277

5-[3-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-1-ethyl-pyridin-2-one 278

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[2-(1-ethylpyrazol-4-yl)phenyl]methyl]- 1,2,4-triazol-3-one 279

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[2-(4- methylsulfonylphenyl)phenyl]methyl]- 1,2,4-triazol-3-one 280

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[2-(4-piperazin-1- ylphenyl)phenyl]methyl]-1,2,4-triazol-3- one 281

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[2-[6-(dimethylamino)-3- pyridyl]phenyl]methyl]-1,2,4-triazol-3- one 282

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[2-(1,3-benzodioxol-5- yl)phenyl]methyl]-1,2,4-triazol-3-one 283

6-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-8-methyl-3,4-dihydro- 1H-quinolin-2-one 284

6-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-1-methyl-3,4- dihydroquinolin-2-one 285

5-[2-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4- yl]methyl]phenyl]-1-ethyl-pyridin-2-one 286

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[4-(1-ethylpyrazol-4-yl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 287

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[3-(1-ethylpyrazol-4-yl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 288

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-[4-(1-ethylpyrazol-4-yl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 289

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[4-[3-(1-ethylpyrazol-4-yl)phenyl]-2- thienyl]methyl]-1,2,4-triazol-3-one 290

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[4-(1-ethylpyrazol-4-yl)phenyl]-3- methyl-2-pyridyl]-1,2,4-triazol-3-one 291

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [5-[3-(1-ethylpyrazol-4-yl)phenyl]-3- methyl-2-pyridyl]-1,2,4-triazol-3-one 292

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1H-pyrazol-4-yl)-2-thienyl]methyl]- 1,2,4-triazol-3-one 293

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-methylsulfonylpyrazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 294

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-cyclopropylsulfonylpyrazol-4-yl)- 2-thienyl]methyl]-1,2,4-triazol-3-one 295

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-[1-(cyclopropylmethyl)pyrazol-4-yl]- 2-thienyl]methyl]-1,2,4-triazol-3-one 296

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-methylpyrazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 297

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-benzylpyrazol-4-yl)-2- thienyl]methyl]-1,2,4-triazol-3-one 298

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[3-fluoro-5-(4-piperazin-1-ylphenyl)-2- thienyl]methyl]-1,2,4-triazol-3-one 299

5-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4- fluoro-2-thienyl]-1-ethyl-pyridin-2-one 300

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1,3-benzodioxol-5-yl)-3-fluoro-2- thienyl]methyl]-1,2,4-triazol-3-one 301

6-[5-[[1-[2-(aminomethyl)-3,3-difluoro- allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4- fluoro-2-thienyl]-1-methyl-3,4- dihydroquinolin-2-one 302

2-[2-(aminomethyl)-3,3-difluoro-allyl]-4- [[5-(1-ethylpyrazol-4-yl)-3-fluoro-2- thienyl]methyl]-1,2,4-triazol-3-one 303

2-(2-(aminomethyl)-3,3-difluoroallyl)-4- ((5-(6-(dimethylamino)pyridin-3-yl)-3- fluorothiophen-2-yl)methyl)-2,4-dihydro- 3H-1,2,4-triazol-3-one 304

6-(5-((1-(2-(aminomethyl)-3,3- difluoroallyl)-5-oxo-1,5-dihydro-4H- 1,2,4-triazol-4-yl)methyl)-4- fluorothiophen-2-yl)-8-methyl-3,4- dihydroquinolin-2(1H)-one *Compounds were isolated as trifluoroacetate or ditrifluoroacetate salts as indicated in the Examples.

Experimental Example 1: Activity Evaluation with Respect to Amine Oxidases

The compounds according to the present technology were evaluated in terms of activity on recombinant human VAP-1 (R&D systems) by measuring the level of hydrogen peroxide in horseradish peroxidase (HRP)-coupled reaction using Amplex Red Hydrogen Peroxide Assay Kit (Molecular Probes, Invitrogen, USA). The experiment was carried out at room temperature using benzylamine as a substrate. In the HRP-coupled reaction, hydrogen peroxide oxidation of 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent) produces resorufin, which is a highly fluorescent compound. Briefly, the test compound was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 20 mM. The dose-response assessment was made by 1:3 serial dilution in DMSO, thereby creating a 8 point curve. The concentration of the upper part was controlled according to the efficacy of the compounds, followed by the dilution with a reaction buffer solution to obtain a final DMSO concentration of less than 1%. To each well of a 96 black well plate, human VAP-1 purified in 50 mM sodium phosphate buffer solution (pH7.4) was added. The test compounds dissolved in DMSO were incubated with the human VAP-1 enzymes at 37° C. for 30 minutes. After 30-minute incubation, each well was added with a reaction mixture containing 200 uM Amplex Red reagent prepared from 50 mM sodium phosphate buffer solution (pH 7.4), 1 mM benzylamine, and 1 U/mL HRP. Fluorescence intensity was measured at several time points during 1-2 hours using a microplate reader (Flexstation3, Molecular Devices) under the wavelength condition exciting at 544 nm and reading the emission at 590 nm. The inhibitory effect of the compounds was measured as a decrease (%) in the signal rate as compared to the control group without any inhibitor (only diluted DMSO). Data was fixed to a logistic model with four variables and IC₅₀ value was calculated using GraphPad Prism program.

In addition, the compounds according to the present technology were evaluated in terms of activity on a recombinant human MAO-A (monoamine oxidase-A, Sigma-Aldrich) and a recombinant human MAO-B (monoamine oxidase-B, Sigma-Aldrich) by using as substrates, 0.5 mM tyramine and 1 mM benzylamine, respectively, with a method similar to the activity evaluation method for recombinant human VAP-1. The compounds according to the present technology were also evaluated in terms of activity on a recombinant human DAO (diamine oxidase, R&D systems) by using as a substrate 1 mM putrescine with a method similar to the activity evaluation method for recombinant human VAP-1.

The results obtained by evaluating the activity against the enzymes as above are shown in Tables 2-5 below.

TABLE 2 Inhibitory Activity (IC₅₀, nM) Example human VAP-1 MAO-A MAO-B DAO 1 2.0 >100,000 39,000 >10,000 2 6.2 >100,000 >100,000 46,000 3 4.0 >100,000 25,000 19,000 4 4.2 >100,000 2,300 58,000 5 2.5 >100,000 4,900 67,000 6 9.4 >100,000 >100,000 >100,000 7 9.4 >100,000 6,100 10,000 8 2.2 >100,000 >100,000 10,500 9 3.5 >100,000 >100,000 7,100 10 7.7 >100,000 >100,000 1,200 11 1.1 >100,000 57,000 >100,000 12 43 >100,000 >10,000 55,000 13 3.6 >100,000 3,600 910 14 1.4 >100,000 40,000 4,100 15 3.0 >100,000 >100,000 >100,000 16 4.6 >100,000 38,000 1,100 17 12 >100,000 >10,000 1,300 18 15 >100,000 >100,000 13,000 19 5.3 >100,000 >10,000 240 20 2.1 >100,000 >100,000 350 21 2.5 36,200 18,000 6,300 22 0.8 >100,000 >100,000 >10,000 23 3.1 >100,000 >100,000 8,400 24 2.7 >100,000 3,300 600 25 1.7 6,280 >10,000 1,300 26 0.7 >100,000 180 71 27 0.4 >100,000 350 380 28 1.2 >100,000 85 1,600 29 0.2 >100,000 150 200 30 0.6 >100,000 300 890 31 0.2 >100,000 870 59 32 1.3 >100,000 17,000 670 33 0.3 11,000 190 17 34 0.3 27,000 770 250 35 0.3 >100,000 33 540 36 0.1 >100,000 160 97 37 0.5 >100,000 880 860 38 0.4 >100,000 450 24 39 1.2 >100,000 46,000 310 40 0.3 >100,000 200 12 41 0.2 >100,000 470 120 42 0.3 >100,000 34 250 43 0.2 >100,000 100 22 44 0.3 >100,000 110 14 45 0.2 >100,000 410 200 46 0.9 >100,000 >100,000 190 47 3.5 >100,000 >100,000 1,900 48 1 >100,000 31,000 61 49 1.6 >100,000 >100,000 490 50 1.5 >100,000 13,000 1,200 51 0.6 >100,000 28,000 520 52 0.9 >100,000 23,000 300 53 1.3 >100,000 >100,000 1,710 54 4.9 >100,000 >100,000 480 55 6.6 >100,000 >100,000 620 56 1.6 >100,000 79,600 75 57 0.9 >100,000 56,400 30 58 2.2 >100,000 >100,000 1,700 59 0.5 >100,000 >100,000 84 60 1.3 >100,000 >100,000 810 61 0.7 >100,000 14,000 19 62 1.5 >100,000 >100,000 160 63 0.7 >100,000 16,000 110 64 0.4 >100,000 480 270 65 0.3 >100,000 12,000 290 66 0.6 >100,000 4,800 250 67 0.9 >100,000 8,300 490 68 0.5 >100,000 55,000 2,100 69 1.2 >100,000 >100,000 >100,000 70 0.7 >100,000 5,800 1,500 71 0.8 >100,000 >100,000 >100,000 72 0.5 >100,000 1,500 57,000 73 0.3 >100,000 7,200 6,100 74 0.3 >100,000 7,500 6,500 75 0.7 >100,000 >100,000 20,000 76 1.1 >100,000 44,000 32 77 1 >100,000 1,600 10 78 0.6 >100,000 9,800 57 79 0.9 >100,000 910 200 80 0.4 >100,000 5,300 36 81 0.4 >100,000 3,500 27 82 0.1 >100,000 3,700 13 83 0.4 >100,000 >10,000 250 84 0.2 >100,000 900 7 85 0.2 >100,000 130 180 86 0.1 >100,000 640 33 87 0.1 >100,000 1,100 22 88 0.3 >100,000 8,200 230 89 0.6 >100,000 1900 2 90 1.3 >100,000 >100,000 30 91 0.5 >100,000 200 1 92 0.2 >100,000 6,200 8 93 0.3 >100,000 50 21 94 0.2 >100,000 860 4 95 0.6 >100,000 1,300 19 96 13 >100,000 220 >100,000 97 1.3 >100,000 20,000 >10,000 98 23 >100,000 13,900 18,600 99 9.3 >100,000 21,000 >100,000 100 0.5 >100,000 11,000 >10,000

TABLE 3 Inhibitory Activity (IC₅₀, nM) Example human VAP-1 MAO-A MAO-B DAO 101 0.3 >100,000 67,000 21,000 102 0.4 >100,000 5,400 >10,000 103 0.9 >100,000 4,200 22,000 104 0.5 >100,000 >10,000 31,000 105 1.5 >100,000 6,500 >10,000 106 4.7 >100,000 >100,000 860 107 3.5 >100,000 46,000 12,000 108 2.0 >10,000 >10,000 42,000 109 1.4 >100,000 >100,000 84,000 110 1.3 >10,000 8,700 >100,000 111 0.4 >100,000 9,400 7,200 112 0.2 >100,000 26,000 >100,000 113 0.6 >100,000 2,700 19,000 114 4.9 >100,000 >100,000 970 115 0.8 >100,000 10,000 11,000 116 1.4 >100,000 >10,000 >100,000 117 1.1 >100,000 >100,000 7,100 118 3.5 >100,000 >100,000 40,000 119 0.5 >100,000 30,000 >10,000 120 6 >100,000 >100,000 >100,000 121 0.9 >100,000 40,000 >10,000 122 0.4 >100,000 25,000 54,000 123 0.9 >100,000 56,000 59,000 124 11 >100,000 >100,000 >100,000 125 2.5 >100,000 >100,000 >100,000 126 0.5 >100,000 760 >100,000 127 0.6 >100,000 1,070 >100,000 128 0.7 >100,000 >100,000 97,000 129 0.7 >100,000 311 21,000 130 0.7 >100,000 >100,000 >100,000 131 0.4 7,800 12,000 >100,000 132 0.2 >100,000 >100,000 >100,000 133 0.2 >100,000 >100,000 >10,000 134 0.3 >100,000 22,000 >100,000 135 0.4 >100,000 >100,000 79,000 136 0.4 >100,000 >100,000 >100,000 137 0.3 >100,000 >100,000 >100,000 138 0.1 >100,000 15,000 13,000 139 1.0 21,000 21,000 73,000 140 0.8 6,600 8,000 6,800

TABLE 4 Inhibitory Activity (IC₅₀, nM) Example human VAP-1 MAO-A MAO-B DAO 141 0.6 8,100 20,000 16,000 142 0.2 >100,000 32,000 16,000 143 0.2 >100,000 6,400 >10,000 144 0.7 >100,000 >100,000 >10,000 145 0.8 >100,000 >100,000 >100,000 146 1.1 >100,000 33,000 9,200 147 11 >100,000 >100,000 2,600 148 0.7 >100,000 8,700 6,300 149 0.6 >100,000 >100,000 >10,000 150 2.9 >100,000 2,800 >10,000 151 0.3 >100,000 26,100 6,600 152 0.2 >100,000 13,400 3,500 153 1.3 >100,000 29,000 36,000 154 4.0 >100,000 >100,000 21,000 155 56 >100,000 >100,000 50,000 156 3.2 >100,000 17,000 9,100 157 2.3 >100,000 >100,000 >100,000 158 7 >100,000 3,800 >100,000 159 5.2 >100,000 >100,000 52,000 160 1.5 >100,000 15,600 5,090 161 0.2 >100,000 >100,000 54,000 162 0.7 >10,000 10,000 >10,000 163 0.4 >100,000 31,000 8,400 164 2.5 4,000 34,000 >10,000 165 0.5 >100,000 5,900 >10,000 166 0.9 >10,000 >10,000 >10,000 167 2.1 >100,000 41,000 >10,000 168 1.0 >10,000 45,000 >100,000 169 0.2 >100,000 >100,000 >100,000 170 0.8 >100,000 14,000 >10,000 171 1.8 >100,000 50,000 >100,000 172 13 >100,000 61,000 >100,000 173 0.3 >100,000 69,000 260 174 1.3 >100,000 >100,000 29 175 0.4 >100,000 14,000 250 176 0.5 >100,000 >100,000 1,100 177 1.2 >100,000 700 2,500 178 0.6 >100,000 >100,000 350 179 0.3 >100,000 >100,000 290 180 0.6 >100,000 61,000 1,900

TABLE 5 Inhibitory Activity (IC₅₀, nM) Example human VAP-1 MAO-A MAO-B DAO 181 2.3 >100,000 >100,000 >10,000 182 0.2 >100,000 >100,000 >100,000 183 1.4 >100,000 2,100 >100,000 184 2.6 >100,000 26,000 72,000 185 1.3 >100,000 28,000 >100,000 186 0.5 >100,000 >100,000 25,000 187 1.1 >100,000 >100,000 8,900 188 3.4 >100,000 >100,000 7,400 189 0.5 >100,000 >100,000 23,000 190 1.4 >100,000 >100,000 63,000 191 0.3 >100,000 44,000 4,200 192 0.4 >100,000 56,000 22,000 193 1.3 >100,000 >100,000 8,700 194 2.9 >100,000 9,200 64,000 195 2 >100,000 38,000 31,000 196 1.4 >100,000 2,900 1,900 197 0.8 >100,000 18,000 2,400 198 4.6 >100,000 23,000 880 199 1.7 >100,000 1,100 15,000 200 1.9 >100,000 740 >100,000 201 2.8 90800 2,000 27,000 202 2 >100,000 >100,000 5,600 203 1.5 >100,000 780 4,000 204 0.5 >100,000 89,900 41,200 205 0.8 >100,000 >100,000 7,674 206 2.3 >100,000 14,570 639 207 0.7 >100,000 >100,000 >100,000 208 2.5 89,940 42,390 >100,000 209 4.3 >100,000 5,185 93,690 210 1.5 >100,000 >100,000 1,227 211 1.1 38,860 42,730 1,861 212 1.5 79140 >100,000 4,319 213 2.5 >100,000 >100,000 1,300 214 1.7 >100,000 >100,000 940 215 0.7 >100,000 >100,000 280 216 1.3 >100,000 >100,000 63 217 1.1 >100,000 13,700 1,500 218 0.8 >100,000 >100,000 130 219 0.2 >100,000 68,500 47 220 1.1 >100,000 >100,000 11,000 221 0.3 20,000 9,000 2,700 222 1 >100,000 >100,000 4,000 223 1.5 >10,000 38,000 37,000 224 0.8 >100,000 1,900 5,500 225 0.5 >100,000 1,600 14,000 226 0.5 >100,000 11,000 >100,000 227 0.7 >100,000 340 4,800 228 0.6 >100,000 3,300 7,700 229 0.6 >10,000 4,100 97,000 230 0.7 >100,000 77,000 24,000 231 0.2 40,400 1,950 3,910 232 0.5 >100,000 1,100 15,000 233 0.2 >100,000 200 36,000 234 0.4 >100,000 1,800 7,500 235 1.4 >100,000 840 >100,000 236 0.8 >100,000 >100,000 6,700 237 0.42 >100,000 84,000 6,100 238 0.14 >100,000 1,800 310 239 2.7 >100,000 14,000 11,000 240 1 >100,000 15,000 30,000 241 1.3 >100,000 6,300 25,000 242 1 >100,000 29,000 4,200 243 0.9 32,700 2,200 4,600 244 0.8 >100,000 37,000 9,000 245 2.7 >100,000 15,000 14,000 246 2.3 >100,000 120,000 59,000 247 0.3 >100,000 >100,000 43,000 248 2.7 >100,000 14,000 >100,000 249 0.9 >100,000 3,100 3,900 250 0.2 >100,000 >100,000 4,300 251 1.5 >100,000 18,000 19,000 252 1 >100,000 35,000 17,000 253 2.8 >100,000 >100,000 8,700 254 8 >100,000 >100,000 >100,000 255 2.3 >100,000 >100,000 35,000 256 2.5 >100,000 >100,000 >100,000 257 2.4 >100,000 101,000 >100,000 258 2.5 >100,000 >100,000 >100,000 259 1.3 >100,000 >100,000 >100,000 260 3.7 >100,000 >100,000 >100,000 261 6.5 >100,000 >100,000 >100,000 262 7.4 >100,000 >100,000 >100,000 263 29 >100,000 >100,000 >100,000 264 1.3 >100,000 >100,000 >100,000 265 1.4 >100,000 >100,000 >100,000 266 9.1 >100,000 >100,000 330 267 1.1 >100,000 >100,000 >100,000 268 2.1 >100,000 1,870 >100,000 269 1 >100,000 >100,000 71,000 270 0.6 >100,000 >100,000 >100,000 271 2.2 >100,000 1,592 >100,000 272 3.2 >100,000 23,780 4,326 273 1.8 >100,000 2,897 39,270 274 3.1 >100,000 125 54,080 275 0.9 >100,000 25,420 5,158 276 0.5 >100,000 2,251 3,084 277 2.5 >100,000 68,620 1,811 278 17 >100,000 >100,000 >100,000 279 >100 >100,000 >100,000 >100,000 280 2,376 >100,000 >100,000 >100,000 281 307 >100,000 >100,000 4,858 282 28 >100,000 >100,000 >100,000 283 154 >100,000 >100,000 >100,000 284 148 >100,000 >100,000 66,360 285 >100 >100,000 >100,000 >100,000 286 1.4 2,619 3,231 2,476 287 0.7 >100,000 12,150 13,940 288 2.6 2,909 3,227 3,777 289 0.6 >100,000 11,950 14,530 290 0.7 >100,000 1,188 2,377 291 0.6 >100,000 3,447 6,158 292 2.7 86,170 >100,000 >100,000 293 2.4 >100,000 >100,000 25,300 294 2.9 >100,000 >100,000 5,379 295 0.3 >100,000 >100,000 >100,000 296 1 >100,000 >100,000 >100,000 297 1.9 >100,000 >100,000 14,810 298 12 >100,000 >100,000 0.2 299 1.4 >100,000 >100,000 9,679 300 1.7 >100,000 11,080 25,340 301 0.5 >100,000 >100,000 2,682 302 1.1 >100,000 >100,000 19,470 303 0.8 >100,000 >100,000 >100,000 304 0.7 >100,000 >100,000 12,570

From the results of Tables 2-5 above, it can be seen that the compounds according to the present technology have excellent inhibitory activity on VAP-1 among various amine oxidases.

Para. A. A compound of Formula X

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

n is 0, 1 or 2; and

A is an aryl group or a heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic; and wherein said aryl group or said heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R; and

R is a substituted or unsubstituted cyclic ring, optionally containing 1 to 5 heteroatom ring members chosen from O, N, or S, and said cyclic ring is aromatic or non-aromatic.

Para. B. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. A, wherein A is aryl optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

Para. C. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. B, wherein A is phenyl substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

Para. D. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. A, wherein A is a heterocyclic group having 1 to 5 heteroatom ring members chosen from O, N, or S; said heterocyclic group is aromatic or non-aromatic; and said heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

Para. E. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. D, wherein A is a heteroaryl group having 1 to 5 heteroatom ring members chosen from O, N, or S; and said heteroaryl group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

Para. F. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. E, wherein A is pyridine, pyrazine, or thiophene, wherein A is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

Para. G. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. A-F, wherein R is a cyclic ring optionally containing 1-5 heteroatom ring members, and said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, pyrrolidinonyl, and pyrrolidinyl.

Para. H. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. A-G, wherein n is 0.

Para. I. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. A-G, wherein n is 1.

Para. J. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. A-G, wherein n is 2.

Para. K. A compound of Formula Y

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

n is 0, 1 or 2;

A is an aryl or heteroaryl group selected from the group consisting of phenyl, pyridine, pyrazine, thiophene, and benzothiophene;

wherein said aryl or heteroaryl group is optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R;

wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 3,4-dihydro-1,4-benzoxazine, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene;

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, pyrrolidinonyl, and pyrrolidinyl.

Para. L. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein n is 0 or 1, and A is phenyl, pyridine or thiophene, optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

Para. M. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein said aryl or heteroaryl group is substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, and —R.

Para. N. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. M, wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole and 3,4-dihydroquinolin-2-one, said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

Para. O. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. N, wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl.

Para. P. The compound or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K,

wherein n is 0;

A is phenyl;

wherein said phenyl is substituted with one or two substituents selected from the group consisting of halogen and —R;

wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, 3,4-dihydroquinolin-2-one and pyrazole; and

wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl.

Para. Q. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein

n is 0;

A is pyridine;

wherein said pyridine is substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, and —R;

wherein said R is a cyclic ring selected from the group consisting of benzene, pyridine, 3,4-dihydroquinolin-2-one and pyrazole; and

wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl.

Para. R. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein

n is 0;

A is thiophene;

wherein said thiophene is substituted with one or two cyclic rings selected from the group consisting of benzene, pyridine, pyridin-2-one, 3,4-dihydroquinolin-2-one and pyrazole; and

wherein said cyclic ring is substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, di-C₁₋₆ alkylamino, and piperazinyl.

Para. S. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein A is phenyl optionally substituted with one or two substituents selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.

Para. T. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. S, wherein A is phenyl substituted with —R.

Para. U. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. T, wherein —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one;

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinonyl.

Para. V. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein A is pyridine substituted with —R.

Para. W. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. V, wherein —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrimidine, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene.

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinonyl.

Para. X. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein A is thiophene substituted with —R.

Para. Y The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. X, wherein —R is a cyclic ring selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 2,3-dihydro-1,4-benzoxazine, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, pyrido[2,3-b][1,4]oxazin-2-one, and 1,4-dihydroquinazolin-2-one;

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

Para. Z. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. K, wherein A is benzothiophene substituted with —R.

Para. AA. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. Z, wherein —R is a cyclic ring selected from the group consisting of benzene, pyridine, pyridin-2-one, pyrazole, benzodioxole, and 3,4-dihydroquinolin-2-one, wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.

Para. AB. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. S-AA, wherein n is 0.

Para. AC. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. S-AA, wherein n is 1.

Para. AD. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. S-AA, wherein n is 2.

Para. AE. A compound of Formula 12

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. AF. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AE, wherein R¹ is hydrogen.

Para. AG. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AE, wherein R¹ is halogen.

Para. AH. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AE, wherein R¹ is C₁₋₆ alkyl.

Para. AI. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. AE-AH, wherein R² is a substituted or unsubstituted aryl group.

Para. AJ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AI, wherein R² is substituted or unsubstituted phenyl.

Para. AK. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AI, wherein R² is phenyl substituted with triazolyl, C₁₋₆ alkylsulfonyl, or piperazinyl.

Para. AL. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AI, wherein R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

Para. AM. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. AE-AH, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. AN. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AM, wherein R² is substituted or unsubstituted pyridine.

Para. AO. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AN, wherein R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino.

Para. AP. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AM, wherein R² is substituted or unsubstituted pyrazole.

Para. AQ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AP, wherein R² is pyrazole substituted with C₁₋₆ alkyl or difluoromethyl.

Para. AR. A compound of Formula 13

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aralkoxy group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

Para. AS. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AR, wherein R¹ is hydrogen.

Para. AT. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AR, wherein R¹ is halogen.

Para. AU. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AR, wherein R¹ is C₁₋₆ alkyl.

Para. AV. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. AR-AU, wherein R² is a substituted or unsubstituted aryl group.

Para. AW. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AV, wherein R² is substituted or unsubstituted phenyl.

Para. AX. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AW, wherein R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl.

Para. AY The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AV, wherein R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

Para. AZ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. AR-AU, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. BA. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AZ, wherein R² is substituted or unsubstituted pyridine.

Para. BB. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BA, wherein R² is pyridine substituted with mono- or di-C₁₋₆ alkylamino.

Para. BC. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. AZ, wherein R² is substituted or unsubstituted pyrazole.

Para. BD. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BC, wherein R² is pyrazole substituted with C₁₋₆ alkyl.

Para. BE. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. AR-AU, wherein R² is substituted or unsubstituted pyridin-2-one.

Para. BF. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BE, wherein R² is pyridin-2-one substituted with C₁₋₆ alkyl.

Para. BG. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. AR-AU, wherein R² is substituted or unsubstituted aralkoxy group.

Para. BH. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BG, wherein R² is substituted or unsubstituted benzyloxy.

Para. BI. A compound of Formula 14

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

Para. BJ. The compound of Para. BI of Formula 14a

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

Para. BK. The compound of Para. BI of Formula 14b

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

Para. BL. The compound of Para. BI of Formula 14c

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

Para. BM. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BI-BL, wherein R¹ is hydrogen.

Para. BN. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BI-BL, wherein R¹ is halogen.

Para. BO. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BI-BL, wherein R¹ is C₁₋₆ alkyl.

Para. BP. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BI-BL, wherein R² is a substituted or unsubstituted aryl group.

Para. BQ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BP, wherein R² is substituted or unsubstituted phenyl.

Para. BR. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BQ, wherein R² is phenyl substituted with one to three substituents selected from the group consisting of with halogen, C₁₋₆ alkoxy, mono- or di-C₁₋₆ alkylamino, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, morpholinylcarbonyl, piperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, and pyrrolidinonyl.

Para. BS. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BP, wherein R² is benzodioxole, benzoxadiazole, benzothiazole, indazole, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, 3,4-dihydroquinolin-2-one, or benzoxazole, wherein R² is optionally substituted with C₁₋₆ alkyl or amino.

Para. BT. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BI-BO, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. BU. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BT, wherein R² is substituted or unsubstituted pyridine.

Para. BV. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BU, wherein R² is pyridine substituted with C₁₋₆ alkoxy, trifluoromethyl, piperazinyl, morpholinyl, or mono- or di-C₁₋₆ alkylamino.

Para. BW. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BT, wherein R² is pyrimidine, 1H-pyrrolo[2,3-b]pyridine, pyrazole, or thiophene, wherein R² is optionally substituted with C₁₋₆ alkyl, difluoromethyl, C₁₋₆ alkoxy-C₁₋₆ alkylamino, or C₁₋₆ alkylcarbonyl.

Para. BX. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BI-BO, wherein R² is substituted or unsubstituted pyridin-2-one.

Para. BY The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BX, wherein R² is pyridin-2-one substituted with C₁₋₆ alkyl.

Para. BZ. A compound of Formula 15

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S group.

Para. CA. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BZ, wherein R¹ is hydrogen.

Para. CB. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. BZ, wherein R¹ is C₁₋₆ alkyl.

Para. CC. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BZ-CB, wherein R² is a substituted or unsubstituted aryl group.

Para. CD. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CC, wherein R² is substituted or unsubstituted phenyl.

Para. CE. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CC, wherein R² is 2,3-dihydro-1,4-benzoxazine or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

Para. CF. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. BZ-CB, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. CG. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CF, wherein R² is substituted or unsubstituted pyridine.

Para. CH. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CG, wherein R² is pyridine substituted with morpholinyl or mono- or di-C₁₋₆ alkylamino.

Para. CI. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CF, wherein R² is 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, or pyrazole, wherein said pyrazole is optionally substituted with C₁₋₆ alkyl.

Para. CJ. A compound of Formula 16

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. CK. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CJ, wherein R² is a substituted or unsubstituted aryl group.

Para. CL. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CK, wherein R² is substituted or unsubstituted phenyl.

Para. CM. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CL, wherein R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl.

Para. CN. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CK, wherein R² is benzodioxole or 3,4-dihydroquinolin-2-one, wherein said 3,4-dihydroquinolin-2-one is optionally substituted with C₁₋₆ alkyl.

Para. CO. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CJ, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. CP. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CO, wherein R² is substituted or unsubstituted pyridine.

Para. CQ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CQ, wherein R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino.

Para. CR. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CO, wherein R² is substituted or unsubstituted pyrazole.

Para. CS. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CR, wherein R² is pyrazole substituted with C₁₋₆ alkyl.

Para. CT. A compound of Formula 17

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

Para. CU. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CT, wherein R¹ is hydrogen.

Para. CV. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CT, wherein R¹ is halogen.

Para. CW. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CT, wherein R¹ is C₁₋₆ alkyl.

Para. CX. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. CT-CW, wherein R² is a substituted or unsubstituted aryl group.

Para. CY The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CX, wherein R² is substituted or unsubstituted phenyl.

Para. CZ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CY, wherein R² is phenyl substituted with one to three substituents selected from the group consisting of C₁₋₆ alkoxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkylsulfonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, mono- or di-C₁₋₆ alkylaminocarbonyl, morpholinylcarbonyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, piperazinyl, and acetylpiperazinyl.

Para. DA. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. CX, wherein R² is 3,4-dihydroisoquinolin-1-one, quinolin-2-one, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 1,4-dihydroquinazolin-2-one, benzothiazole, benzoxadiazole, indazole, benzodioxole, 1,3-dihydroindol-2-one, or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl, C₁₋₆ alkylcarbonylamino, or halogen.

Para. DB. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. CT-CW, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. DC. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DB, wherein R² is substituted or unsubstituted pyridine.

Para. DD. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DC, wherein R² is pyridine substituted with one to three substituents selected from the group consisting of halogen, trifluoromethyl, C₁₋₆ alkoxy, piperazinyl and mono- or di-C₁₋₆ alkylamino.

Para. DE. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DB, wherein R² is substituted or unsubstituted pyrazole.

Para. DF. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DE, wherein R² is pyrazole substituted with C₁₋₆ alkyl, difluoromethyl, benzyl, (cycloalkyl)alkyl, alkylsulfonyl, or cycloalkylsulfonyl.

Para. DG. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DB, wherein R² is 5,6,7,8-tetrahydronaphthyridine, pyrimidine, imidazole, or triazolo[1,5-a]pyridine; wherein R² is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, amino, and C₁₋₆ alkoxy-C₁₋₆ alkylamino.

Para. DH. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DG, wherein R² is [1,2,4]triazolo[1,5-a]pyridine.

Para. DI. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. CT-CW, wherein R² is tetrahydropyridine or pyridin-2-one, wherein said tetrahydropyridine and said pyridin-2-one are optionally substituted with C₁₋₆ alkyl or C₁₋₆ alkylcarbonyl.

Para. DJ. A compound of Formula 18

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. DK. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DJ, wherein R¹ is hydrogen.

Para. DL. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DJ, wherein R¹ is halogen.

Para. DM. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DJ, wherein R¹ is C₁₋₆ alkyl.

Para. DN. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. DJ-DM, wherein R² is a substituted or unsubstituted aryl group.

Para. DO. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DM, wherein R² is substituted or unsubstituted phenyl.

Para. DP. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DM, wherein R² is 2,3-dihydro-1,4-benzoxazine or 3,4-dihydroquinolin-2-one.

Para. DQ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. DJ-DM, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. DR. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DQ, wherein R² is substituted or unsubstituted pyridine.

Para. DS. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DR, wherein R² is pyridine substituted with morpholinyl or mono- or di-C₁₋₆ alkylamino.

Para. DT. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DQ, wherein R² is substituted or unsubstituted pyrazole.

Para. DU. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DT, wherein R² is pyrazole substituted with C₁₋₆ alkyl.

Para. DV The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DQ, wherein R² is 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, or pyrido[3,2-b][1,4]oxazin-3-one.

Para. DW. A compound of Formula 19

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. DX. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DW, wherein R¹ is hydrogen.

Para. DY The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DW, wherein R¹ is halogen.

Para. DZ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. DW, wherein R¹ is C₁₋₆ alkyl.

Para. EA. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. DW-DZ, wherein R² is a substituted or unsubstituted aryl group.

Para. EB. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EA, wherein R² is substituted or unsubstituted phenyl.

Para. EC. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EB, wherein R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl.

Para. ED. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EA, wherein R² is benzodioxole or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl.

Para. EE. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. DW-DZ, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. EF. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EE, wherein R² is substituted or unsubstituted pyridine.

Para. EG. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EF, wherein R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino.

Para. EH. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EE, wherein R² is substituted or unsubstituted pyrazole.

Para. EI. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EH, wherein R² is pyrazole substituted with C₁₋₆ alkyl.

Para. EJ. A compound of Formula 20

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;

wherein

R¹ is hydrogen, halogen, or C₁₋₆ alkyl; and

R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members chosen from O, N, or S, and said heterocyclic group is aromatic or non-aromatic.

Para. EK. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EJ, wherein R¹ is hydrogen.

Para. EL. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EJ, wherein R¹ is halogen.

Para. EM. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EJ, wherein R¹ is C₁₋₆ alkyl.

Para. EN. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. EJ-EM, wherein R² is a substituted or unsubstituted aryl group.

Para. EO. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EN, wherein R² is substituted or unsubstituted phenyl.

Para. EP. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EO, wherein R² is phenyl substituted with C₁₋₆ alkylsulfonyl or piperazinyl.

Para. EQ. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EN, wherein R² is benzodioxole or 3,4-dihydroquinolin-2-one; wherein R² is optionally substituted with C₁₋₆ alkyl.

Para. ER. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. EJ-EM, wherein R² is a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members chosen from O, N, or S.

Para. ES. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. ER, wherein R² is substituted or unsubstituted pyridine.

Para. ET. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. ES, wherein R² is pyridine substituted with trifluoromethyl or mono- or di-C₁₋₆ alkylamino.

Para. EU. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. ER, wherein R² is substituted or unsubstituted pyrazole.

Para. EV The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EU, wherein R² is pyrazole substituted with C₁₋₆ alkyl.

Para. EW. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of any one of Paras. EJ-EM, wherein R² is a substituted or unsubstituted pyridine-2-one.

Para. EX. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. EW, wherein R² is pyridine-2-one substituted with C₁₋₆ alkyl.

Para. EY The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of Para. A, which is selected from the group consisting of:

-   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-fluorophenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(3-bromophenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(3,4-difluorophenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-3-fluoro-phenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-fluoro-phenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-methyl-phenyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-3-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(4-bromo-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(2-bromo-4-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromo-3-methyl-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-4-methyl-3-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-5-methyl-3-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromo-3-fluoro-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(6-bromo-3-methyl-2-pyridyl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-(5-bromopyrazin-2-yl)-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(dimethylamino)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1,3-benzodioxol-5-yl)phenyl]-1,2,4-triazol-3-one; -   6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-ethylpyrazol-4-yl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-4-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-3-fluoro-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-3-fluoro-phenyl]-1,2,4-triazol-3-one; -   6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-fluoro-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-3-fluoro-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-fluoro-4-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-2-fluoro-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-2-fluoro-phenyl]-1,2,4-triazol-3-one; -   6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-fluoro-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-2-fluoro-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-methylsulfonylphenyl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-piperazin-1-ylphenyl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(trifluoromethyl)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-3-pyridyl]-1,2,4-triazol-3-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1-ethylpyrazol-4-yl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-[6-(dimethylamino)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1,3-benzodioxol-5-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   6-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-4-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[4-(1-ethylpyrazol-4-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(4-methylsulfonylphenyl)-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(4-piperazin-1-ylphenyl)-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[6-(dimethylamino)-3-pyridyl]-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(1,3-benzodioxol-5-yl)-4-pyridyl]-1,2,4-triazol-3-one; -   6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[4-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(1-ethylpyrazol-4-yl)-4-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(dimethylamino)-3-pyridyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-methyl-6-(4-methylsulfonylphenyl)-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-methyl-6-[6-(trifluoromethyl)-3-pyridyl]-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[6-(dimethylamino)-3-pyridyl]-5-methyl-3-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(1,3-benzodioxol-5-yl)-5-methyl-3-pyridyl]-1,2,4-triazol-3-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl-2-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-3-methyl-2-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-(4-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-(4-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-fluoro-5-[6-(trifluoromethyl)-3-pyridyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)-3-fluoro-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-fluoro-3-pyridyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-fluoro-3-pyridyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)-3-fluoro-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(4-methylsulfonylphenyl)-pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(4-piperazin-1-ylphenyl)pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(trifluoromethyl)-3-pyridyl]pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[6-(dimethylamino)-3-pyridyl]pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzodioxol-5-yl)pyrazin-2-yl]-1,2,4-triazol-3-one; -   6-[5-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]pyrazin-2-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-ethylpyrazol-4-yl)pyrazin-2-yl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(4-benzyloxyphenyl)methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(5-bromo-2-thienyl)methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(4-bromo-2-thienyl)methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[(5-bromo-3-methyl-2-thienyl)methyl]-1,2,4-triazol-3-one; -   4-[[5-(4-acetylphenyl)-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methylsulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3-methyl     sulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   3-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N,N-dimethyl-benzenesulfonamide; -   4-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N-methyl-benzamide; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3,4,5-trimethoxyphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(3-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   4-[[5-[4-(4-acetylpiperazin-1-yl)phenyl]-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-morpholine-4-carbonyl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1H-pyrazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(6-methoxy-3-pyridyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(6-piperazin-1-yl-3-pyridyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-5-fluoro-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-aminopyrimidin-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-ethoxypyrimidin-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2-methoxyethylamino)pyrimidin-5-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2-chloro-3-methyl-imidazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-methyl-pyridin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-ethyl-pyridin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-isopropyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1H-indazol-6-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(2,1,3-benzoxadiazol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-7-fluoro-indolin-2-one; -   N-[6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,3-benzothiazol-2-yl]acetamide; -   7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3,4-dihydro-2H-isoquinolin-1-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-methyl-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-fluoro-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-8-fluoro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(5-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-4H-1,4-benzoxazin-3-one; -   7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   7-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-4-methyl-1,4-benzoxazin-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-methyl     sulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(dimethylamino)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1,3-benzodioxol-5-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-ethylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-(4-methylsulfonylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-methyl-5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-3-methyl-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one; -   7-[(E)-2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]vinyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-[6-(dimethylamino)-3-pyridyl]ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(6-morpholino-3-pyridyl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-3,4-dihydro-1H-quinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   7-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one; -   7-[2-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]ethynyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-(2-thienyl)ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(4-methyl     sulfonylphenyl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(4-piperazin-1-ylphenyl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-[6-(trifluoromethyl)-3-pyridyl]-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-[6-(dimethylamino)-3-pyridyl]-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(1,3-benzodioxol-5-yl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2-thienyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[5-[2-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]ethyl]-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-[5-(1-ethylpyrazol-4-yl)-2-thienyl]ethyl]-1,2,4-triazol-3-one; -   3-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-N,N-dimethyl-benzamide; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-2-thienyl]-3-methyl-1,4-dihydroquinazolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[1-(difluoromethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-isopropylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-3-methyl-1,4-dihydroquinazolin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-isopropyl-pyridin-2-one; -   4-[[4-[4-(4-acetylpiperazin-1-yl)phenyl]-2-thienyl]methyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-8-fluoro-1H-quinolin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-methyl-pyridin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-3,4-dihydro-1H-quinolin-2-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-thienyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[1-(difluoromethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-isopropylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(4-piperazin-1-ylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-[6-(trifluoromethyl)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-[6-(dimethylamino)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(1,3-benzodioxol-5-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-6-yl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-6-yl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[6-(1-ethylpyrazol-4-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-methylsulfonylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(4-piperazin-1-ylphenyl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   5-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[6-(dimethylamino)-3-pyridyl]benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]benzothiophen-5-yl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)benzothiophen-2-yl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(6-piperazin-1-yl-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[4-(morpholine-4-carbonyl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(6-morpholino-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-(3-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[6-[3-(dimethylamino)-4-fluoro-phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   5-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1-ethyl-pyridin-2-one; -   7-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-pyridyl]-1,4-dihydro-3,1-benzoxazin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(6-piperazin-1-yl-3-pyridyl)-2-pyridyl]-1,2,4-triazol-3-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-4H-1,4-benzoxazin-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2-methoxyethylamino)pyrimidin-5-yl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3,4,5-trimethoxyphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(6-methoxy-3-pyridyl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   4-[5-(2-amino-1,3-benzothiazol-5-yl)-3-methyl-2-pyridyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(2,1,3-benzoxadiazol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1,3-benzoxazol-5-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[4-(2-oxopyrrolidin-1-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   4-[5-(5-acetyl-2-thienyl)-3-methyl-2-pyridyl]-2-[2-(aminomethyl)-3,3-difluoro-allyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[3-(1H-pyrazol-3-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1H-indazol-6-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3-methylsulfonylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(3-piperazin-1-ylphenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[4-(morpholine-4-carbonyl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-(4-morpholinophenyl)-2-pyridyl]-1,2,4-triazol-3-one; -   4-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-N,N-dimethyl-benzenesulfonamide; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[3-(1H-1,2,4-triazol-3-yl)phenyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[2-(1-methylpyrazol-4-yl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-[6-(dimethylamino)-3-pyridyl]ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-methyl-5-[2-(6-morpholino-3-pyridyl)ethynyl]-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[2-(2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)ethynyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-1H-pyrido[2,3-b][1,4]oxazin-2-one; -   7-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one; -   6-[2-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]ethynyl]-3,4-dihydro-1H-quinolin-2-one; -   6-[6-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-5-methyl-3-pyridyl]-3-methyl-1,4-dihydroquinazolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[1-(difluoromethyl)pyrazol-4-yl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-(1-isopropylpyrazol-4-yl)-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-(4-methylsulfonylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-(4-piperazin-1-ylphenyl)phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-[6-(trifluoromethyl)-3-pyridyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[6-(dimethylamino)-3-pyridyl]-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1,3-benzodioxol-5-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one; -   6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl-phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[3-[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]-2-methyl-phenyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-ethylpyrazol-4-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-[1-(difluoromethyl)pyrazol-4-yl]-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[3-(1-isopropylpyrazol-4-yl)-2-methyl-phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[2-methyl-3-[3-(1H-1,2,4-triazol-3-yl)phenyl]phenyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(4-piperazin-1-ylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   6-[4-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   5-[4-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   6-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-methyl-3,4-dihydroquinolin-2-one; -   5-[3-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(1-ethylpyrazol-4-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(4-methylsulfonylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(4-piperazin-1-ylphenyl)phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-[6-(dimethylamino)-3-pyridyl]phenyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[2-(1,3-benzodioxol-5-yl)phenyl]methyl]-1,2,4-triazol-3-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-8-methyl-3,4-dihydro-1H-quinolin-2-one; -   6-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-methyl-3,4-dihydroquinolin-2-one; -   5-[2-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[4-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[3-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[4-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[4-[3-(1-ethylpyrazol-4-yl)phenyl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[4-(1-ethylpyrazol-4-yl)phenyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[5-[3-(1-ethylpyrazol-4-yl)phenyl]-3-methyl-2-pyridyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1H-pyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methylsulfonylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-cyclopropylsulfonylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-[1-(cyclopropylmethyl)pyrazol-4-yl]-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-methylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-benzylpyrazol-4-yl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[3-fluoro-5-(4-piperazin-1-ylphenyl)-2-thienyl]methyl]-1,2,4-triazol-3-one; -   5-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4-fluoro-2-thienyl]-1-ethyl-pyridin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1,3-benzodioxol-5-yl)-3-fluoro-2-thienyl]methyl]-1,2,4-triazol-3-one; -   6-[5-[[1-[2-(aminomethyl)-3,3-difluoro-allyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-4-fluoro-2-thienyl]-1-methyl-3,4-dihydroquinolin-2-one; -   2-[2-(aminomethyl)-3,3-difluoro-allyl]-4-[[5-(1-ethylpyrazol-4-yl)-3-fluoro-2-thienyl]methyl]-1,2,4-triazol-3-one; -   2-(2-(aminomethyl)-3,3-difluoroallyl)-4-((5-(6-(dimethylamino)pyridin-3-yl)-3-fluorothiophen-2-yl)methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;     and -   6-(5-((1-(2-(aminomethyl)-3,3-difluoroallyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)methyl)-4-fluorothiophen-2-yl)-8-methyl-3,4-dihydroquinolin-2(1H)-one;

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

Para. EZ. A pharmaceutical composition comprising the compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient

Para. FA. A method of inhibiting vascular adhesion protein (VAP-1), comprising administering to a mammal, a therapeutically effective amount of the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof according to any one of Paras. A-EY

Para. FB. A method of treating NASH in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition according to Para. EZ.

Para. FC. Use of the compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of NASH.

Para. FD. A compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use in treating NASH.

Para. FE. A compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of NASH.

Para. FF. A composition according to Para. EZ for use in treating NASH.

Para. FG. A compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use in inhibiting VAP-1.

Para. FH. A compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use as a medicament for the inhibition of VAP-1.

Para. FI. A composition according to Para. EZ for use in inhibiting VAP-1.

Para. FJ. A method of treating a disease mediated by VAP-1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition according to Para. EZ.

Para. FK. The method of Para. FJ, wherein the disease mediated by VAP-1 is selected from the group consisting of lipid and lipoprotein disorders, conditions and diseases which result from chronic fatty and fibrotic degeneration of organs due to accumulated lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways, Type I or Type II Diabetes and clinical complications of Type I and Type II Diabetes, chronic intrahepatic or some forms of extrahepatic cholestatic conditions, liver fibrosis, acute intraheptic cholestatic conditions, obstructive or chronic inflammatory disorders that arise out of improper bile composition, gastrointestinal conditions with a reduced uptake of dietary fat and fat-soluble dietary vitamins, inflammatory bowel diseases, obesity and metabolic syndrome (combined conditions of dyslipidemia, diabetes and abnormally high body-mass index), persistent infections by intracellular bacteria or parasitic protozoae, non-malignant hyperproliferative disorders, malignant hyperproliferative disorders, colon adenocarcinoma and hepatocellular carcinoma in particular, liver steatosis and associated syndromes, Hepatitis B infection, Hepatitis C infection and/or of cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis, liver failure or liver malfunction as an outcome of chronic liver diseases or of surgical liver resection, acute myocardial infarction, acute stroke, thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis, osteoarthritis, rheumatoid arthritis, psoriasis, and cerebral infarction, individually or any combination thereof.

Para. FL. A compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use in treating a disease mediated by VAP-1.

Para. FM. A compound according to any one of Paras. A-EY, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of a disease mediated by VAP-1.

Para. FN. The compound for use of Para. FL or Para. FM, wherein the disease mediated by VAP-1 is selected from the group consisting of lipid and lipoprotein disorders, conditions and diseases which result from chronic fatty and fibrotic degeneration of organs due to accumulated lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways, Type I or Type II Diabetes and clinical complications of Type I and Type II Diabetes, chronic intrahepatic or some forms of extrahepatic cholestatic conditions, liver fibrosis, acute intraheptic cholestatic conditions, obstructive or chronic inflammatory disorders that arise out of improper bile composition, gastrointestinal conditions with a reduced uptake of dietary fat and fat-soluble dietary vitamins, inflammatory bowel diseases, obesity and metabolic syndrome (combined conditions of dyslipidemia, diabetes and abnormally high body-mass index), persistent infections by intracellular bacteria or parasitic protozoae, non-malignant hyperproliferative disorders, malignant hyperproliferative disorders, colon adenocarcinoma and hepatocellular carcinoma in particular, liver steatosis and associated syndromes, Hepatitis B infection, Hepatitis C infection and/or of cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis, liver failure or liver malfunction as an outcome of chronic liver diseases or of surgical liver resection, acute myocardial infarction, acute stroke, thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis, osteoarthritis, rheumatoid arthritis, psoriasis, and cerebral infarction, individually or any combination thereof.

Para. FO. A method of preparing a compound of Formula 1aa, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

the method comprising

(a) reacting a compound of Formula 2 with a compound of Formula 3a or a compound of Formula 3b to obtain a compound of Formula 1a

wherein

Boc is an amine protecting group;

n is 0, 1, or 2;

A′ is aryl or heteroaryl group selected from the group consisting of phenyl, pyridine, pyrazine, thiophene, and benzothiophene; wherein said aryl or heteroaryl group is optionally substituted with C₁₋₃ alkyl or halogen;

Z is boronic acid (B(OH)₂) or boronic acid pinacol ester;

R′ is —R, —CH═CH—R, or —C≡C—R; and

R is a substituted or unsubstituted cyclic ring, optionally containing 1 to 5 heteroatom ring members chosen from O, N, or S, and said cyclic ring is aromatic or non-aromatic; and

(b) removing Boc from the compound of Formula 1a under reaction conditions to obtain the compound of Formula 1aa, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof.

Para. FP. The method of Para. FO, wherein the cyclic ring is selected from the group consisting of benzene, pyridine, tetrahydropyridine, pyridin-2-one, pyrimidine, imidazole, pyrazole, benzodioxole, benzoxadiazole, benzothiazole, indazole, 1,3-dihydroindol-2-one, quinolin-2-one, 3,4-dihydroisoquinolin-1-one, 3,4-dihydroquinolin-2-one, 3,4-dihydro-1,4-benzoxazine, 2,3-dihydro-1,4-benzoxazine, 1,4-benzoxazin-3-one, 1,4-dihydro-3,1-benzoxazin-2-one, 5,6,7,8-tetrahydronaphthyridine, triazolo[1,5-a]pyridine, 2,3-dihydro-pyrido[2,3-b][1,4]oxazine, 3,4-dihydro-pyrido[3,2-b][1,4]oxazine, pyrido[2,3-b][1,4]oxazin-2-one, pyrido[3,2-b][1,4]oxazin-3-one, 1,4-dihydroquinazolin-2-one, 1H-pyrrolo[2,3-b]pyridine, benzoxazole, and thiophene;

wherein said cyclic ring is optionally substituted with one to three substituents selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl. 

The invention claimed is:
 1. A compound of Formula X

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein n is 0, 1, or 2; and A is an aryl group or a heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members independently chosen from 0, N, and S, and said heterocyclic group is aromatic or non-aromatic; and wherein said aryl group or said heterocyclic group is optionally substituted with one or two substituents independently selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R; and R is a substituted or unsubstituted cyclic ring, optionally containing 1 to 5 heteroatom ring members independently chosen from O, N, and S, and said cyclic ring is aromatic or non-aromatic.
 2. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 1, wherein A is aryl optionally substituted with one or two substituents independently selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.
 3. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 2, wherein A is phenyl substituted with one or two substituents independently selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.
 4. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 1, wherein A is a heterocyclic group having 1 to 5 heteroatom ring members chosen from O, N, and S; said heterocyclic group is aromatic or non-aromatic; and said heterocyclic group is optionally substituted with one or two substituents independently selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.
 5. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 4, wherein A is an aromatic heterocyclic-group having 1 to 5 heteroatom ring members chosen from O, N, and S; and said aromatic heterocyclic group is optionally substituted with one or two substituents independently selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.
 6. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 5, wherein A is pyridinyl, pyrazinyl, or thiophenyl, wherein A is optionally substituted with one or two substituents independently selected from the group consisting of C₁₋₃ alkyl, halogen, benzyloxy, —R, —CH═CH—R, and —C≡C—R.
 7. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 1, wherein R is a cyclic ring optionally containing 1-5 heteroatom ring members independently chosen from O, N, and S, and said cyclic ring is optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, (cycloalkyl)alkyl, benzyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkyl sulfonyl, cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, C₁₋₆ alkylpyrazolyl, triazolyl, pyrrolidinonyl, and pyrrolidinyl.
 8. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 1, wherein n is
 0. 9. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 1, wherein n is
 1. 10. The compound, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of claim 1, wherein n is
 2. 11. The compound of claim 1 of Formula 12

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen, halogen, or C₁₋₃ alkyl; and R² is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members independently chosen from O, N, and S.
 12. The compound of claim 1 of Formula 13

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen, halogen, or C₁₋₃ alkyl; and R² is a benzyloxy group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members independently chosen from O, N, and S, and said heterocyclic group is aromatic or non-aromatic.
 13. The compound of claim 1 of Formula 14

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen, halogen, or C₁₋₃ alkyl; and R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members independently chosen from O, N, and S, and said heterocyclic group is aromatic or non-aromatic.
 14. The compound of claim 13 of Formula 14a

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
 15. The compound of claim 13 of Formula 14b

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
 16. The compound of claim 13 of Formula 14c

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
 17. The compound of claim 1 of Formula 15

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen or C₁₋₃ alkyl; and R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl, wherein said heteroaryl group has 1 to 5 heteroatom ring members independently chosen from O, N, and S group.
 18. The compound of claim 1 of Formula 16

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members independently chosen from O, N, and S.
 19. The compound of claim 1 of Formula 17

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen, halogen, or C₁₋₃ alkyl; and R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members independently chosen from O, N, and S, and said heterocyclic group is aromatic or non-aromatic.
 20. The compound of claim 1 of Formula 18

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen, halogen, or C₁₋₃ alkyl; and R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members independently chosen from O, N, and S.
 21. The compound of claim 1 of Formula 19

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen, halogen, or C₁₋₃ alkyl; and R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl group, wherein said heteroaryl group has 1 to 5 heteroatom ring members independently chosen from O, N, and S.
 22. The compound of claim 1 of Formula 20

or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen, halogen, or C₁₋₃ alkyl; and R² is a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, wherein said heterocyclic group has 1 to 5 heteroatom ring members independently chosen from O, N, and S, and said heterocyclic group is aromatic or non-aromatic.
 23. A pharmaceutical composition comprising the compound according to claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
 24. A method of inhibiting vascular adhesion protein-1 (VAP-1) in a mammal, comprising administering to the mammal, a therapeutically effective amount of the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof according to claim
 1. 25. A method of treating nonalcoholic hepatosteatosis (NASH) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
 26. A method of treating a disease mediated by vascular adhesion protein-1 (VAP-1) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to claim 1, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
 27. The method of claim 26, wherein the disease mediated by VAP-1 is selected from the group consisting of a lipid disorder, lipoprotein disorder, condition or disease which results from chronic fatty and fibrotic degeneration of organs due to accumulated lipid, triglyceride accumulation and subsequent activation of a profibrotic pathway, Type I Diabetes, Type II Diabetes, complication of Type I or Type II Diabetes, chronic intrahepatic cholestatic condition, extrahepatic cholestatic condition, liver fibrosis, acute intrahepatic cholestatic condition, obstructive or chronic inflammatory disorder that arises out of improper bile composition, gastrointestinal condition with a reduced uptake of dietary fat or fat-soluble dietary vitamin, inflammatory bowel disease, obesity, metabolic syndrome, combined conditions of dyslipidemia, diabetes and abnormally high body-mass index, persistent infection by intracellular bacteria or parasitic protozoae, non-malignant hyperproliferative disorder, malignant hyperproliferative disorder, colon adenocarcinoma, hepatocellular carcinoma, liver steatosis or associated syndrome, Hepatitis B infection, Hepatitis C infection, a cholestatic and fibrotic effect that is associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis, liver failure or liver malfunction as an outcome of chronic liver disease or of surgical liver resection, acute myocardial infarction, acute stroke, thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis, osteoarthritis, rheumatoid arthritis, psoriasis, and cerebral infarction, or a combination thereof.
 28. A method of preparing a compound of Formula 1 aa, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

the method comprising (a) reacting a compound of Formula 2 with a compound of Formula 3a or a compound of Formula 3b to obtain a compound of Formula 1a

Z—R′  (Formula 3a) HC≡CR  (Formula 3b)

wherein Boc is an amine protecting group; n is 0, 1, or 2; A′ is phenyl, pyridinyl, pyrazinyl, thiophenyl, or benzothiophenyl; wherein said phenyl, pyridinyl, pyrazinyl, thiophenyl, or benzothiophenyl is optionally substituted with C₁₋₃alkyl or halogen; Z is boronic acid (B(OH)₂) or boronic acid pinacol ester; R′ is —R, —CH═CH—R, or —C≡C—R; and R is a substituted or unsubstituted cyclic ring, optionally containing 1 to 5 heteroatom ring members chosen from O, N, and S, and said cyclic ring is aromatic or non-aromatic; and (b) removing Boc from the compound of Formula 1a under reaction conditions to obtain the compound of Formula 1aa, or the stereoisomer thereof, or the pharmaceutically acceptable salt thereof.
 29. The method of claim 28, wherein the cyclic ring is selected from the group consisting of phenyl, pyridinyl, tetrahydropyridinyl, pyridin-2-on-yl, pyrimidinyl, imidazolyl, pyrazolyl, benzodioxolyl, benzoxadiazolyl, benzothiazolyl, indazolyl, 1,3-dihydroindol-2-onyl, quinolin-2-onyl, 3,4-dihydroisoquinolin-1-onyl, 3,4-dihydroquinolin-2-onyl, 3,4-dihydro-1,4-benzoxazinyl, 2,3-dihydro-1,4-benzoxazinyl, 1,4-benzoxazin-3-onyl, 1,4-dihydro-3,1-benzoxazin-2-onyl, 5,6,7,8-tetrahydronaphthyridinyl, triazolo[1,5-a]pyridinyl, 2,3-dihydro-pyrido[2,3-b][1,4]oxazinyl, 3,4-dihydro-pyrido[3,2-b][1,4]oxazinyl, pyrido[2,3-b][1,4]oxazin-2-onyl, pyrido[3,2-b][1,4]oxazin-3-onyl, 1,4-dihydroquinazolin-2-onyl, 1H-pyrrolo[2,3-b]pyridinyl, benzoxazolyl, and thiophenyl; wherein said cyclic ring is optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl, difluoromethyl, trifluoromethyl, C₁₋₆ alkoxy, amino, mono- or di-C₁₋₆ alkylamino, C₁₋₆ alkoxy-C₁₋₆ alkylamino, C₁₋₆ alkylcarbonylamino, mono- or di-C₁₋₆ alkylaminocarbonyl, mono- or di-C₁₋₆ alkylaminosulfonyl, C₁₋₆ alkyl sulfonyl, C₁₋₆ alkylcarbonyl, morpholinylcarbonyl, piperazinyl, acetylpiperazinyl, morpholinyl, pyrazolyl, triazolyl, and pyrrolidinyl.
 30. A method of treating nonalcoholic hepatosteatosis (NASH) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim
 23. 31. A method of treating a disease mediated by vascular adhesion protein-1 (VAP-1) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim
 23. 32. The method of claim 31, wherein the disease mediated by VAP-1 is selected from the group consisting of a lipid disorder, lipoprotein disorder, condition or disease which results from chronic fatty or fibrotic degeneration of organs due to accumulated lipid, triglyceride accumulation and subsequent activation of a profibrotic pathway, Type I Diabetes, Type II Diabetes, complication of Type I or Type II Diabetes, chronic intrahepatic cholestatic condition, extrahepatic cholestatic condition, liver fibrosis, acute intrahepatic cholestatic condition, obstructive or chronic inflammatory disorder that arises out of improper bile composition, gastrointestinal condition with a reduced uptake of dietary fat or fat-soluble dietary vitamin, inflammatory bowel disease, obesity, metabolic syndrome, combined conditions of dyslipidemia, diabetes and abnormally high body-mass index, persistent infection by intracellular bacteria or parasitic protozoae, non-malignant hyperproliferative disorder, malignant hyperproliferative disorder, colon adenocarcinoma, hepatocellular carcinoma, liver steatosis or associated syndrome, Hepatitis B infection, Hepatitis C infection, cholestatic and fibrotic effect that is associated with alcohol-induced cirrhosis or with viral-borne forms of hepatitis, liver failure or liver malfunction as an outcome of a chronic liver disease or of surgical liver resection, acute myocardial infarction, acute stroke, thrombosis which occurs as an endpoint of chronic obstructive atherosclerosis, osteoarthritis, rheumatoid arthritis, psoriasis, and cerebral infarction, or a combination thereof. 